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General introduction 
General Introduction 
Platelets are traditionally known for their role in primary hemostasis, a process in which 
platelet plugs seal off an injury to a blood vessel to prevent further bleeding. Platelets also 
play a fundamental role in progression of atherosclerosis and acute cardiovascular events 
(1). Beyond these apparent functions in hemostasis and thrombosis, it is increasingly 
recognized that platelets are key cells in immunity and inflammation. Platelets can 
interact with different immune cells and alter their phenotype (2). Platelets can also 
release antimicrobial peptides (3) and trigger the formation of neutrophil extracellular 
traps (4), highlighting their involvement in the innate host response against infectious 
diseases. Infection/inflammation and hemostasis are thus two processes which interact 
with each other, and platelets play a crucial role in this bidirectional interaction. 
Severe infections and the related changes in inflammation may have differential effects 
on platelets. High platelet numbers are commonly seen in infectious diseases such as 
tuberculosis (5), whereas low platelet counts are a feature of viral infections, such as 
dengue (6). The changes in platelet numbers and function may not only be a result 
of inflammation, but also be a direct or indirect effect of the micro-organisms itself. 
The present research mainly focuses on how infection and inflammation alter platelet 
numbers and function, and whether and how these platelet changes alter the innate 
immune response against these infections. 
Platelet 
function 
Infection J 
Inflammation 
L""- Ji ~;J 
Platelet structure, lifespan and reactivity 
Platelets have an individual lifespan of 8-10 days, with 100 billion platelets produced 
daily by megakaryocytes to maintain the normal count of 150-400 x 109 platelets per 
liter of blood. Although small in size (with a diameter of 1.5-3 filll), they are present 
in large numbers in the circulation. Platelets have a large surface area due to an open 
canalicular system which can take up proteins and molecules and re-release them 
upon activation. Platelets contain 3 principal types of granules: the a-granules, dense 
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granules and lysosomes. These granules store over 300 biologically active molecules 
which can be released to the circulation or translocated to the platelet membrane 
during platelet activation (2). The platelet a-granules are the most abundant (50-
80 per platelet) and contain a large variety of biologically active substances such as 
membrane proteins (aiibP3 integrin, P-selectin and CD36), adhesive molecules 
(fibrinogen, von WUlebrand factor [VWF], vitronectin and multimerin 1), coagulant 
factors (factor V, IX and XIII) and chemokines with direct microbicidal properties. 
Platelet a-granules are also participating actively in inflammation due to the secretion of 
pro-inflammatory and immune-modulating factors (7). P-selectin (CD62P) is a platelet 
a-granule transmembrane protein which is expressed on the surface membrane after an 
activation signal and interacts with its counter-ligand, P-selectin glycoprotein ligand-1 
(PSGL-1), mediating the interaction between platelets and leukocytes (8). The platelet 
dense granules (3-8 per platelet) contain high concentration of calcium, phosphate and 
hemostatic agonists such as adenosine diphosphate (ADP) and adenosine triphosphate 
(ATP), whereas platelet lysosomes contain acid hydrolase, cathepsin and lysosomal 
proteins (2). 
Platelets have a diverse array of receptors that trigger their activation upon exposure to 
hemostatic agonists or subendothelial matrix. The initial tethering of platelets at sites 
of vascular injury is mediated by the glycoprotein (GP) Ib/V/IX, a structurally unique 
receptor complex expressed by platelets. One of the component of this complex, GPib, 
interacts with VWF as its major ligand (9). Besides GPib, other collagen receptors for 
platelet tethering are present on the platelet surface, including GPVI and GPia/IIa (or 
a2~1 integrin), members of the immunoglobulin superfamily (10). Activated platelets 
release arachidonic acid from membrane phospholipids, which is subsequently converted 
to thromboxaneA2 (TxA2) . As a consequence, TxA2 is secreted and acts on other platelets 
through the TP receptors, which belong to the major receptor family G-protein coupled 
receptors (GPCRs), leading to further platelet activation (11). After activation, platelets 
undergo rapid change of shape and release their granule content. One soluble platelet 
agonist released from dense granules is ADP, which activates platelets through their P2Y1 
and P2Y12 receptors ( 12). Thrombin, another platelet agonist, binds another GPCR named 
protease-activated receptors (PARs). Thrombin-mediated platelet activation in humans 
occurs through the activation ofPAR-1 and PAR-4 (13). Additionally, platelet activation 
causes a conformational change in allb~3 integrin, enabling the binding of fibrinogen, 
which form bridges between adjacent platelets and facilitate platelet aggregation (13) . 
Thus, platelet activation is the product of many signals from different receptors, which 
each contribute to the formation of a platelet plug. 
Platelets as immune cells: the crosstalk with immunity 
Platelets play important roles in innate immunity by participating in antimicrobial host 
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defense, leukocyte trafficking and immunothrombosis (14). Platelets can interact with 
immune cells such as monocytes, neutrophils, dendritic cells and memory T cells, and 
as a result alter their phenotypes. Among all leukocytes, monocytes show the highest 
affinity for platelets (15). This platelet-monocyte crosstalk triggers the release of pro-
inflammatory cytokines, monocyte recruitment and extravasation, monocyte CD16 
expression and a more pro-coagulant phenotype ( 16-19). However, this crosstalk 
can also switch monocytes into an anti-inflammatory phenotype, for example by 
up regulating ofiL-1 0 and suppressing TNF-a and IL-6 responses to lipopolysachharide 
(LPS), thyroglobulin or Porphyromonas gingiva/is (20). 
Toll-like receptors (TLRs) form an important part of host defense against invading 
pathogens by recognition of danger-associated molecular patterns (DAMPs) and 
pathogen-associated molecular patterns (PAMPs). Platelets also harbor different TLRs 
and different studies have confirmed the functionality of both platelet surface TLRs 
(TLR1, TLR2, TLR4 and TLR6) and intracellular TLRs (TLR3, TLR7, TLR9) 
(reviewed by (21)). TLR2 and TLR4 are predominantly known to recognize common 
cell wall components of Gram-positive and Gram-negative bacteria, respectively. TLR2 
ligates peptidoglycan and lipoteichoic acid bacterial cell wall components of Gram-
positive bacteria (22), whereas LPS from Gram-negative bacteria is recognized by 
TLR4 (23). Pam3CSK4, a synthetic ligand ofTLR2, has been shown to have strong 
thrombotic platelet activating properties, in contrast to LPS (24). In addition to innate 
immune responses, platelets are also recognized to be involved in adaptive immunity. 
For example, platelets facilitate lymphocyte homing, immunoglobulin class switch, and 
germinal center formation (25, 26). 
Platelet function assays 
Unlike data on changes in platelet number, which can be easily monitored, surprisingly 
few data are available on the effect of infectious diseases on platelet reactivity. The 
limited availability of reliable analytical assays to capture in vivo platelet function 
and the fact that platelet samples need to be processed immediately without prior 
storage are likely to account for this. The traditional method of platelet function test 
utilizes light transmission aggregometry. This test performs poorly when patients are 
thrombocytopenic and requires prior isolation of platelet-rich plasma. Another option is 
to measure platelet activation and the platelet response to ex vivo activation by different 
platelet ligands using flow cytometry. Recently, our collaborators developed a whole 
blood, flow cytometry-based platelet reactivity assay (27), which has the advantages 
that blood manipulation to produce PRP is not required and that it can be employed in 
thrombocytopenic conditions. Readout of this assay is the expression of the a-granule 
protein P-selectin and activation of the allb~3 integrin by measuring the binding of 
fibrinogen. This is measured in unstimulated samples and after ex vivo stimulation with 
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different platelet agonists such as collagen-related peptide (CRP-XL), thrombin receptor 
activating peptide (TRAP) and adenosine diphosphate (ADP). In the present thesis, this 
new whole blood, flow cytometry-based assay has been used to assess how infection and 
inflammation alter platelet numbers and function, and whether and how these platelet 
changes alter the innate immune response against these infections. The different studies 
involved both healthy volunteers as well as patients with various infectious diseases. 
Studies in healthy volunteers 
The level of platelet reactivity varies between individuals and is determined by both 
genetic and non-genetic factors (28). Studies have identified genetic variations which 
regulate platelet reactivity (29-31) or immune responses (32, 33) but have not interlinked 
these two processes. Although platelet reactivity is likely to influence inflammatory and 
immune responses and vice versa, the mechanisms of these interactions have not been 
well-established. In chapter 2, the interaction between platelets and inflammation was 
therefore explored in 500 healthy volunteers. In this study, we were also able to explore 
how the genetic variation that determine platelet reactivity can also exert its influence 
on the cytokine responses of whole blood and peripheral blood mononuclear cells 
(PBMCs). 
As platelets are important in the development of thrombotic vascular events, platelet 
function inhibitors, especially aspirin and P2Y12 receptor antagonists, have become the 
therapeutic and preventive cornerstones of cardiovascular diseases. Aspirin prevents 
prostanoid synthesis via inhibition of cyclooxygenase 1 (COX-1) and COX-2, thus 
abolishing platelet production of TxA2, an important platelet agonist (34). Mter the 
release of ADP from platelet dense granules, P2Y1 and P2Y12 receptors are activated and 
act as an important feedback loop for other agonists including collagen, von Wille brand 
factor (vWF) and TxA2. Previous evidence has shown a clear role ofP2Y12 receptors in 
potentiating dense granule secretion, fibrinogen-receptor activation, thrombus formation 
and for irreversible platelet aggregation (12, 35, 36). P2Y12 receptor antagonists such 
as clopidogrel, and the recently developed ticagrelor, have not only been shown to 
reduce platelet reactivity but also the formation of platelet-leukocyte complexes (37). 
In chapter 3, we explored the differential effects of platelets and platelet inhibition by 
ticagrelor on TLR2- and TLR4-mediated inflammatory responses. Through a series of 
ex vivo experiments, we determined the effects of isolated washed platelets on cytokine 
responses of peripheral blood mononuclear cells (PBMCs) from healthy volunteers to 
Pam3CSK4 and LPS stimulation. Additionally, in a double blind, placebo-controlled 
crossover trial of a single oral dosage of ticagrelor in healthy volunteers, we investigated 
cytokine production in blood exposed to Pam3CSK4 and LPS. 
At present, more data on the effects of platelet inhibitors, including ticagrelor, on 
inflammation are available. Some studies for example, demonstrated the benefit ofP2Y12 
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inhibition in sepsis patients. Sepsis is a potentially lethal condition that arises when the 
body's response to an infection injures its own tissues and organs. The pathogenesis of 
sepsis involves a dysregulated host response with both exaggerated inflammation and 
immune suppression (38, 39). In sepsis, platelets can be activated due to the triggering 
of inflammatory and coagulation cascades, endothelial damage, and direct interactions 
with pathogens (40). Platelet activation may result in thrombocytopenia and 
microthrombosis, both of which have been associated with increased mortality in sepsis 
(41). A common in vivo model of systemic inflammation is the human endotoxemia 
model, whereby purified LPS (endotoxin) from Escherichia coli or other Gram-negative 
bacteria is administered intravenously to healthy volunteers. This model induces an 
acute systemic inflammatory response, which, although only partially, mimics the 
inflammatory response of early sepsis and other acute inflammatory conditions (42). 
A frequent consequence of sepsis is the development of acute kidney injury (AKI) (43, 
44). Platelets are thought to play a role in the pathogenesis of sepsis-associated AKI ( 45). 
In two phase II trials, bovine-derived alkaline phosphatase (AP) was shown to have a 
renal protective effect in critically ill patients with sepsis-associated acute kidney injury 
(AKI) (46). AP is a dephosphorylating glycoprotein enzyme with four different types of 
isoenzymes, namely placental, germ cell, intestinal, and tissue-nonspecific (liver/bone/ 
kidney) AP. Three studies from the late 1980s showed that bovine-derived kidney AP 
inhibits platelet aggregation, although the precise mechanisms remained unclear (47-
49). In vitro studies on renal cells showed that the anti-inflammatory effect of AP was 
related to its dephosphorylating activity on LPS and ADP (50). Recently, a human 
recombinant AP (recAP) was developed with enhanced stability and enzymatic activity 
(51), and in chapter 4, through a series of ex vivo experiments on whole blood from 
healthy volunteers and sepsis patients, we explored the platelet-inhibiting effect of recAP 
on platelets and involved pathways. 
Concurrent with systemic inflammation in sepsis and critical illness, systemic hypoxia 
is common in critically ill patients, and is independently associated with adverse 
outcome. Tissue hypoxia may arise during inflammatory conditions as a result of 
enhanced metabolic demands, and decreased oxygen delivery (52). Hypoxia has also 
been implicated in the activation of coagulation, due to its association with thrombotic 
events (53). In rats, hypoxia has been shown to increase platelet reactivity (54). For the 
aforementioned reasons, it is plausible that hypoxia may contribute to altered platelet 
function and coagulopathy in critically ill patients, increasing their risks for organ 
dysfunction. However, the limited number of human studies available have mainly 
focused on the effects of hypoxia on plasmatic coagulation (55, 56), and human in vivo 
studies have only investigated the effects of hypoxia on platelet function during very 
mild (57) or using very short bouts of hypoxia (58). Although hypoxia and inflammation 
may both affect platelet function and plasmatic coagulation, human in vivo data on the 
17 
Chapterl 
interaction between hypoxia and inflammation on coagulation are completely lacking. 
In chapter 5, we investigated the effects of systemic hypoxia during experimental human 
endotoxemia on platelet function, endothelial cell activation and plasmatic coagulation. 
Studies in patients with infectious diseases 
Changes in platelet function during infections may be important for two reasons: 
increased platelet reactivity may contribute to the development of thrombotic vascular 
complications, whereas platelet hyporeactivity may increase the risk for bleeding. The 
latter risk is especially high when thrombocytopenia is also present, like in haemorrhagic 
fevers, such as leptospirosis and dengue virus infections. 
The risk for thrombotic vascular events, such as myocardial infarctions and stroke are 
indeed increased in infectious diseases (59). A high incidence of myocardial infarction 
and stroke was reported in patients with community acquired pneumonia (CAP) (60-
62). Streptococcus pneumoniae, a Gram-positive bacterium, is a major cause of CAP. S. 
pneumoniae has been shown to interact with and activate platelets ex vivo (63), but in 
vivo studies of platelet function in animal models or patients are lacking. We speculated 
that excessive platelet activation may also contribute to the vascular comorbidity 
in pneumococcal infections. In chapter 6, we investigated platelet activation and 
hyperreactivity using a novel porcine model of intravenous S. pneumoniae infection. 
Furthermore, the utilization of bacterial whole genome sequencing for understanding 
pathogen virulence, including that of S. pneumoniae, allows prediction for the potential 
of a bacterial isolate to cause severe disease from the genome sequence alone ( 64, 65). We 
investigated therefore the association between the genotype of S. pneumoniae and disease 
outcome in 349 patients with pneumococcal bacteremia (chapter 7). More specifically, 
we explored the relevance of a phage-derived pblB gene, that encodes a platelet-binding 
protein of which the effects on platelet activation were previously unknown. 
Acute bacterial infections are associated with an increased risk for CVE and stroke, but 
the magnitude of this risk depends on the type of infection (59, 66, 67). Clinical studies 
have shown a high incidence of thrombotic vascular complications in patients with 
Gram-positive bacterial infections (60, 68). This risk appears lower for urinary tract 
infections, which are usually caused by Escherichia coli or other Gram-negative bacteria 
(59, 69). In addition, infective endocarditis is predominantly caused by Gram-positive 
bacteria (70). Although studies have demonstrated both increased and decreased platelet 
activation in sepsis (71-74), its distinct pathogenic causes have not been considered. In 
chapter 8, we compared platelet reactivity in patients with Gram-positive or Gram-
negative sepsis. 
Another infection associated with increased platelet reactivity is HIV (75, 76). Platelets 
can internalize HIV, a process that is increased by platelet activation (77). On the other 
hand, increased platelet-monocyte complex formation and platelet reactivity to platelet 
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agonists are found in HIV-infected patients and this is thought to contribute to a higher 
risk for cardiovascular diseases (CVD) (75, 76). The impact of different regimens of 
antiretroviral therapy (ART) on platelet reactivity and PMC formation has not been 
rigorously studied. Intensification of ART with the integrase inhibitor raltegravir 
(RAL) was shown to suppress residual viral replication and reduce plasma levels of the 
coagulation marker d-dimer, although this finding was not replicated in another study 
(78, 79). A switch from a protease inhibitor to raltegravir decreased inflammatory and 
coagulation biomarkers (80). This suggests that a raltregravir-based regimen may also 
be associated with reduced platelet hyperreactivity In chapter 9, we studied platelet 
reactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a 
raltegravir-based regimen, in comparison with those receiving nonnucleoside reverse 
transcriptase inhibitor (NNRTI) or protease inhibitor (PI) regimens as well as healthy 
controls. 
On the contrary, infections may also lead to decreased platelet reactivity. A study from 
our group demonstrated that dengue was associated with thrombocytopathy, which 
may contribute to the bleeding complications (81). Another infectious disease in which 
bleeding is an important complication is leptospirosis, which is caused by pathogenic 
spirochetes of the genus Leptospira. Leptospirosis incidence during outbreaks and in 
high exposure risk groups are estimated to exceed 100/100.000 per year. The clinical 
manifestations ofleptospirosis range from a mild, self-limited febrile illness to a fulminant 
life-threatening illness with multi-organ failures (82). Hemorrhagic manifestations are 
clinically important complications occurring in up to 60% of all hospitalized patients, 
with severe pulmonary haemorrhage showing an alarmingly high mortality of >50% 
(83). The pathophysiological mechanisms responsible for bleeding in leptospirosis 
remains incompletely understood. We investigated platelet reactivity in patients with 
leptospirosis and its association with bleeding complications in chapter 10. 
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Outline of thesis 
Studies in healthy volunteers 
• Platelet number and reactivity are associated with immune responses and 
inflammation (chapter 2) 
• Differential effects of platelets and platelet inhibition by ticagrelor on TLR2-
and TLR4-mediated inflammatory responses (chapter 3) 
• Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in 
humans (chapter 4) 
• Effects of hypoxia on platelet function and coagulation during systemic 
inflammation in humans in vivo (chapter 5) 
Studies in patients with and animal model of infectious diseases 
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• Invasive pneumococcal disease leads to activation and hyperreactivity of platelets 
(chapter 6) 
• Phage-derived protein induces increased platelet activation and is associated 
with mortality in patients with invasive pneumococcal disease (chapter 7) 
• Higher platelet reactivity and platelet-monocyte complex formation in Gram-
positive sepsis compared to Gram-negative sepsis (chapter 8) 
• Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-
infected individuals receiving a raltegravir-based regimen (chapter 9) 
• Thrombocytopathycontributes to bleeding complications in human leptospirosis 
(chapter 10) 
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Abstract 
Introduction: Platelets are increasingly recognized as key cells in inflammation and 
immunity. Whether the number and hemostatic function of platelets are related 
with inflammation and the host immune responses and vice versa is still unknown. 
Platelet function and immune responses also have strong genetic determinants, but 
these have yet to be examined together. 
Objectives: We systematically and comprehensively characterized the interaction 
between platelet function, immune responses, and their genetic variation in 
The 500-Human Functional Genomics (500FG) cohort of approximately 500 
Caucasian, healthy individuals as part of the Human Functional Genomics Project 
(HFGP). 
Methods: We analyzed the association of platelet number, platelet activation 
status and platelet reactivity to adenosine diphosphate (ADP) and collagen-related 
peptide (CRP-XL), with inflammatory markers and whole blood and peripheral 
blood mononuclear cell (PBMC) cytokine responses to stimulation with different 
Toll-like receptor ligands, bacterial and fungal stimuli. We then selected single 
nucleotide polymorphisms (SNPs) previously associated with platelet traits and 
related these to cytokine responses, and vice versa. 
Results: Platelet numbers were strongly associated with plasma levels of IL-l~. 
Platelet activation and reactivity were positively correlated with ex vivo whole blood 
and PBMC IL-l~ and IL-6 responses, whereas they were negatively correlated with 
IFN-y responses. Addition of platelets to PBMC also upregulated IL-l~ and IL-6 
responses to LPS, Candida albicans and Staphylococcus aureus while it downregulated 
the IFN-y responses. On the other hand, the addition of recombinant IL-6, IL-l~ 
and IFN-y did not alter platelet reactivity. Single nucleotide polymorphisms (SNPs) 
known to regulate platelet number, mean platelet volume and function correlated 
with cytokine responses to different pathogens. 
Conclusion: In healthy individuals, platelet number is associated with plasma IL-
l~ levels. There are both functional associations as well as genetic overlap between 
platelet reactivity and cytokine responses. Our findings further show that platelets 
and their reactivity are interrelated with inflammation and immune responses. 
Platelet number and reactivity are associated with immune responses and inflammation 
Introduction 
Platelets are traditionally known for their role in thrombosis and hemostasis. More 
recent evidence highlighted another role for platelets as important effector cells of 
inflammation and host defense (1, 2). Platelets are able to respond rapidly to threats by 
virtue of their large numbers and their ability to release different granules containing a 
diverse array of inflammatory cytokines, growth factors and inflammatory mediators ( 1, 
3, 4). A multitude of platelet surface receptors and integrins mediate these hemostatic 
and inflammatory responses (1, 5, 6). Platelets are also able to interact with and change 
the phenotype of monocytes, lymphocytes and neutrophils (7, 8). Depending on the 
stimuli involved, platelets may enhance or dampen monocyte cytokine responses (9-11). 
Given the role of platelets at the cross-road of hemostasis, innate immunity and 
inflammation, platelet function is likely to influence inflammatory and immune 
responses and vice versa. The extent and direction of these interactions have not been 
well-established. To date, most data were derived from in vitro or animal studies 
[reviewed in (1, 2, 6)], and from clinical studies in patients with infections (12-14) 
or chronic inflammation (15-18). Whereas the level of platelet reactivity is consistent 
over time within an individual (19-22), it varies considerably between individuals 
and is determined by both genetic and non-genetic factors(19-26). The same applies 
to the capacity to produce cytokines (27). Studies have identified single nucleotide 
polymorphisms (SNPs) regulating platelet function (28-30) or immune responses (31, 
32) but have not interlinked these two processes. 
Using data from the 500 Functional Genomics (500FG) cohort, which is part of the 
Human Functional Genomics Project (HFGP; www.humanfunctionalgenomics.org), 
we take the first steps to systematically unravel the complex interactions between platelet 
function, inflammation and cytokine responses, and genetic variation. 
In approximately 500 Caucasian healthy individuals, platelet function was assessed by 
whole blood flow cytometry as previously described (33). In short, P-selectin expression 
(a marker of platelet degranulation) and fibrinogen bound to the activated aiib~3 
integrin (a marker for platelet aggregation) were measured after ex vivo stimulation 
of whole blood with adenosine diphosphate (ADP) and collagen-related peptide 
(CRP-XL), which is a glycoprotein VI (GPVI)-specific collagen mimetic. We selected 
these agonists due to their major role in platelet activation and representation of two 
distinct pathways: an early signaling of platelet activation through the GPVI receptor 
pathway and a later one through the P2Y1 and P2Y12 receptors (34, 35). Platelet 
count, plasma concentrations of the platelet a-granule protein ~-thromboglobulin (~­
TG), the plasmatic coagulation marker thrombin-antithrombin complex (TAT), and 
inflammatory cytokines and adipokines were also measured. Immune responses were 
assessed by measuring cytokine concentrations in whole blood and supernatant of 
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isolated peripheral blood mononuclear cells (PBMCs) to a range of synthetic, bacterial 
and fungal stimuli. 
We first explored associations between platelet count, platelet reactivity, and TAT levels 
with a range of non-genetic host factors, inflammatory markers and cytokine responses. 
Significant correlations between platelets and cytokine responses were confirmed in 
separate laboratory experiments. Next, we investigated associations between known 
platelet SNPs with cytokine responses, and vice versa, between known cytokine SNPs 
with platelet reactivity. Finally, we examined the overlap of platelet SNPs with human-
disease-associated SNPs. 
Results 
Characteristics of participants, platelet parameters and correlation with non-genetic host 
factors 
Data from a total of 489 healthy participants from the 500FG cohort were analyzed for 
this study. Characteristics have been published recently (36). The median (IQR) age was 
23 years (21-27 years) and 56% were female. The median BMI was 22.3 (20.7-24.4) 
and 83.1% had a BMI£25. Forty-eight percent of women used an oral contraceptive 
and 13.2% of subjects regularly used tobacco. 
We obtained four measures of platelet reactivity by calculating the area under the 
curve (AU C) of P-selectin expression and platelet-bound fibrinogen in response to ex 
vivo stimulation with 8 increasing concentrations of ADP (P-selectin, APR, n=489; 
platelet-bound fibrinogen, AFR, n=396) or CRP-XL (CPR and CFR, both n=302). 
Representative platelet reactivity curves and data on the distribution of these platelet 
responses are shown in Supplementary Fig. 1. Fig 1 illustrates the correlations between 
platelet count, platelet reactivity measures and plasma concentration of~-TG and TAT. 
As expected, the four readouts of platelet reactivity correlated well with each other, 
with the strongest correlations between those in response to the same platelet agonist. 
Whereas platelet reactivity readouts did not show an association with platelet count, 
there was a positive relation between ~-TG plasma concentrations and platelets count, 
and this was reason to normalize ~-TG levels for platelet mass in further analyses. The 
positive associations between total plasma concentration of ~-TG and APR as well as 
TAT were no longer present after normalizing ~-TG for platelet count. 
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Figure 1. Correlations between platelet and plasmatic coagulation parameters. 
(A) P values of the correlations of platelet and coagulation parameters, corrected for multiple testing using 
the False Discovery Rate (FDR) method. The color legend indicates the range of P values. (B) Scatterplots 
of highly significant correlations &om (A). The red line shows the LOESS fit to the data. PLT count, platelet 
count; APR, ADP-induced P-selectin expression; AFR, ADP-induced platelet-fibrinogen binding; CPR, 
CRP-XL-induced P-selectin expression; CFR, CRP-XL-induced platelet-fibrinogen binding; ~-TG, plasma 
concentration of ~-thromboglobulin; TAT, plasma concentration of thrombin-antithrombin complex. 
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We next tested for associations of platelet parameters with age and a range of 
environmental and intrinsic non-genetic host factors. We did not find significant 
associations between platelet reactivity measures or ~-TG levels with age, gender, BMI, 
sex, oral contraceptive usage, smoking and vitamin D concentrations. In contrast, 
females had a significantly higher platelet count than males with median (interquartile 
range, IQR) values of280 (218-352) x 109/L vs. 251 (201-319) x 109/L (P=0.002), an 
observation previously reported by Biino et al (37). Oral contraceptive use is known to 
activate coagulation (38, 39) and females using oral contraceptives (n=155) indeed had 
higher TAT levels (3963 pM, 2526-5597 pM) compared with females not using oral 
contraceptives (n=l66) (2824 pM, 1941-4215 pM; P<O.OOOl) and males (2640 pM, 
1856-4235 pM; P<O.OOOl) in our study (Supplementary Fig. 2). 
Associations of platelet and coagulation parameters with circulating cytokines, acute phase 
proteins and adipokines 
We examined the interrelationship between platelet function and circulating 
concentrations of cytokines (IL-l~, IL-6, IL-lRA and VEGF-A), acute phase proteins 
(C-reactive protein, CRP, and alpha-1-antitrypsin, AAT) and adipokines (leptin and 
adiponectin) (Fig 2). We found a strong positive association between platelet count and 
the pro-inflammatory cytokine IL-1~, but not with IL-6, IL-lRA and VEGF-A (Fig 
2A). Concentrations of these inflammatory cytokines also did not correlate with platelet 
reactivity and TAT levels. Both AAT and adiponectin levels were strongly positively 
correlated with ~-TG/ 106 platelets, and to a lesser extent with platelet reactivity (Fig 
2B). In contrast, AAT and adiponectin were negatively correlated with platelet count. 
Among the parameters measured, only TAT showed association with CRP level. 
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Figure 2. Correlations of circulating inflammatory mediators with platelet parameters and 
TAT. 
(A) Pvalues (FDR corrected) of correlations of circulating cytokines with platelet parameters and TAT as 
well as scatterplot of the correlation between IL-113 and platelet numbers. (B) P values (FDR corrected) 
of correlations of acute phase proteins (high sensitive C-reactive protein, hsCRP, and alpha-1-antitrypsin, 
AAT) and adipokines (leptin and adiponectin) with platelet parameters and TAT as well as scatterplot 
of the most significant correlations. The color legend indicates the range of P values. The red line shows 
the LOESS fit to the data. PLT count, platelet count; APR, ADP-induced P-selectin expression; AFR, 
ADP-induced platelet-fibrinogen binding; CPR, CRP-XL-induced P-selectin expression; CFR, CRP-
XL-induced platelet-fibrinogen binding; 13-TG/PLT, 13-thromboglobulin/106 platelets; TAT, plasma 
concentration of thrombin-antithrombin complex. 
Platelet reactivity is associated with cytokine responses 
To capture the relationship between platelet reactivity and cytokine responses of 
immune cells, we measured and analyzed the production of the monocyte derived (IL-
l~ and IL~6) and lymphocyte-derived cytokines (IFN~y) after ex vivo stimulation of 
whole blood and peripheral blood mononuclear cells (PBMCs) with the following five 
stimuli: two purified s-ynthetic microbial ligands: LPS or Pam3CSK4; two bacterial 
stimuli: Escherichia coli and Staphylococcus aureus; and one fungal stimulus: Candida 
albicam conidia. This resulted in the analyses of a total of 21 cytokine measurements 
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for each of the participants in this study. We also tested the associations between the 
cytokine responses of PBMCs and platelet reactivity because previous experiments by 
our group revealed that isolated PBMC pellets still contain considerable numbers of 
platelets (data not shown). 
In whole blood, we found an inverse association of platelet reactivity to CRP-XL and 
IFN-y responses to S. aureus and LPS (Fig 3A). ~-TG levels also showed and inverse 
association with the IFN-y response to S. aureus, and TAT levels an inverse association 
with IFN-y responses to LPS and C. albicans. In contrast, platelet reactivity to ADP was 
positively associated with IL-6 responses to C. albicans and S. aureus in whole blood 
and with LPS- and E. coli-induced IL-l~ and IL-6 responses and Pam3CSK4- and S. 
aureus-induced IL-6 responses in PBMC isolates. In addition, ~-TG showed a positive 
association with LPS-induced IL-6 and E. coli-induced IL-l~ responses. Representative 
scatter plots are depicted in Fig 3B-C. 
Next, we validated these observations of an opposite association of platelet reactivity 
with IFN-y and IL-l ~/IL-6 cytokine responses in a set of in vitro experiments. We 
incubated isolated PBMCs with LPS, E. coli, C. albicans and S. aureus in the presence 
and absence of isolated washed platelets. The need for direct cell to cell contact was 
assessed by using a transwell system. In line with the observations from our cohort, 
the addition of platelets decreased IFN-y production in response to C. albicans and S. 
aureus, whereas IL-l~ and IL-6 responses to all stimuli were significantly increased (Fig 
3D). Physical separation of PBMC and platelets reversed these cytokine-modulating 
effects of platelets. 
We also investigated whether direct effects of cytokines on platelet function contributed 
to the observed interrelationship of cytokine responses with platelet reactivity in our 
cohort. Platelet-rich plasma (PRP) was incubated with recombinant IL-l~. IL-6 or 
IFN-y and the expression of P-selectin and fibrinogen binding were measured. These 
cytokines did not have any effect on P-selectin expression and platelet-fibrinogen 
binding with or without additional ADP and CRP-XL stimulation (Supplemental Fig 
3). The recombinant cytokines also did not lead to differences in PMC formation (data 
not shown). 
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(A) P values (FDR corrected) of the correlations of peripheral blood mononuclear cells (PBMCs) and 
whole blood cytokine responses with platelet parameters and TAT. The color legend indicates the range of 
Pvalues. (B) Scatterplots of the highly significant correlations of whole blood cytokine responses from (A). 
(C) Scarrerplots of the highly significant correlations of PBMC cytokine responses from (A). The red line 
shows the LOESS fit ro the data. (D) PBMCs were co-cultured for 24 h with isoiated washed piateiets and 
Pam3CSK4 or LPS with or without physical separation of platelets and PBMC using a Transwell system. 
Interleukin (IL-)1- ~' IL-6 and IFN-y concentrations were determined in the culture supernatant. Platelets 
were added in a ratio of 150 platelets for every PBMC. Presented data are means with standard error of the 
mean (SEM) from 6 healthy donors.* P < 0.05, ** P < 0.01, *** P < 0.005. 
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Genetic relationship with platelet parameters 
There is a marked and reproducible variation in platelet number and reactivity between 
individuals and genetic association studies have identified an ever growing number of 
SNPs that modifY these platelet parameters (30, 40, 41). We aimed to associate genetic 
variations that determine platelet parameters with cytokine responses and vice versa. 
Genotyping in our cohort was performed using Illumina HumanOmniExpressExome 
SNP chip and was imputed to obtain genotypes at ~ 7 million SNPs. We first tested 
association of ~4 million SNPs, showing a minor allele frequency ~5%, with platelet 
count, platelet reactivity to ADP and CRP-XL (APR, AFR, CPR, CPR), PMC 
formation, plasma 13-TG and TAT complexes. No significant genome-wide associations 
for any of these parameters were found with the exception of one novel significant 
quantitative trait loci (QTL) for TAT complexes (rs1149961; P < 5 x 10-~; Fig 4A). 
Next, we examined the associations ofSNPs that were identified in previous studies with 
platelet traits in our cohort. A list of 133 SNPs was made, including those implicated 
in platelet number (29, 42-45), platelet reactivity (23, 28, 30, 46-48) and mean platelet 
volume (MPV) (29, 42, 49). Even though the latter parameter was not measured in 
our cohort, it was included as platelet size is related to the number of integrins on 
the platelet membrane (23, 42) and genetic variance in MPV was also associated with 
platelet reactivity (29) . 
Seventy-four SNPs were detected in our cohort and 30 (41 o/o) of these showed at least 
one suggestive association with platelet reactivity, platelet number PMC formation 
or 13-TG (Fig 4B) . We not only replicated a number of prior associations, but also 
identified a variety of novel associations. The strongest associations with platelet 
reactivity were with SNPs in the genes encoding the surface proteins glycoprotein VI 
(collagen receptor; GP6), ADP receptor P2Yl (P2RY1), platelet endothelial aggregation 
receptor 1 (PEARl) and in the gene]M]DlC As expected, rs1613662 and rs1671152 
in GP6 were positively associated with CRP-XL-induced reactivity, while rs3755711 
and rs701265 in P2RY1 inversely with ADP-induced reactivity. In contrast, significant 
associations with reactivity to both ADP and CRP-XL were found for rs11264579 in 
PEARl and rs10761741 and rs2393967 in ]M]DlC, supporting previous data (30) 
that these loci function in a relatively agonist-independent manner. PEARl is involved 
in the amplification of allbl33 activation in a P13K-dependent manner (50) whereas 
]M]Dl C encodes a histone demethylase and plays a role in megakaryocyte development 
and function (51, 52). 
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Figure 4. Manhattan plot showing the genome-wide QTL mapping result and associations 
between platelet SNPs and platelet parameters. 
(A) Manhattan plot showing the mapping result for thrombin-antithrombin complex (TAT). (B) The color 
legend indicates the range of P values. P values were obtained from linear regression model of platelet 
parameters on genotype data. MPV, mean platelet volume; CP, collagen-induced P-selectin expression; CF, 
collagen-induced platelet-fibrinogen binding; AP, ADP-induced P-selectin expression; AF, ADP-induced 
platelet-fibrinogen binding; WB FACS, whole blood flow cytometry. 
Genetic relationship between platelet parameter and cytokine responses 
Next, we examined whether these 30 platelet SNPs in our cohort were associated with 
whole blood and PBMC cytokine responses. Twenty-two SNPs showed at least marginal 
association (p<0.05) with one or more cytokine responses and five (rsl0761741, 
rs6734238, rs3 794153, rs3091242 and rs 11602954) had more than five associations (Fig 
5A). SNPs in the genes GP6 and P2YRI, which had strong associations with reactivity 
to CRP-XL and ADP, respectively, were not associated with cytokine responses with 
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the exception of a marginal association of rs3755711 in P2YRJ with IL-17 responses 
to Mycobacterium tuberculosis. In contrast, rsl0761741 in]M]DJC showed a variety of 
associations with PBMC and whole blood cytokine responses. In PBMC stimulations, 
the minor allele in this SNP was negatively associated with IFN-y (to Borrelia burgdoiferi 
and Bacteroides) and IL-22 (to B. Burgdoiferi, Bacteroides andM tuberculosis) responses, 
and positively associated with IL-6 (to CpG and polyiC) and TNF-a (to S. aureus and 
Pam3CSK4) responses. In whole blood stimulations, negative associations were found 
for IFN-y, ILl-band TNF-a responses to Candida. In contrast, rs2393967 in]M]DJC 
and rsl1264579 in PEARl, which were also relatively strongly associated with platelet 
reactivity, only showed marginal association with TNF-a responses to Pam3CSK4, S. 
aureus (both PBMC) and Candida (whole blood, rs2393967) and IL-6 to S. aureus and 
IFN-y to Cryptococcus (rsll264579). 
Of the other four SNPs with more moderate platelet effects, but with more than five 
cytokine associations, the strongest associations with cytokine responses was found for 
rs6734238 (ILJFJO!!LJRN) region. This SNP is located downstream of ILJFJO and 
upstream of ILJRN (53), an inflammatory gene region of the interleukin-1 cytokine 
gene family (54), and had been associated with C-reactive protein (CRP) levels (55, 56). 
Recently, this variant was reported to be associated with mean corpuscular hemoglobin 
and leukocyte and platelet number (29). In our cohort, rs6734238 was associated with 
plasma ~-TG levels, but also with reduced IFN-y, IL-17, IL-22, IL-1~, IL-6 and TNF-a 
responses to the differentligands in PBMC and whole blood. The ST5 variant rs379415 3, 
which had previously been associated with platelet count (29), was associated with APR 
in our cohort and had overlapping multiple positive associations with IL-l~' TNF-a 
and IFN-y responses. ST5 regulates the activation of MAPKI/ERK2 (57), which is 
known to play important role in both immune responses (58) and platelet activation 
(59). rs3091242 in TMEM50A has previously been related with platelet number (29) 
and was associated in our cohort with APR This SNP was associated with IFN-g/IL-22 
and ILl-~/TNF-a which were largely in the opposite direction. Finally, rsl1602954 in 
BETJL was positvely associated with multiple cytokine responses. 
Recently, we reported different SNPs related with cytokine responses in our cohort 
(60). We therefore tested whether these cytokine SNPs were also associated with platelet 
responses in our cohort (Fig 5B). Multiple associations with platelet traits were found. 
Notably, rsl0908219, located near FGF19, FGF4, and FGF3, was positively associated 
with ADP and CRP-XL-induced allb~3 integrin activation whereas rs4491463 was 
negatively associated with ADP-induced aiib~3 integrin activation and levels of 
~-TG. We also found several other cytokine SNPs associated with a single platelet trait. 
rs4496335 near ILIRN had previously been associated with IL-lRA levels (61), while 
rs6834581, rsl0108108, rsl0908219, rs4491463 and rs7256586 were shown to be 
associated with a cytokine responses to a range of different pathogens (60). 
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Figure S. SNPs associated with overlapping platelet traits and cytokine responses in whole 
blood and PBMCs. 
(A) The P values of the associations of cytokine responses with platdet SNPs and P values were from linear 
regression analysis of cytokine responses on genotype data. (B) The P values of the associations of platelet 
parameters with cytokine SNPs. P values were from linear regression analysis of platelet parameters on 
genotype data. The color legend indicates the range of Pvalues. 
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Platelet SNPs overlap with SNPs associated with immune-mediated disea-
ses 
We tested whether SNPs that were previously associated with human diseases, particularly 
with immune-mediated diseases, are enriched with platelet SNPs. We extracted GWAS 
SNPs from the National Human Genome Research Institute GWAS catalog (62) and 
binned them into eight categories on the basis of their association with different human 
phenotypes (Online Methods). Next we identified all SNPs that were associated with 
platelet levels at P < lxl0-4 and tested whether they are also GWAS SNPs or their 
proxies (r2 >0.8). We found that 0.15% of immune-mediated disease-associated SNPs 
were also associated with platelet traits (Fig 6). 
IAalatloliQ traits 
T2D related traits 
Hearl-i'tllaled nails 
0.0000 0.0005 0.0010 
~orSNPswilll piiOTL 
Threshold=l0-4 
Figure 6. Platelet SNPs overlap with SNPs associated with immune-mediated diseases. 
The percentage of SNPs associated with each category of disease that also qualified as platdet SNPs. 
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Discussion 
In the present study, we explored the interactions between platelet function, inflammation, 
cytokine responses, and genetic variation by assessing these elements together in a 
cohort of approximately 500 healthy individuals. We found that platelet count was 
strongly associated with IL-113 concentrations, but not with other cytokines. Platelet 
reactivity correlated inversely with ex vivo IFN-y responses, aT cell-derived cytokine, 
and positively with IL-113/IL-6 responses, which are monocyte-derived cytokines. We 
were able to validate these opposite associations in a set of ex vivo experiments, whereby 
platelets attenuated IFN-y responses to C. albicans and S. aureus, and increased IL-113/ 
IL-6 responses to the aforementioned stimuli, E. coli and LPS. The effects of platelets on 
cytokine responses were dependent on direct contact between platelets and PBMCs. On 
the other hand, recombinant IFN-y, IL-113 and IL-6 did not alter the platelet expression 
of P-selectin or activation of the allbb3 integrin. Consistent with these findings were 
genetic associations of variants in genes related with platelet function and cytokine 
responses. There was a substantial overlap of the associations between previously-
reported platelet SNPs with both platelet traits and cytokine responses. We also found 
associations between cytokine SNPs and platelet traits, and that platelet SNPs intersect 
with SNPs of immune-mediated diseases. 
Platelet count was strongly associated with circulating IL-113 levels, but not with other 
cytokines, suggesting that platelets either contributed significantly to the amount of 
circulating IL-113 or that IL-l~ drives platelet production. IL-113 is an inflammatory 
cytokine which is mainly produced by monocytes, macrophages, and dendritic cells 
(63). Platelets were known to harbor and release mature IL-113 upon activation (64, 
65), but their contribution to circulating IL-113levels is unknown (66). Megakaryocytes 
also respond to IL-113 by increasing platelet production (67-69) through the increase in 
thrombopoietin and transcription factors (70). They were also shown to secrete IL-113 
as a positive feedback loop for megakaryopoiesis (71). Our results further show that in 
vivo, platelet numbers and plasma IL-113 are interrelated even in a non-inflammatory, 
non-infectious setting. 
Previous ex vivo laboratory studies have determined the effects of platelets on cytokine 
responses (9, 11, 72-74). This present study adds by further showing, in our cohort of 
healthy individuals, the in vivo differential associations of platelet reactivity with IFN-y 
and IL-113/IL-6 responses to various synthetic and bacterial ligands. To the best of our 
knowledge, the opposing effects of platelets on the monocyte-derived and T-cell-derived 
cytokines have not been reported previously. There are several possible mechanisms that 
can explain the associations between platelet reactivity and cytokine responses. First, 
more reactive platelets may interact more strongly with PBMCs in our ex vivo system. 
Platelets are present in isolated PBMCs preparation and their complete elimination is not 
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possible (9). Both IL-6 and IL-l~ are cytokines synthesized in a nuclear factor-kappa B 
(NF-kB)-dependent pathway (75-77). The interaction between P-selectin and monocyte 
P-selectin glycoprotein ligand (PSGL)-1 triggers nuclear translocation of NF-kB and 
activation of the NF-kB-dependent inflammatory genes (72, 73), and this mechanism 
likely contributes to the increased in vitro IL-l ~/IL-6 responses of PBMCs with the 
addition of platelets, as also previously found by our group (9). The second mechanism 
may be that more reactive platelets secrete more immune-modulating proteins. Platelet 
microparticles could prevent the differentiation of peripheral blood-derived regulatory 
T cells into IL-17- and IFN-y-producing cells, and as such inhibit IL-17 and IFN-y 
production (78). Activated platelets may also secrete IL-l~ generated from intraplatelet 
pre-mRNA that undergoes post-transcriptional splicing and translation upon activation 
(64, 65), which may in turn modulate inflammatory response in leukocytes (65). IFN-y 
inhibits IL-l~ at the level of transcription (79) and suppresses IL-l production and 
infection-induced immunopathology through the inhibition ofNLRP3 inflammasome 
(80), both in a nitric oxide (NO)-dependent manner. IFN-y may also attenuate the 
binding of NF-kB to the IL-l~ promoter independently of NO (81). The observed 
opposite modulatory effect on cytokine responses by platelets in our study may be 
a result of this counter-regulatory activity. Our in vitro findings that recombinant 
cytokines failed to induce changes in platelet reactivity were similar to that of Brown 
et al., whereby IL-1~ pre-treatment did not potentiate platelet reactivity to ADP and 
CRP-XL (66). IL-l~, similar to LPS, is known to be an atypical agonist that failed to 
promote platelet degranulation that increases surface P-selectin expression or platelet-
fibrinogen binding (66, 82). 
The third mechanism that may explain the association between platelet reactivity and 
cytokine response is the genetic overlap between these functions. Indeed, we found 
substantial overlap of our platelet SNPs with cytokine responses, indicating a shared 
genetic influence on regulatory and functional mechanisms among the different cells. 
Previously, platelet SNPs were already found to overlap with erythrocytes, leukocyte and 
lipid traits (29). We found that SNPs in the platelet surface receptors GP6, P2Y12 and 
PEARl that were strongly associated with platelet reactivity, displayed no or only weak 
overlapping associations with cytokine responses. In contrast, ]M]D 1 C showed strong 
associations with platelet reactivity and a range of associations with PBMC and whole 
blood cytokine responses, which may be due to its effect on gene expression. ]M]D 1 Cis 
involved in epigenetic regulation, probably through histone demethylation (83), and in 
androgen receptor-mediated transcription (84). This gene plays a role in megakaryocytes 
proliferation (51) and has also been associated with leukocyte (85) and platelet count, 
MPV and platelet reactivity (28), indicating its multilineage effects on hematopoiesis. 
To our knowledge, variations in these aforementioned genes have previously not been 
related to immune function. 
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Other SNPs with more modest associations with platelet function overlapped with broader 
cytokine responses, indicating their more dominant role in the inflammatory pathways 
as these SNPs were located in genes which were known to regulate immune properties 
or pathway: the ILIFJOIILIRN region, ST5 and TMEM50. The ILIFIOIILIRN 
region for example, had been associated with several inflammation-related biomarkers, 
including CRP, IL-lRA, and fibrinogen (86-88). ILIFIO encodes IL-38 which inhibits 
Thl7 immune responses and stimulates IL-6 cytokine production in vitro (89). ILIRN 
encodes IL-l receptor antagonist (IL-l RA), which regulates diverse interleukin-1-related 
immune and inflammatory responses, as it prevents receptor binding of either IL-l a or 
IL-l~ (63). ST5 encodes for the protein activating MAPK11ERK2 (57), which regulates 
cytokine production via both transcriptional and post-transcriptional mechanisms (90). 
Interestingly, the TMEM50A variant was also associated with opposite directions of 
IFN-y/IL-22 and IL-113/TNF-a responses, which mirrored the functional associations 
between platelet reactivity and opposite IFN-y and IL-l ~/IL-6 responses. TMEM50A, 
located at the RH gene locus, is a gene of unknown function and was described as 
showing homology to an open reading frame on chromosome 21, which is an IFN/IL-
10 receptor gene cluster (91, 92). In support of our findings that platelet function and 
cytokine responses overlap each other at the functional and genetics level, we found that 
approximately 0.15% of immune-mediated disease-associated SNPs were also platelet 
SNPs. It is plausible that SNPs with overlapping traits are pleiotropic genetic variants, 
in which the single gene or genetic variant have independent effects on platelets and the 
inflammatory response. Locus level views of overlapping trait scans already suggested 
extensive pleiotropy in some platelet-related regions such as ABO, SH2B3, HBSIL (41). 
The limitations in this study include the unavailability of MPV as an outcome measure 
and that CRP-XL-induced platelet reactivity was only measured in 302 individuals. 
Furthermore, our conclusions on the interaction between platelets and cytokine 
responses are derived from separate measurements; in vivo platelet reactivity and platelet 
counts were assessed once blood was drawn whereas cytokine responses were measured 
after 24h, 48h and 7 days of incubation with various stimuli. This study did not examine 
the associations of SNPs from other studies which are rare frequency allele and were not 
present in this cohort. Lastly, our study was unable to demonstrate whether the SNPs 
with overlapping platelet and cytokine associations were pleiotropic variants. 
In conclusion, we found that platelet counts are associated with plasma IL-113 levels. 
We also showed both functional associations as well as genetic overlap between platelet 
reactivity and cytokine responses. The overlap of SNPs regulating platelet traits and 
cytokine responses further shows that platelets and their reactivity are interrelated with 
the inflammatory and immune response. Additionally, pleiotropic SNPs may provide 
important dues to the new pathways and functions of genes in inflammation beyond 
their recognized role in shaping the platelet traits. Future studies would be required to 
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address the functional and genetic mechanisms by which circulating IL- l~ is associated 
with platelet numbers, as well as novel pathways regulating inflammation and platelet 
function. 
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Supplemental Figure 1. Representative plot of the platelet reactivity curve and histograms 
of the platelet and coagulation parameters. 
(A) Sample curves of ADP-induced P-selecrin expression on platelets, as measured by whole blood flow 
cytometry and depicted as median fluorescence intensity (MFI). (B) Histograms showing distributions of 
the platelet and coagulation parameters. All values of the platelet and coagulation parameters were loglO 
transformed. Normality of the distribution was tested using Shapiro-Wilk test for normality with a cut-off 
of P<0.05. 
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(A) The Pvalues (FDR corrected) of the correlations between platelet and coagulation parameters with age, 
BMI, sex, oral contraceptive usage, smoking and vitamin D concentrations. The color legend indicates the 
range of P values. (B) Comparisons of plasma levels of thrombin-antithrombin complex in subjects with 
and without oral contraceptive use. 
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Supplemental Figure 3. Platelet activation and reactivity after stimulation with ADP or 
CRP-XL were not affected by recombinant IL-l~, IL-6 and IFN-v. 
Platelet-rich plasma (PRP) from healthy donors was pre-treated with medium, recombinant IL-l~, IL-6 
and IFN-y (100 ng/rnl) for 60 minutes in 37"C and subsequently stimulated with the platelet agonists 
adenosine diphosphate (ADP; 7.8 and 31 f!M) and collagen-related peptide (CRP-XL; 39 and 625 f!M). 
The median fluorescence intensity (MFI) of the platelet surface expression of P-selectin and platelet-
fibrinogen binding was measured by using flow cytometry. Data are presented as means with standard error 
of the means (SEM) from 6 healthy donors. 
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Methods (online supplement) 
Study population 
Ethics statement 
The 500FG study was approved by the Ethical Committee of Radboud University 
Nijmegen (NL42561.091.12, 2012/550). Inclusion of volunteers and experiments were 
conducted according to the principles expressed in the Declaration of Helsinki. Samples 
of venous blood were drawn after written informed consent was obtained. 
Cohort description 
The 500 Functional Genomics (500FG) study was performed in a cohort of 534 healthy 
individuals of Caucasian origin and is part of the Human Functional Genomics Project 
(HFGP). The volunteers were sampled between July 2013 and December 2014 at the 
Radboud university medical center. The Netherlands. Inclusion criteria were age> 18 
years and Western-European descent. Exclusion criteria were pregnancy/breastfeeding, 
chronic or acute disease at the time of sampling, and use of any medication in the last 
month before the study. 
Measurements of platelet function and coagulation activation 
Platelet reactivity 
Venous blood was collected in citrated Vacutainer tubes (3.2% sodium citrate; Becton 
Dickinson, USA). Platelet reactivity was determined by a whole blood flow cytometry 
assay that had been described earlier (33, 93). In short, the platelet membrane expression 
of the alpha-granule protein P-selectin and the binding of fibrinogen to the activated 
integrin aiib~3 are measured in unstimulated samples and after ex vivo platelet 
stimulation by 8 increasing concentrations of adenosine diphosphate (ADP, 7.8-125 
IJ.M, Sigma-Aldrich, USA) or crosslinked collagen-related peptide (CRP-XL, 9-625 ng/ 
ml, kind gift from Pro£ dr. R. Farndale, Cambridge, UK). Whole blood was added 
to a mixture of HEPES-buffered saline and saturating concentrations of PE-labeled 
anti-CD62P (P-selectin; Bio-Legend, San Diego, USA), FITC-labeled anti-fibrinogen 
(DAKO Ltd., High Wycombe, UK) and PC7-labeled anti-CD61 (platelet identification 
marker; Beckman Coulter, France) . After 20 minutes incubation at room temperature, 
0.2% paraformaldehyde was added and samples were analyzed using a FC500 flow 
cytometer within 4 hours (Beckman Coulter, France). Platelets were gated based on 
their forward- and sideward-scatter properties and positivity for CD61, which was 
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defined as a median fluorescence intensity (MFI) exceeding the that of the matched 
isotype control; 10 000 single platelets were measured in each sample. Next, ADP- and 
CRP-XL-induced platelet P-selectin (termed as APR and CPR) and platelet-fibrinogen 
reactivity to either ADP or CRP-XL (termed as AFR and CFR) were determined by 
calculating the area under curve from the MFI of CD62P or fibrinogen on CD61-
positive events generated from the 8 increasing concentrations of ADP or CRP-XL. 
Platelet-monocyte complexes 
The formation of PMC, which is considered a sensitive marker for platelet activation 
(94) was determined by incubating citrated whole blood with PC7-labelled anti-CD61 
and PE-labelled anti-CD14 [a glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein; Bio-Legend] as a monocyte identification marker. Optilyse B (Beckman 
Coulter, USA) was added after 30 min followed by distilled water. The PMC formation 
was quantified based on the MFI ofCD61 on C014-positive cells. 
6-thromboglobulin and thrombin-antithrombin complexes 
Plasma concentrations of the platelet a-granule protein, 13-thromboglobulin (j3-TG), 
a plasma soluble marker for platelet activation, and thrombin-antithrombin (TAn 
complexes, a marker for coagulation activation, from all samples were measured at 
once using ELISA as previously described (95). Human ~-thromboglobulin (MAB393, 
BAF393) was purchased form R&D systems, Abbington, UK, and sheep anti-human 
thrombin (SAHT-AP, SAHT-HRP) antibodies was purchased from Kordia/Affinity 
Biologicals, USA. 
Stimulation of whole blood and peripheral blood mononuclear cells 
Whole blood experiments 
100~ of heparin blood was added to a 48 wells plate and subsequently stimulated in a 
total volume of 500Jll for 48 hours at 3rC and 5% C02• Supernatants were collected 
and stored at -20oC until used for ELISA. 
Peripheral blood mononuclear cell (PBMC) experiments 
PBMC were isolated by density centrifugation of diluted EDTA-anticoagulated blood 
over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in 
saline and suspended in medium (RPMI 1640) supplemented with gentamicin (1 0 
mg/mL), L-glutamine (10 mM) and pyruvate (10 mM). The PBMC were counted 
in a Coulter counter (Coulter Electronics, Buckinghamshire, England) and their 
concentration was adjusted to 5x106/mL. 5x105 PBMC in a total volume of 200JlL 
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per well were stimulated in round-bottom 96-wells plates (Greiner) with the different 
stimuli for either 24 hours or 7 days at 37oC and 5% C02• When cells were stimulated 
for 7 days this was done in the presence of 10% human pooled serum. Supernatants 
were collected and stored in -20oC until used for ELISA. 
ELISA analysis 
Samples of all experiments were measured at once using the following ELISA kits: 
In the 24-hour PBMC stimulation experiments we measured concentrations of human 
IL-113, IL-6 as well as TNF-a (PeliKine Compact or R&D Systems). Supernatants of 
the 7 days stimulation assays were used to measure IL-22, IL-17 or IFN-y (PeliKine 
Compact or R&D Systems). For the whole blood samples IL-6, TNF-a, IL-113 as well 
as IFNy levels were determined (PeliKine used for IL-6 and TNF-a measurements 
(PeliKine Compact or R&D Systems). 
Measurements of circulating mediators and vitamin D 
The circulating mediators hsCRP, leptin, adiponectin, and alpha-1 antitrypsin (AAT) 
were measured in EDTA plasma using the R&D Systems DuoSet ELISA kits following 
the manufactures standard protocol. The plasma cytokines !LIRa were measured using 
R&D Quantikine kits following the manufacturer's standard protocol. Additional details 
are available in the Supplemental Information. 25-hydroxy vitamin D3 was analyzed by 
LCMSMS after protein precipitation and solid-phase extraction. Additional details are 
available in the Supplemental Information. 
Correlation analysis 
Associations for each measurements of platelet count, platelet function and TAT in 
connection with the acute reactive proteins, adipokines, circulating cytokines and whole 
blood/PBMC cytokine responses were analyzed using Spearman correlation coefficient 
in combination with Benjamini-Hochberg correction to account for multiple hypothesis 
testing (significance threshold a~ 0.1). For whole blood samples, cytokine measurements 
were obtained from 456 samples. For PBMCs, samples from 401 and 466 individuals 
were available for cytokine measurements after 1 day and 7 days, respectively. 
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In vitro validation experiments 
Study population and ethics statement 
All studies with human blood samples were conducted in the Radboud University 
Nijmegen Medical Centre and the use of healthy volunteers was approved by the 
institutional ethics review board. All healthy volunteers donated blood samples after 
providing written informed consent. 
Isolation of peripheral blood mononuclear cells (PBMC) and platelets 
PBMCs were isolated from huffY coats isolated from healthy volunteers (Sanquin 
Bloodbank, Nijmegen, the Netherlands) using differential density centrifugation on 
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) and adjusted to 3x106 cells/ml. 
To minimise platelet contamination, the PBMC pellet was washed five times with normal 
saline, which was two additional washing steps in comparison with the commonly-used 
PBMC isolation protocol. The PBMC to platelet ratio after the five washing steps was 
approximately two PBMC to one platelet. PBMC were suspended in culture medium 
(RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA, USA) enriched with 10 11g/ml 
gentamicin, 10 mM L-glutamine and 10 mM pyruvate. 
Washed platelets were isolated by centrifugation of whole blood from healthy volunteers 
anticoagulated with 3.2% sodium citrate (Becton Dickinson, Franklin Lakes, NJ, USA) 
for 15 minutes (min) at 156 g without brake to obtain platelet-rich plasma (PRP). 
PRP was further supplemented with 1/10 acid citrate dextrose (ACD) and centrifuged 
twice at 330 g without brake for 15 min. The pellets were subsequently resuspended in 
HEPES tyrode (HT) buffer with a pH of7.2. Prostacyclin (PGI2) 10 ng/ml was added 
to inhibit platelet activation after the isolation procedure. Platelets were let to rest for 30 
min before being used in the experiments. 
In vitro stimulation assays 
PBMCs (3x 106 cells/ml) were co-cultured with either washed platelets in a PBMC: platelet 
ratio of 1:150 or RPMI in round bottomed 96-well plates (Greiner, Alphen, Netherlands). 
Subsequently, LPS (6 ng/ml), C albicans conidia (106 CFU/mL), and S. aureus (106/ 
mL) were added. The requirement for direct interaction between PBMC and platelets was 
studied using a trans-well culture system (Costar 3413, Corning Life Sciences, Amsterdam, 
The Netherlands) in which PBMC and the stimuli were placed in the lower compartment. 
Lipopolysaccharide (LPS) (Escherichia coli serotype 055:B5) was purchased from Sigma 
and an extra purification step was performed as described previously (96). C albicans 
conidia was heat-killed for 1 h at 100°C. S. aureus (ATCC 25923) was heat killed for 30 
min at 1 oooc. 
Supernatants were collected after 24 h of incubation at 37 ac, unless stated otherwise, 
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and stored at -20°C until cytokine levels were measured. 
Cytokine measurements 
The concentration ofiL-1 ~, IL-6 and IFN-y were measured in cell culture supernatants 
using enzyme-linked immunosorbent assay (ELISA) (IL-113: R&D Systems; IL-6, 
IFN-y: Sanquin), according to the instructions of the manufacturer. 
Platelet reactivity 
Whole blood was collected from 6 consenting healthy volunteers by using venipuncture 
from the antecubital vein into citrate-anticoagulated tubes (3.2%; BD Vacutainer, 
Becton Dickinson). In addition, platelet-rich plasma (PRP) for selected experiments was 
obtained by centrifuging citrated-whole blood (n=6) for 15 minutes at 156 g without 
brake. Isolated PRP was pre-treated with recombinant IL-6, recombinant IL-l~, and 
recombinant IFN-y {10-1 00 ng/ml) at 3rat 37060 minutes in 1.5 ml Eppendorf tubes 
(Eppendorf Biopur, Hamburg, Germany) and platelet reactivity to different platelet 
agonists was subsequently determined by flow cytometry. Pre-treatment was also 
performed with HEPES-buffered saline as control medium. 
Platelet reactivity in PRP samples were determined by flow cytometric quantification 
of the platelet membrane expression of P-selectin (CD62P) and platelet-fibrinogen 
binding. In short, pre-treated samples were added to a mixture ofHEPES-buffered saline 
and saturating concentrations of the following combinations of monoclonal antibodies: 
PE-labeled anti-CD62P (FITC-labeled Bio-Legend, San Diego, USA), FITC-labeled 
anti-fibrinogen (DAKO Ltd., High Wycombe, UK) and PC7-labeled anti-CD61 
(platelet identification marker; Beckman Coulter, France). Platelets were activated with 
ADP (7.8 ~and 31.2 ~), CRP-XL (39 ~and 625j..tM). After incubation for 20 
minutes at room temperature, a fixative solution (0.2% paraformaldehyde) was added 
and samples were analyzed using an FC500 flow cytometer (Beckman Coulter, France). 
Platelets were gated based on their forward- and sideward-scatter (FSC/SSC) properties 
and positivity for CD61, which was defined as a median fluorescence intensity (MFI) 
exceeding the MFI of the matched isotype control. Next, the MFI of CD62P and 
fibrinogen on CD61-positive events were determined. 
Statistical analysis 
For the in vitro experiments, results from 6 biological replicates (n=6 PBMC donors) 
were pooled and dataare provided as mean with standard error of the mean (SEM). 
When values were below the detection limit of the ELISA, the corresponding detection 
limit was used. Differences between groups were analyzed with Student's t-tests. All 
analyses were carried out using Graphpad Prism software (La Jolla, CA, USA). The level 
of significance was set at P< 0.05. 
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Abstract 
Platelets and platelet-monocyte interaction play an important role in inflammation. 
Both pro- and anti-inflammatory effects of platelet inhibition have been reported 
in animal models. This study aimed to investigate the effect of platelets and platelet 
inhibition by the new P2Y12 receptor antagonist ticagrelor on monocyte function, 
as assessed by cytokine responses to Toll-like Receptor (TLR) ligands. In a set of 
in vitro experiments, peripheral blood mononuclear cells (PBMC) incubated with 
the TLR2 ligand Pam3CSK4 produced less cytokines in the presence of platelets, 
whereas platelets increased the production of cytokines when PBMC were exposed 
to TLR4ligand lipopolysaccharide (LPS). These effects of platelets were dependent 
on direct platelet-leukocyte aggregation and for the Pam3CSK4-induced response, 
on phagocytosis of platelets by monocytes. In a double blind, placebo-controlled 
crossover trial in healthy volunteers, a single oral dosage of 180 mg ticagrelor 
reduced platelet-monocyte complex (PMC) formation. This was associated with 
an increase in pro-inflammatory cytokines in blood exposed to Pam3CSK4, but 
a decrease in these cytokines in blood exposed to LPS. These findings show that 
platelets differentially modulate TLR2- and TLR4-mediated cytokine responses 
of PBMC. Through inhibition of platelet-leukocyte interaction, P2Y12 receptor 
antagonists may either exert a pro- or anti-inflammatory effect during infections 
depending on the TLR primarily involved. 
Keywords 
Platelets, ticagrelor, inflammation, Toll-like receptor, platelet-monocyte complex 
Differential effects of platelets and 
platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses 
Introduction 
Platelets are increasingly recognized to constitute an important part of the inflammatory 
response and host defense, apart from their role in hemostasis (1, 2). Activated platelets 
release an array of proteins with immune modulatory properties, including cytokines 
and chemokines, which enhance the activation of leukocytes and/or have a direct 
bactericidal effect (1). Furthermore, activated platelets form complexes with circulating 
leukocytes. This interaction is primarily mediated by the binding ofP-selectin (CD62P) 
on the platelet membrane to its counter-ligand on leukocytes, P-selectin glycoprotein 
ligand-1 (PSGL-1) (3). The formation of platelet-monocyte complexes has been reported 
to enhance the activation status of both leukocytes and platelets (3-7). 
The inflammatory function of platelets and their interaction with monocytes are 
especially interesting in view of the increasing use of platelet function inhibitors in 
prevention of cardiovascular events. The class ofP2Y12 receptor antagonists, such as the 
thienopyridines, clopidogrel, prasugrel and the most recently developed ticagrelor, are of 
special interest because they have been shown to reduce P-selectin expression on platelets 
and as such the formation of platelet-leukocyte complexes (8, 9). Interestingly, in the 
PLATelet inhibition and patient Outcomes (PLATO) trial, the lower overall mortality 
in patients treated with ticagrelor compared to clopidrogrel was partly the result of a 
lower death rate from pulmonary adverse events and sepsis (1 0). 
The effects of platelets and platelet inhibition on the immune response may also depend 
on the type of pathogen involved. Pretreatment of mice with clopidogrel reduced the 
pro-inflammatory response following exposure to the Toll like receptor (TLR)-4ligand 
LPS (11-13), but increased the inflammatory response in an arthritis model in rats 
induced by: the peptidoglycan polysaccharide from group A streptococci, which is 
primarily a TLR2 ligand (14). This suggests that antiplatelet drugs may differentially 
influence the host defence against pathogens that primarily ligate TLR2 or TLR4. 
We hypothesized that differences in platelet responses and platelet-monocyte complex 
formation to TLR2 and TLR4ligands influence the inflammatory response by leukocytes 
and that this also explains the opposing effects of P2Y12 inhibitors on the inflammatory 
responses in the animal studies outlined above. We therefore studied in vitro whether 
platelets differently influence the inflammatory response of monocytes after stimulation 
with TLR2 and TLR4 ligands. We subsequently explored the potential role of platelet 
inhibition in modulating this opposite inflammatory effects. In a randomized placebo-
controlled crossover study, healthy volunteers were exposed to a single dose of ticagrelor 
and ex vivo cytokine production in whole blood stimulated by LPS and the TLR2/TLR1 
ligand Pam3CSK4 challenge were determined in relation to platelet-monocyte complex 
formation. 
63 
Chapter3 
Materials and methods 
In vitro studies 
Isolation of peripheral blood mononuclear cells (PBMC) and platelets 
PBMCs were isolated from EDT A-anticoagulated blood from healthy volunteers using 
differential density centrifugation on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, 
Sweden) and adjusted to 3x106 cells/mi. To minimize platelet contamination, the 
PBMC pellet was washed five times with normal saline. The PBMC to platelet ratio 
after the five washing steps was approximately two PBMC to one platelet. PBMC were 
suspended in culture medium (RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA) 
enriched with 10 f!g/ml gentamicin, 10 mM L-glutamine and 10 mM pyruvate. 
Washed platelets were isolated by centrifugation of whole blood anticoagulated with 
3.2% sodium citrate (Becton Dickinson) for 15 minutes at 156g without brake to 
obtain platelet-rich plasma (PRP). PRP was further supplemented with 1110 acid 
citrate dextrose (ACD) and centrifuged twice at 330g without brake for 15 minutes. 
The pellets were subsequently resuspended in HEPES tyrode (HT) buffer with a pH 
of 7.2. Prostacyclin (PGI2) 10 ng/ml was added to inhibit platelet activation after the 
isolation procedure. Platelets were let to rest for 30 minutes before being used in the 
experiments. Frozen-fragmented platelets (FFP) were obtained by freeze-thawing of 
washed platelets for 3 cycles. Washed platelets, in the concentration of 4.5x108 platelets/ 
ml in RPMI, were subjected to 3 cycles of freeze-thawing to produce frozen fragmented 
platelets (FFP). In selected experiments, FFPs were treated with 10 U/ml RNAse A/T1 
(Invitrogen, Carlsbad, CA) for 1 hour at 3rC. 
In vitro stimulation assays 
PBMCs (3x106 cells/ml) were co-cultured with either washed platelets in a PBMC: 
platelet ratio of 1:150 or 1:50, FFP (4.5xl08 fragmented cells/ml) or RPMI in round 
bottomed 96-well plates (Greiner, Netherlands). After one hour at 3rC, Pam3CSK4 
(6 flg/ml) or LPS (6 ng/ml) were added. Supernatants were collected after 24 hrs of 
incubation at 3rC, unless stated otherwise, and stored at -20oC until cytokine levels 
were measured. 
The requirement for direct interaction between PBMC and platelets was studied 
using a trans-well culture system (Costar 3413, Corning Life Sciences, Amsterdam, 
The Netherlands) in which PBMC and the TLR ligands were placed in the lower 
compartment. Phagocytosis of platelets by monocytes was inhibited by pre-incubation 
ofPBMC with cytochalacin B (1 ~g/ml) at 3rC for 30 minutes. 
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Measurement of cytokine concentrations 
The concentration of pro-inflammatory cytokines in culture supernatant was measured 
using commercially available ELISAs for tumor necrosis factor (TNF)-a and IL-l~ (both 
from R&D, Abingdon, UK) and for IL-6 and interferon (IFN)-y (both from Sanquin, 
Amsterdam, The Netherlands) according to the instructions of the manufacturers. 
Platelet-monocyte complexes (PMC) and TLR2 and TLR4 expression by flow cytometry 
PMC were measured by adding hepes-buffered saline with FITC-labeled anti-CD42b 
(anti-glycoprotein (GP)-lba; Bio-Legend, San Diego, USA) and PE-labeled anti-CD14 
(a glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein; Bio-Legend, San 
Diego, USA) to 50 ul of whole blood (ex vivo study) or the PBMC-platelet cell suspension 
(in vitro studies). After 30 minutes incubation, Optilyse B (Beckman Coulter, Fullerton, 
CA) was added to lyse erythrocytes. Monocytes were identified and gated based on their 
CD14 positivity. Platelet- monocyte complex formation was determined by quantifYing 
CD 14+ cells that were also positive for the platelet identification marker CD42b. For 
the expression ofTLR2 and TLR4 expression on the membrane of monocytes, PBMCs 
were incubated with anti-TLR2-Alexa-488 or anti-TLR4-Alexa-488 monoclonal 
antibodies (eBiosdence, San Diego, CA), respectively and the expression ofTLR2 and 
TLR4 was determined on CD14+ cells. Analyses of all Bow cytometry experiments 
were carried out using a FC500 flow cytometer with CXP software (Beckman Coulter, 
Fullerton, CA, USA) within 1 h. 
Platelet phagocytosis by monocytes 
PRP was incubated with 5 uM ofCellTracker Green 5-chloromethylBuorescein diacetate 
(CMFDA; Life Technologies) for 45 minutes at 3rC for internal labelling of platelets. 
Excess CMFDA dye was removed by washing platelets with PBS and the platelet density 
was adjusted to 4.5xl08 platelets/ml in RPMI. PBMCs were isolated as previously 
described. The CMFDA-labelled platelet solution was co-incubated with PBMC coated 
on a six wells Bat bottom plate in the presence of Pam3CSK4 (6 ug/ml), LPS (6 ng/ 
ml) or RPMI for 90 min at 3rC. Uningested platelets were removed by treating the 
PBMC with 0.5mmol/L EDTA (Versene; Life Technologies) for 30 minutes at 3rC, 
followed by detachment of the PBMCs using PBS. PBMC were pelleted at 200g for 
5 minutes and incubated with PE-labelled anti-CD14 to identifY monocytes and the 
surface platelet marker PC7-labelled anti-CD61. After washing of the PBMCs with 
PBS platelet phagocytosis by monocytes was determined by Bow cytometry. The gating 
strategy was set to separate monocytes with ingested platelets (CMFDN/CD6I-) from 
monocytes with platelets bound to the surface (CMFDN/CD6I+). The percentage of 
phagocytosis was calculated as the proportion of monocytes with ingested platelets in 
the total number of monocytes analyzed. 
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TLR2 and TLR4 mRNA expression 
RNA was extracted from PBMC co-incubated with or without platelets and TLR 
ligands for 4 hrs using TRiwl (Sigma, St. Louis, MO). Chloroform and 2-propanol 
(Merck, Darmstadt, Germany) were used to separate the RNA from DNA and proteins. 
After washing the preparation with 75% ethanol, the RNA was dissolved in 50 ul of 
diethylpyrocarbonate water. Isolated RNA was reverse-transcribed into complementary 
DNA using iScript eDNA synthesis kit (Bio-Rad). Relative expression of RNA was 
determined using the Step-one Plus (Applied Biosystems) real-time PCR apparatus 
with SYBR Green (Applied Biosystems). Real-time quantitative PCR data were 
corrected for expression of the housekeeping gene human B2M The following primers 
were used (5'-3'): GAATCCTCCAATCAGGCTTCTCT (forward) and GCCC 
TGAGGGAATGGAGTTTA (reverse) for TLR2, GGCATGCCTGTGCTGAGTT 
(forward) and CTGCTACAACAGATACTACAAGCACACT (reverse) for TLR4, and 
ATGAGTATGCCTGCCGTGTG (forward) and CCAAATGCGGCATCITCAAAC 
(reverse) for ~2microglobulin (B2M) (Biolegio, The Netherlands). RelativernRNAexpression 
of the target genes were calculated by correcting the Ct-values of respective genes with the 
Ct-value of the housekeeping gene ~2 microglobulin and using the formula of 2 -/).Ctx 1000 • 
Ex vivo study 
Design 
Seven healthy male volunteers, aged 19-26 years who did not use any medication were 
enrolled in a randomized, double blind, placebo-controlled crossover study. The volunteers 
received a single oral dose of 180 mg ticagrelor followed by a placebo two weeks later or 
vice-versa (supplemental data figure 1). Whole blood was collected from the cubital vein 
in citrate and lithium-heparin tube (BD Vacutainer, USA) two hours after administration 
of the study drug. The regional medical ethics committee (CMO Regio Arnhem-
Nijmegen) approved the study protocol, and informed consent was obtained from all 
healthy volunteers. This study was registered at www.clinicaltrials.gov (NCT01996735). 
Whole blood stimulation and platelet-monocyte complex formation 
For the whole blood stimulation, heparinized whole blood was diluted 1:5 with RPMI 1640 
and incubated in 24-well plates for 24 hours at 37oC with 120 ug/ml Pam3CSK4 (EMC 
Microcollections, Ttibingen, Germany) and 100 nglml LPS (E coli serotype 055:B5; Sigma 
Chemical Co. St. Louis, MO), which was used after an extra purification step as previously 
described (15). Cytokines were measured in the culture supernatant by ELISA Platelet-
monocyte complexes were determined by flow cytometry on citrate anticoagulated blood 
before and after one hour of co-incubation with Pam3CSK4 and LPS, as described below. 
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Fluw cytometry-based platelet function test 
Inhibition of ADP-induced platelet reactivity was determined using a flow cytometry-
based platelet function test, of which the details have been described previously (16, 
17). In summary, sodium citrate (3.2%) anticoagulated venous blood was incubated 
with PE-labeled anti-CD62P antibodies and FITC-labeled anti-CD42b antibodies 
(Bio-Legend, San Diego, USA) or FITC-labeled anti-fibrinogen (Dako, Glostrup, 
Denmark) and PE-labeled anti-CD42b antibodies (Bio-Legend, San Diego, USA) and 
two concentrations (7 .8 and 31.2 uM) of the platelet agonist adenosine diphosphate 
(ADP). After incubation for 20 minutes at room temperature, 0.2% paraformaldehyde 
was added as fixative. Platelets were gated based on their forward- and sideward-scatter 
(FSC/SSC) properties and positivity for CD42b and the mean fluorescence intensity 
(MFI) of CD62P and fibrinogen on CD42b positive events was measured. 
Statistical analysis 
Differences in the ex vivo study were analyzed using the Wilcoxon signed-rank tests for 
non-parametric data. For the in vitro experiments, results from three sets of experiments 
(involving n~9 PBMC donors, unless otherwise specified) were pooled and data are 
provided as mean with standard error of the mean (SEM). Differences between groups 
were analysed with Student's t-tests. All analyses were carried out using Graphpad Prism 
software (La Jolla, CA, USA). The level of significance was set at p<0.05. 
Results 
Platelets have opposite effects on cytokine production after stimulation 
with Pam3CSK4 or LPS 
We exposed isolated PBMCs to Pam3CSK4 or LPS for 24 hrs in the presence or absence 
of washed isolated platelets and measured cytokines in the supernatants. While platelets 
significantly increased concentrations of IL-l~ and IL-6 in LPS exposed samples, the 
opposite was found in Pam3CSK4 exposed samples (Figure 1). Addition of platelets to 
Pam3CSK4 exposed PBMCs resulted in a strong and general downregulation of the pro-
inflammatory cytokines IL-l~, IL-6 and TNFa and the anti-inflammatory cytokines 
IL-10 and IL-l receptor antagonist (IL-lRa) (IL-lRa data presented in supplemental 
data figure 2). In addition, LPS stimulation of PBMC in the presence of platelets also 
led to the suppression ofiL-1 0. Pam3CSK4 or LPS did not induce a significant increase 
in IFN-y concentrations (supplemental data figure 2). Addition of platelets to PBMC 
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without TLR ligands or incubation of platelets with LPS or Pam3CSK4 did not lead to 
detectable IL-l~ or IL-6 release. The modulating effects of platelets also did not require 
intact platelets as frozen-fragmented platelets (FFP) elicited the same responses as intact 
washed platelets (supplemental data figure 3). 
Figure 1 
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Figure 1. Differential effects of platelets on cytokine production by peripheral blood mon-
onuclear cells (PBMC) following exposure to Pam3CSK4 or LPS. 
PBMC were co-incubated with LPS or Pam3CSK4 for 24 hrs in the absence and presence of washed platelets. 
The panels show concentrations of the pro-inflammatory cytokines interleukin (IL-) 113, IL-6 and tumor necrosis 
fuctor (TNF)-a and the anti-inflammatory cytokine IL-10 in the culture supernatant. The concentrations are 
expressed as mean with standard error of mean (SEM) from at least 3 experiments using 3 PBMC donors each. + 
50 platelets for every PBMC, ++ 150 platelets for every PBMC. * p < 0.05, ** p < 0.01, *** p < 0.005. 
Role of direct platelet-leukocyte interaction and platelet phagocytosis 
Adhesion of washed platelets to monocytes and platelet phagocytosis were measured 
by flow cytometry after one hour of co-culturing of PBMC with washed platelets in 
the presence of either Pam3CSK4 or LPS. Exposure to Pam3CSK4 resulted in a strong 
increase in platelet adhesion to monocytes and in a significant increase in platelet 
phagocytosis (Figure 2; gating strategies described in supplemental data figure 4), as 
previously described (18). Platelet phagocytosis could be reduced by adding the actin 
polymerization inhibitor cytochalasin B. In contrast, LPS did not lead to a detectable 
increase in PMC formation or in platelet phagocytosis. 
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Figure 2 
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Figure 2. Platelet-monocyte complex (PMC) formation and platelet phagocytosis by monocy-
tes following exposure to Pam3CSK4 or LPS. 
PBMC were co-cultured with washed platelets for one hour in the presence of Pam3CSK4 or LPS. PMC 
formation was determined by flow cytometry and expressed as the mean fluorescence intensity (MFI) of the 
platelet marker CD42b on CD14 positive cells (Panel A). Phagocytosis of platelets by monocytes was also 
determined using flow cytometry, Monocytes with ingested platelets were defined as CD14 positive cells 
that were positive for the internal platelet label CMFDA, but negative for the platelet surface marker CD61 
(Panel B) .. Cytochalasin B was used to inhibit platelet phagocytosis. Data presented are means with SEM 
from at least 3 experiments. Additional details with optical scatter plots of PMC formation and platelet 
phagocytosis are presented in supplemental data figure 4. RPMI, culture medium; WP, washed platelets; 
PBMC, peripheral blood mononuclear cells. * p < 0.05, ** p < 0.01. 
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To study whether inhibition ofPMC formation and platelet phagocytosis would reverse the 
observed changes in cytokine concentrations, we first repeated the PBMC incubation with 
Pam3CSK or LPS in the presence and absence of platelets in a transwell system, in which the 
PBMC and platelets were physically separated. This abolished both the attenuating effects 
of platelets on Pam3CSK4-induced cytokine production and the enhancing effects on LPS-
induced cytokine production (Figure 3A). We next studied the effect of inhibiting platelet 
phagocytosis by monocytes. Cytochalasin B reversed the attenuating effects of platelets on 
cytokine production following Pam3CSK4 stimulation, but did not reverse the stimulating 
effects of platelets upon LPS stimulation (Figure 3B). Cytochalasin B has also been reported 
to prevent platelet activation (19) and inhibition of platelet-monocyte interaction might 
have contributed to the reversal of the platelet-mediated attenuation of cytokine responses 
to Pam3CSK4. However, no reduction in platelet-monocyte interaction was observed using 
cytochalasin B in our in vitro system (supplemental data figure 5). 
Figure 3 
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Figure 3. Changes in IL-113 and IL-6 production by PBMC by physical separation of PBMC and 
platelets and by inhibition of platelet phagocytosis. 
PBMCs were co-cultured for 24 hours with washed platelets and Pam3CSK4 or LPS with or without 
physical separation of platelets and PBMC using a Transwell system (Panel A) or in the presence or absence 
of cytochalasin B, which inhibits phagocytosis (Panel B). Interleukin (IL) 113 and IL-6 concentrations were 
determined in the culture supernatant. Platelets were added in a ratio of 150 platelets for every PBMC. 
Presented data are means with SEM from at least 3 experiments. PBMC, peripheral blood mononuclear 
cells.* p < 0.05, ** p < 0.01, *** p < 0.005. 
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Figure 4. Platelet-induced change in monocyte surface expression and mRNA expression of 
Toll-like receptor (TLR)2 and TLR4. 
PBMC were co-cultured with or without platelets and Pam3CSK4 or LPS for 1 hour. Surface expression 
ofTLR2 and TLR4 on CD1 4 positive cells was measured by flow cytometry. Cytochalasin B was used 
to inhibit platelet phagocytosis (Panel A and B). PBMC were co-cultured with or without platelets and 
Pam3CSK4 or LPS for four hours. TLR2 and TLR4 mRNA expression was determined by real-time PCR. 
The relative TLR2 and TLR4 mRNA expression was calculated by correcting the Ct-values for the Ct-value 
of the housekeeping gene ~2 microglobulin (Panel C) . Presented data are means with SEM from at least 3 
experiments. PBMC, peripheral blood mononuclear cells. ** p < 0.01, *** p < 0.005. 
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Changes in TLR membrane expression and transfer of functional platelet 
RNA 
We next explored mechanisms through which PMC formation and platelet phagocytosis 
modulate cytokine responses to TLR ligands. First, we investigated whether platelet 
binding and phagocytosis changed the expression of TLR2 and TLR4 on monocytes. 
Exposure of PBMC to Pam3CSK4 in the presence of platelets for one hour resulted 
in a significant decrease in TLR2 expression (Figure 4 panel A). In contrast, there was 
no change in TLR4 expression following exposure to LPS in presence of platelets. 
Cytochalasin B reversed the decline of surface TLR2 expression after stimulation with 
Pam3CSK4 (Figure 4 panel B), while there was no change in TLR2 mRNA expression 
(Figure 4 panel C), suggesting that internalization during platelet phagocytosis was 
responsible for the decreased expression. 
Another possible mechanism through which platelets may influence monocyte function 
is the transfer of functional RNA from phagocytosed platelets to monocytes. Frozen-
fragmented platelets were incubated with RNAse AJTI prior to co-culture with PBMC 
and Pam3CSK4 or LPS. This resulted in a complete reversal of the decrease in IL-l~ 
upon Pam3CSK4 stimulation, but it had no effect on IL-6 concentrations (Figure 5). 
RNAse AJTI also had no effect on platelet-induced cytokine production upon LPS 
stimulation. 
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Figure 5 
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Figure S. Effect of degradation of platelet RNA on platelet-induced changes In cytokine 
production by PBMC. 
Frozen-fragmented platelets (FFP) or FFP pre-incubated with RNAse NTl to degrade platelet RNA 
were co-incubated with PBMC and Pam3CSK4 {Panel A) or LPS (Panel B) for 24 hours. IL-1~ and IL-6 
concentrations were measured in the culture supernatant. Presented data are means with SEM. PBMC, 
peripheral blood mononuclear cells. * p < 0.05. 
Ticagrelor has opposite effects on cytokine production in LPS- and 
Pam3CSK4-stimulated whole blood and reduces platelet-monocyte complexes 
P2Y12 receptor antagonists are known to reduce PMC formation and we therefore 
determined the effect of ticagrelor on the observed platelet-mediated immune effects. 
In a cross-over study, seven healthy male volunteers were given a single dose of 180 mg 
ticagrelor or placebo. As expected, intake of ticagrelor resulted in a full inhibition of 
ADP-induced platelet P-selectin expression and platelet-fibrinogen binding (Figure 6A). 
Blood of the volunteers was collected two hours after the administration of placebo or 
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ticagrelor for whole blood stimulation with Pam3CSK4 or LPS and determination of 
PMC formation. Data on LPS stimulation in one volunteer were missing. In agreement 
with the findings from the in vitro experiments above, ticagrelor had opposite effects 
on cytokine production by PBMC (Figure 6B). In six of seven volunteers, ticagrelor 
induced an increase in the concentration of IL-l~ and IL-6 in the supernatant of 
Pam3CSK4 stimulated samples with median (IQR) values increasing from 98.4 pg/ml 
(89.9 to 245.7 pg/ml) to 227.9 pg/ml (179.1 to 867.1 pg/ml; P=0.031) and from 6.0 
ng/ml (2.1 to 29.7 ng/ml) to 21.2 ng/ml (3.5 to 68.4 ng/ml; P=0.016) for ILl~ and 
IL-6, respectively. In contrast, ticagrelor resulted in a reduction in the concentrations of 
these cytokines in LPS stimulated samples with median IL-l~ and IL-6 concentrations 
decreasing from 2,231 pg/ml (1,337 to 2,890 pg/ml) to 1,799 pg/ml (1,039 to 2,289 
pg/ml; P=0.048) and from 59,9 ng/ml (36.4 to 71 ng/ml) to 36,7 ng/ml (28.1 to 53.4 
ng/ml; P=0.035), respectively. 
PMC were measured before and after one hour stimulation. Pam3CSK4 stimulation 
resulted in pronounced PMC formation, with roughly 10-fold higher mean fluoresence 
intensity (MFI) of the platelet marker CD42b on gated monocytes. In contrast, LPS 
stimulation did not lead to a detectable increase in PMC formation. A significant decline 
in PMC formation compared with placebo was observed after ticagrelor in unstimulated 
and Pam3CSK4 and LPS stimulated samples (Figure 6C). 
Figure 6. Ticagrelor-induced changes on ex vivo whole blood cytokine production and PMC 
formation upon stimulation by Pam3CSK4 or LPS. 
Seven healthy volunteers received a single dose of ticagrelor or placebo in a cross over trial. Whole blood 
was taken two hours after intake of ticagrelor or placebo, and platelet reactivity was determined within 30 
minutes of blood drawing. Whole blood was incubated with FITC- or PE-labeled anti-CD42b antibodies 
as platelet identification marker and PE-labeled anti-CD62P (P-selectin) antibodies or FITC-labeled anti-
fibrinogen as markers of platelet degranulation and activation of the fibrinogen receptor, respectively. The 
expression ofP-selectin and platelet-fibrinogen binding following incubation with a low (7.8 uM) and high 
(31.2 uM) concentration of the platelet agonist ADP was determined by flow cytometry (Panel A) Whole 
blood was stimulated for 24 hours by Parn3CSK4 or LPS. Ex vivo IL-l~ and IL-6 were measured in the 
culture supernatant (Panel B). PM C formation was determined by flow cytometry and expressed as the mean 
fluorescence intensity (MFI) of the platelet marker CD42b on CD14 positive cells. PMC was determined 
two hours after intake of ticagrelor or placebo and one hour after start of whole blood stimulation by 
Pam3CSK4 or LPS. Data on LPS stimulation from one volunteer were missing (Panel C). Presented data 
are means with SEM. Asterisks correspond to statistical differences with baseline unstimulated samples. ** 
p < 0.01, *** p < 0.005. 
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Figure 6 
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Discussion 
In the present study, we show that platelets have different effects on the inflammatory 
response by leukocytes, depending on whether TLR2 or TLR4 ligands stimulate the 
cells. Platelets attenuated the production of pro-inflammatory cytokines following 
PBMC stimulation with the TLR2/TLR1 ligand Pam3CSK4, whereas they increased 
production of these cytokines following stimulation with the TLR4 ligand LPS. The 
effects of both stimulants were dependent of direct contact between platelets and 
PBMC. Pam3CSK4 strongly induced PMC formation, in contrast to LPS, and induced 
platelet phagocytosis by monocytes. Phagocytosis of platelets was a necessary step for the 
downregulation of cytokine production in Pam3CSK4-stimulated monocytes. 
The potential clinical relevance of these findings is that platelet inhibition may influence 
the immune response during infections and that the direction of this influence may differ 
depending on the micro-organism and the TLR pathway involved. The P2Y12 receptor 
antagonists have become a cornerstone of antiplatelet therapy for patients with acute 
coronary diseases. In line with the findings from our in vitro experiments, we found that 
ticagrelor administered to healthy volunteers increased pro-inflammatory cytokines in 
whole blood stimulated ex vivo with Pam3CSK4, while it decreased cytokines in LPS-
stimulated blood, along with a reduction in PMC formation. So far, data from clinical 
studies in humans on the effects of P2Y12 receptor antagonists on the susceptibility and 
outcome of infections are limited. Clopidogrel has been reported to increase the risk for 
surgical site infections and bacteremia following coronary artery bypass surgery (20), 
as well as community acquired pneumonia, but its use was also associated with a more 
favorable outcome in pneumonia and sepsis (13, 21). In the PLATO trial, ticagrelor 
was associated with lower mortality following pulmonary adverse events and sepsis 
compared with clopidogrel (10). 
Our observations are in accordance with previous studies demonstrating activation 
of monocytes by interaction with platelets (4, 7, 22, 23). Activated platelets express 
P-selectin, which ligates with monocyte PSGL-1, inducing nuclear translocation of 
nuclear factor-kappa B (NF-kB) and the NF-kB-dependent inflammatory genes (4, 22). 
This mechanism likely contributes to the increased cytokine responses to LPS by addition 
of platelets. The protein CD 14 mediates recognition of LPS by TLR4 and addition 
of recombinant or purified CD 14 in our system might have further increased platelet 
responses to LPS. Whereas LPS failed to induce platelet phagocytosis, Pam3CSK4 
resulted in strong PMC formation and platelet phagocytosis. How Pam3CSK4-
induced platelet phagocytosis leads to downregulation of cytokine production needs 
further study. We found that degradation of platelet RNA by RNAse A/T1 prevented 
the decrease in monocyte cytokine production. Platelets contain a diverse and complex 
mRNA and microRNA repertoire (24) which can be transferred to nucleated cells (18). 
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Which platelet microRNAs or RNA transcripts might be responsible for the general 
downregulation in cytokine production requires additional studies and was beyond the 
scope of our current work. Another possible mechanism was the decrease in surface 
TLR2 expression on monocytes following co-incubation of PBMC with platelets and 
Pam3CSK4. Inhibition of platelet phagocytosis using cytochalasin B prevented this 
decrease in TLR2 expression which makes shielding ofTLR2 by attached platelets less 
likely. Our group previously reported internalization ofTLR2 following phagocytosis 
of conidia of Aspergillus fomigatus (25) and we speculate that internalization of 
TLR2 during platelet phagocytosis is responsible for these observations. Recently, 
Gudbrandsdottir and colleagues (26) also reported that activated platelets have anti-
inflammatory properties. However, opposite to our findings, platelets also reduced 
TNFa production by LPS stimulated monocytes. The fact that thrombin-receptor-
activating peptide (TRAP) was used in their experiments to stimulate platelets may 
explain these seemingly discordant results. 
Our present findings also provide a mechanistic explanation for the seemingly contrasting 
results on the effects of platelets and the use of platelet antagonists on inflammatory 
responses in animal studies. Whereas both thrombocytopenia and clopidrogel therapy 
have been reported to decrease inflammatory responses in response to LPS in mice 
(11-13, 27), clopidogrel increased inflammation to cell wall components of group A 
streptococcus, which ligate TLR2 (14). 
No other P2Y12 inhibitors beyond ticagrelor were included in our study and our 
observation therefore cannot be automatically translated to the other members of 
this class. This is especially relevant since ticagrelor has a dual mode of action through 
inhibition of not only the P2Y12 receptor but also adenosine uptake (28). As adenosine 
is a well-known modulator of inflammation (29), its upregulation via equilibrative 
nucleoside transporter (ENT)-1 inhibition may also have contributed to our observations. 
On the other hand, inhibition of PMC formation, which was a necessary step for the 
platelet-induced effects on cytokine production, has been described for multiple P2Y12 
antagonists (9, 30) and appears to be a class effect ofP2Y12 inhibitors in general. 
The limitations of our study include the relatively low number of healthy volunteers 
who were exposed to ticagrelor and placebo. The crossover design, however, in which 
participants are their own controls allows us to draw statistical valid conclusions with 
such a limited number of participants. Secondly; as mentioned above, no other P2Y12 
inhibitors beyond ticagrelor were used. Thirdly, cytokine responses were determined ex 
vivo in whole blood. While experimental human endotoxemia models are available, in 
vivo challenges using TLR2ligands or other Gram-positive ligands are not available to our 
knowledge. Fourthly, neutrophil activation and platelet-neutrophil complex formation 
were not addressed in our study, principally because IL-6 and Il-l~ are predominantly 
produced by activated monocytes in the circulation. Still, platelet-neutrophil complexes 
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may also influence the host immune response to infections. 
In conclusion, platelets and platelet-leukocyte interaction augment TLR4-mediated 
responses by leukocytes, whereas those mediated by TLR2 are attenuated. Through 
the inhibition of platelet-monocyte complex formation, P2Y12 receptor antagonists 
can either exert a pro- or anti-inflammatory effect in infections depending on the TLR 
primarily involved. 
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Supplemental data figures 
Supplemental data figure 1. 
Washout period 
Placebo 2 weeks Placebo 
Ticagrelor Ticagrelor 
Supplemental data figure 1. Design of the ex vivo study. 
Seven healthy volunteers received a single oral dose of 180 mg ticagrdor followed by a placebo two weeks 
later or vice-versa. 
Supplemental data figure 2. 
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Supplemental data figure 2. Platelet-induced changes in production of interferon (IFN)-gam-
ma and interleukin-1 receptor antagonist (IL-1RA) by peripheral blood mononuclear cells 
(PBMC) upon exposure to Pam3CSK4 or LPS. 
PBMC were co-incubated with LPS or Pam3CSK4 for 24 hrs in the absence and presence of washed 
platelets (ratio PBMC: platdet of 1:50). The panels show concentrations of IFN-y and IL-lRA in the 
culture supernatant. The concentrations are expressed as mean with standard error of mean (SEM) from at 
least 3 experiments using 3 PBMC donors each.** p<O.Ol. 
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Supplemental data figure 3. 
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Supplemental data figure 3. Interleukin(IL)-113 and IL-6 production by PBMC stimulated by 
Pam3CSK4 or LPS in presence of either intact washed platelets or frozen-fragmented plate-
lets (FFP). 
PBMCs were co-cultured for 24 hours with intact platelets or FFP and Pam3CSK4 or LPS IL-113 and IL-6 
concentrations were determined in the culture supernatant. Presented data are means with SEM from at 
least 3 experiments using 3 PBMC donors each.* p < 0.05, ** p < 0.01, *** p < 0.005. 
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Supplemental data figure 4. 
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Supplemental data figure 4. Gating strategy and optical scatter plots for PMC formation 
and platelet phagocytosis (as shown in figure 2). 
Platelets were incubated with CD42b antibodies (for determination of PMC) or CD61 antibodies together 
with the internal platelet label CMFDA (for determination of platelet phagocytosis). PBMCs were co-
incubated for one hour with washed platelets and Pam3CSK4 or LPS. Gating strategy for PMC formation 
with optical side (FS, X axis) and forward scatter (SS, Y axis) plot of PBMC and gating of monocytes 
by CD14 positivity (Panel A). For platelet phagocytosis, monocytes were first gated based on CD14 
positivity. Monocytes with platelets inside were defined as CMFDA positive/PC7-CD61 negative cells; 
while monocytes with surface-bound platelets were identified by being PC7-CD61 positive. Cytochalasin 
B was used to inhibit platelet phagocytosis (Panel B). 
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Supplemental data figure 5. 
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Supplemental data figure S. Cytochalasin B does not modulate PMC formation. 
PBMC were co-incubated with washed platelets for 1 hour in presence or absence of cytochalasin B. PMC 
formation was determined by flow cytometry and expressed as the mean fluorescence intensity (MFI) of the 
platelet marker CD42b on CD 14 positive cells. 
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Abstract 
Sepsis-associated acute kidney injury (AKI) is associated with high morbidity and 
mortality. Excessive platelet activation contributes to AKI through the formation 
of microthrombi and amplification of systemic inflammation. Two phase II trials 
demonstrated that bovine-intestinal alkaline phosphatase (AP) improved renal 
function in critically ill patients with sepsis-associated AKI. In this study, we 
characterized the platelet-inhibiting effects of a human recombinant AP. Whole 
blood and platelet-rich plasma (PRP) of healthy volunteers (n=6) was pre-treated 
ex vivo with recAP, whereafter platelet reactivity to ADP, collagen-related peptide 
(CRP-XL) and Pam3CSK4 was determined by flow cytometry. RecAP (40 VI 
ml) reduced the platelet reactivity to ADP (inhibition with a median of 47%, 
interquartile range 43-49%; P<O.OOl) and tended to reduce platelet reactivity to 
CRP-XL (9%, 2-25%; P=0.08) in whole blood. The platelet-inhibiting effects of 
recAP were more pronounced in PRP both for ADP- (64%, 54-68%; P=0.002) and 
CRP-XL-stimulated samples (60%, 46-71 %; P=0.002). RecAP rapidly converted 
ADP into adenosine, whereas antagonism of the A2A adenosine receptor partially 
reversed the platelet inhibitory effects of recAP. Platelets of septic shock patients 
(n=5), who showed 31% (22-34%; P=0.03) more pronounced reactivity compared 
to healthy volunteers, was completely reversed by recAP treatment. In conclusion, 
we demonstrate that recAP inhibits ex vivo human platelet activation through 
dephosphorylation of ADP and formation of adenosine as its turnover product. 
RecAP is able to reverse the platelet hyperreactivity present in septic shock patients. 
These effects may contribute to the beneficial effects of recAP as a new therapeutic 
candidate for sepsis-associated AKI. 
Keywords: platelet activation, antiplatelet agents, sepsis, acute kidney injury, 
alkaline phosphatase 
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans 
Introduction 
The morbidity and mortality of severe sepsis and septic shock remains high despite 
advances in medical care (1). A frequent consequence of sepsis is the development 
of acute kidney injury (AKI), which increases mortality to >50% and progresses to 
chronic kidney disease in up to one-third of critically ill patients (2, 3). New therapies to 
improve the prognosis of sepsis and sepsis-associated AKI patients are therefore urgently 
needed. An example of a promising novel therapy is the dephosphorylating enzyme 
alkaline phosphatase (AP). AP is a membrane-bound homodimeric glycoprotein of 
which four isozymes are known: placental, germ cell, intestinal, and tissue-nonspecific 
(liver/bone/kidney) (4). In two phase II trials, bovine-derived AP was shown to have a 
renal protective effect in critically ill patients with sepsis-associated AKI (5, 6). 
Subsequently, a human recombinant AP (recAP) was developed with important 
advances over bovine-derived AP in terms of immunity, stability and enzymatic activity 
(7). This novel chimeric enzyme was developed by replacing the crown domain of a 
human intestinal AP with the crown domain of human placental AP. How exactly AP 
exerts its beneficial effects is still incompletely understood. In vitro studies indicate 
that the anti-inflammatory effects of recAP is related to its dephosphorylating activity 
on lipopolysaccharide (LPS), which is involved in the inflammatory cascade observed 
in sepsis patients, and the conversion of the pro-inflammatory molecule adenosine 
triphosphate (ATP) and adenosine diphosphate (ADP) into tissue-protective adenosine 
(4, 8-10). ADP is one of the most potent platelet activators which interacts with the 
P2Y12 and P2Y1 receptors. P2Y12 is the major target of platelet inhibitory drugs 
such as dopidogrel, prasugrel and ticagrelor (11, 12). Platelets themselves also contain 
large quantities of ATP and ADP in dense granules, which are released when they are 
activated. In contrast, adenosine inhibits platelet activation through the A2A and A2B 
adenosine receptor (13). 
Three studies from the late 1980s showed that bovine-derived kidney AP inhibited 
platelet aggregation (14-16), but since then, the platelet-modulating effects of AP has 
not received much attention. Nevertheless, these effects may be relevant as accumulating 
evidence supports a key role for platelets in sepsis and subsequent kidney damage. First, 
excessive platelet activation during sepsis leads to platelet sequestration and platelet-
rich microthrombi, blocking the microcirculation and thereby compromising the 
kidney function. Second, activated platelets release an array of proteins with immune 
modulatory properties that contribute to the amplification of systemic inflammation, 
and form complexes with leukocytes, altering their phenotype (17-19). 
The aims of our study were to investigate the effects of recAP on platelet activation, 
identify involved pathways with special emphasis on ADP and adenosine, and determine 
the effect of recAP on sepsis-associated platelet hyperreactivity. 
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Methods 
Materials 
Human recombinant alkaline phosphatase (recAP) and inactivated recAP were kindly 
provided by AM-Pharma (Bunnik, The Netherlands). Adenosine 5'-diphosphate (ADP) 
was purchased from Sigma-Aldrich (StLouis, MO, USA), cross-linked collagen-related 
peptide (CRP-XL) was a generous gift from Pro£ dr. R. Farndale (Cambridge, UK). 
Pam3CSK4 (N-palmitoyl-S-[2,3-bis(palmitoyloxy)- (2RS)-propyl] -[R]- cysteinyl-[5]-
seryl- [5]- lysyl- [5]- lysyl-[5]-lysyl-[5]-lysine x 3 HCl) was purchased from lnvivoGen 
(San Diego, CA, USA). The A2A adenosine receptor (AR) antagonist ZM-241385 and 
A2BAR antagonist PSB-1115 were purchased from Tocris Bioscience (Bristol, UK). 
HEPES-buffered saline was used as control medium. 
Platelet function assays 
Platelet reactivity 
Whole blood was collected from 6 consenting healthy volunteers for the ex vivo 
experiments by using venipuncture from the antecubital vein into citrate-anticoagulated 
tubes (3.2%; BD Vacutainer, Becton Dickinson). In addition, platelet-rich plasma (PRP) 
for selected experiments was obtained by centrifuging citrated-whole blood (n=6) for 15 
minutes at 156 g without brake, and platelet concentration was adjusted to lxl08/ml. 
Whole blood or PRP was pre-treated with different concentrations of recAP (10-100 U/ 
ml) at 37"C for 45 minutes in 1.5 ml Eppendorf tubes (Eppendorf Biopur, Hamburg, 
Germany) and platelet reactivity to different platelet agonists was subsequently 
determined by flow cytometry. Pre-treatment was also performed with HEPES-buffered 
saline, inactivated recAP (in protein concentration equivalent to recAP) and potato 
apyrase as controls. 
Platelet reactivity was determined by flow cytometric quantification of the platelet 
membrane expression of P-selectin (CD62P) and platelet-fibrinogen binding, which 
correspond with platelet activation and aggregation, respectively, as previously described 
(20, 21). In short, pre-treated samples were added to a mixture ofHEPES-buffered saline 
and saturating concentrations of the following combinations of monoclonal antibodies: 
PE-labeled anti-CD62P (FITC-labeled Bio-Legend, San Diego, USA), FITC-labeled 
anti-fibrinogen (DAKO Ltd., High Wycombe, UK) and PC7-labeled anti-CD61 
(platelet identification marker; Beckman Coulter, France). Platelets were activated 
with ADP (7.8 llM and 31.2 llM), CRP-XL (39 llM and 625 !J.M) or Pam3CSK4 
(60 ug/ml). After incubation for 20 minutes at room temperature, a fixative solution 
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(0.2% paraformaldehyde) was added and samples were analyzed using an FC500 flow 
cytometer (Beckman Coulter, France). Platelets were gated based on their forward- and 
sideward-scatter (FSC/SSC) properties and positivity for CD61, which was defined as a 
median fluorescence intensity (MFI) exceeding the MFI of the matched isotype control. 
Next, the MFI ofCD62P and fibrinogen on CD61-positive events were determined. 
To study the washed-out effect of recAP on platelet membrane proteins, PRP was 
exposed to recAP (40 U/ml) at 3rC for 45 minutes, samples were centrifuged for 15 
minutes at 330 g without brake to pellet platelets, and the supernatant was removed. 
Pelleted platelets were subsequently resuspended in fresh-autologous plasma to its 
original PRP volume and platelet reactivity was determined. In experiments where the 
adenosine receptor antagonists were used, whole blood and PRP was co-incubated with 
ZM-241385 and PSB-1115 (30 IJ.M) for 15 minutes prior to recAP pre-treatment at 
37°C. 
Platelet-monocyte complex formation 
Platelet-monocyte complex formation leads to reciprocal activation of both cells and is 
regarded as a sensitive marker of platelet activation (22, 23). Platelet-monocyte complex 
formation was determined by adding whole blood samples to HEPES-buffered saline 
mixture containing saturating concentrations of PE-labelled anti-CD14 (a glycosyl-
phosphatidylinositol (GPI)-linked membrane glycoprotein; Biolegend) and PC7-
labelled anti-CD61 as monocyte and platelet markers, respectively. After 20 minutes 
of incubation at room temperature, Optilyse B (Beckman Coulter, CA, USA) , a lysing 
solution which also contains 3.4% formaldehyde, was added to lyse erythrocytes. 
Monocytes were gated based on CD14 positivity. Platelet-monocyte complex formation 
was determined by quantifYing the MFI of CD61 on the CD 14-positive cells. 
In our experiments, whole blood was incubated for 45 minutes at 3rC in the presence 
or absence of recAP. Platelets may be pre-activated by ex vivo handling prior to the start 
of the experiments or by the use oflysing buffer. We therefore determined the extent of 
platelet activation in whole blood with or without 45 minutes of incubation in 3 r, and 
whether differential platelet activation occurred when Optilyse B was used as a lysing 
buffer. 
Measurement of purine content 
In a set of control experiments using PRP from 4 healthy volunteers, adenosine, AMP, 
ADP and ATP content was determined by HPLC. In brief, PRP were pre-treated for 
45 minutes in 37 with medium, recAP (40 U/ml) or inactivated recAP (in equivalent 
protein content). Subsequently, platelet activation was induced by incubation withADP 
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or CRP-XL for 20 minutes in room temperature, and samples were centrifuged for 15 
minutes at 330 g without brake to obtain the supernatant. Thereafter, four volumes 
of supernatant (400 f!l) were mixed with 1 volume of chloroacetaldehyde (6x diluted 
in 1M acetate buffer, pH 4.5; Sigma-Aldrich, Zwijndrecht, Netherlands), followed by 
derivatization (60 min, 70 oc, 500rpm) and centrifugation (3 min, RT, 13400 rpm), 
whereafter the supernatant was transferred to a HPLC vial and injected. Purines were 
separated by HPLC system (Thermo Scientific, Illinois, USA) using a Polaris C18-A 
column (150 x 4.6 mm) with gradient elution using eluent A (O.lM KzHP04, 10 
mM TBAHS (pH 6.5), and 2o/o MeOH) and eluent B (H20 : ACN: THF; 50:49:1) . 
Retention times were 7.1 (adenosine), 8.4 (AMP), 12.5 (ADP), 16.2 (ATP) and 14.8 
min (cAMP). Quantification was based on peak areas of the samples and reference 
standards measured with fluorescence (excitation and emission wavelengths set at 280 
and 420 nm, respectively). 
Ex vivo study of sepsis patients 
A total of five patients with septic shock according to the definitions stated by ACCP 
and SCCM consensus conference (24) admitted to the Intensive Care Unit of the 
Radboud university medical center (Radboudumc) were enrolled between July 2014 
and February 2015. Exclusion criteria were the use of any medication which could 
affect platelet count and function. The study was carried out in accordance with the 
applicable rules concerning the review of the local ethical committee and informed 
consent. Citrate-anticoagulated whole blood was collected on day 1, 3, 5 and 7 and 
was directly pre-treated with recAP (40 U/ml) or HEPES-buffered saline as a control 
at 3rC for 45 minutes. Platelet reactivity to ADP (31 uM) and CRP-XL (39 uM), 
as well as platelet-monocyte complex formation were measured by flow cytometry, as 
previously described. 
Statistical analyses 
Data are expressed as medians with interquartile range (IQR). This is an exploratory study 
and non-parametric statistical analyses was selected due to the small sample size. For the 
experiments with healthy volunteers, differences between multiple groups were tested 
using the Kruskall-Wallis test with Dunn's post hoc test. Data from the patient study 
were analyzed using the Mann-Whitney U test. Statistical analyses were performed using 
Graphpad Prism 6 (San Diego, USA). P < 0.05 was considered statistically significant. 
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Results 
RecAP inhibits ex vivo platelet activation in whole blood of healthy volun-
teers 
The extent of which recAP inhibits platelet activation was determined by pre-treatment 
of whole blood with recAP, followed by stimulation with the platelet agonists ADP 
(31 j.!M) and CRP-XL (39 j.lM). Whole blood samples pre-treated with 40 U/ml of 
recAP demonstrated an impairment in ADP-induced platelet reactivity with the 
median (interquartile range [IQR]) maximum inhibition of 47o/o (43-49o/o; P=0.0009) 
in P-selectin expression on platelets, while the reactivity to CRP-XL stimulation was 
reduced to a lesser extent (9o/o, 2-25o/o; P=0.08). Similar trends were observed in the 
platelet-fibrinogen binding (Figure 1A; representative histograms are presented in 
Figure 1B, with gating strategies described in Suppl. Figure 1). We explored the use 
of increasing concentrations and pre-treatment duration of recAP, as well as different 
concentrations of ADP and CRP-XL. Increasing the recAP concentration beyond 40 
U/ml or the pre-treatment duration beyond 45 minutes did not further augment the 
inhibition of platelet activation and these aforementioned conditions were therefore 
chosen for subsequent experiments (Suppl. Figure 2). 
Platelet-monocyte complex formation induced by ADP and CRP-XL was strongly 
inhibited by recAP (Figure 1C). We additionally tested the platelet response to 
immunological stimulation by using Pam3CSK4 (60 llg/ml), a synthetic agonist ofToll-
like-receptor 2 (TLR2). RecAP also demonstrated strong inhibition of Pam3CSK4-
induced platelet expression of P-selectin, platelet-fibrinogen binding and platelet-
monocyte complex formation (Suppl. Figure 3). 
Pre-activation of unstimulated platelets may occur by ex vivo handling prior to the start 
of experiments. However, in our setting, the percentage of platelets expressing P-selectin 
between samples with and without 45 minutes of incubation in 3r were comparable 
(4.3o/o, 3.3-4.7% vs. 4.1 o/o, 3.2-4.7%; P=0.8). Whole blood samples fixated and lysed 
with Optilyse B for the measurement of platelet-monocyte complex also did not show 
increased platelet pre-activation when compared with the 0.2o/o paraformaldehyde-
fixated samples (data not shown). 
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Figure 1. RecAP inhibits platelet activation by ADP and CRP-XL. 
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(A) Whole blood from healthy volunteers was pre-treated with medium or recAP (40 U/ml) for 45 
minutes and subsequently stimulated with the platelet agonises adenosine diphosphate (ADP; 31 f!M) 
and collagen-related peptide (CRP-XL; 39 f!M). The median fluorescence intensity (MFI) of the platelet 
surface expression of P-selectin and platelet-fibrinogen binding was measured by using flow cytometry. 
(B) Representative histograms for ADP and CRP-XL stimulation shown. (C) Platelet-monocyte complex 
formation after exposure to ADP and CRP-XL was determined by quantifying the MFI of the platelet 
marker CD61 on CD14+ cells. Data are presented as medians with interquanile range (IQR) from 6 
healthy donors.* P < 0.05, ** P < 0.001. 
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The effect of recAP is dependent on its dephosphorylating activity 
To determine whether the enzymatic dephosphorylating activity of recAP is required 
for its platelet-inhibitory effect, whole blood was pre-treated with recAP or inactivated 
recAP, the latter having no enzymatic dephosphorylating activity (10), and subsequently 
stimulated with ADP and CRP-XL. No reduction of platelet P-selectin or platelet-
fibrinogen binding was found in samples containing inactivated recAP (Figure 2A). 
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Figure 2. RecAP inhibition of platelet activation is dependent on its enzymatic dephosphory-
lating activity. 
(A) Whole blood was pre-treated for 45 minutes with medium, recAP (40 U/rnl) or inactivated recAP 
(in equivalent protein content) prior to stimulation with ADP (31 j!M) or CRP-XL (39 j!M). Platelet 
expression of P-selectin and binding with fibrinogen was determined by flow cytometry. (B) Whole blood 
was pre-treated with medium, recAP, apyrase (5 U/ml), or a combination of both recAP and apyrase, before 
exposure to ADP or CRP-XL. (C) Platelet-rich plasma (PRP) was pre-treated for 45 minutes with either 
medium or recAP. RecAP in the PRP samples was subsequently either washed-out, with the remaining 
platelets resuspended in fresh autologous platelet-poor plasma (washed-out recAP samples), or not (recAP 
samples). Samples are subsequently incubated with medium, ADP or CRP-XL. Data are presented as 
medians with IQR from 6 healthy donors. * P < 0.05, ** P < 0.01. 
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Next, we compared the effects of recAP with those of apyrase as both compounds 
demonstrate ADP-degrading activity. Apyrase is also known to inhibit ADP-dependent 
platelet aggregation (25, 26). Pre-treatment of whole blood with recAP and potato-
derived apyrase had a comparable platelet-inhibiting effect on samples stimulated with 
ADP and CRP-XL (Figure 2B). The combination of both compounds had no synergistic 
effect, suggesting that both shared similar ADP-dependent mechanism and already fully 
inhibited ADP-dependent platelet activation. 
A previous study suggested that AP might also exert its platelet-inhibitory effects through 
the dephosphorylation of platelet membrane proteins (15). To study this mechanism, we 
pre-treated PRP with recAP, thereby exposing the membrane of platelets to recAP. We 
subsequently isolated the platelets from PRP and resuspended them in fresh autologous 
platelet-poor plasma, thereby washing out any potentially remaining recAP. No platelet 
inhibition occurred once the recAP-containing plasma was washed out and replaced 
with fresh plasma, indicating that there is no persisting, residual dephosphorylating 
effect of recAP on the platelet membrane, and that the platelet-inhibiting activity of 
recAP is dependent on its presence in test medium (Figure 2C). 
The effect of recAP is exerted directly on platelets 
Leukocytes can secrete inflammatory mediators that activate platelets or the coagulation 
system. Furthermore, ADP can also alter the function of leukocytes, which in turn 
can affect platelet activation (9, 23). In order to explore the direct effect of recAP on 
platelets, we performed experiments on platelet-rich plasma (PRP). RecAP pre-treatment 
on PRP resulted in platelet inhibition of ADP-stimulated (64%, 54-68%; P=0.002). 
Interestingly, in PRP samples, those stimulated with CRP-XL showed significant platelet 
hyporeactivity after pre-treatment with recAP (60%, 46-71 %; P=0.002) , a finding 
not present in whole blood samples. These data confirmed that recAP acts directly on 
platelets. Similar to data from whole blood, inactivated recAP did not demonstrate any 
platelet-inhibiting effect, and potato-derived apyrase had a comparable inhibiting effect 
on both ADP- and CRP-XL-induced platelet activation in PRP (Figure 3). Data on the 
effect of different doses and pre-treatment duration of recAP on PRP is presented on 
Suppl. Figure 4. 
Formation of adenosine contributes to the platelet-inhibiting effect of recAP 
Next to a direct dephosphorylating effect of recAP on ADP, we studied whether increased 
adenosine formation may also contribute to the observed platelet-inhibiting effects. APs 
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are the only known ectonucleotidases whkh can degrade extracellular ATP, ADP and 
AMP into adenosine (9). Adenosine exerts both anti-inflammatory and tissue-protective 
effects, and signals by binding with 1 of its 4 receptors: AlAR, A2AAR, A2BAR or A3AR. 
Adenosine signaling via the A2AAR and A2BAR was reported to inhibit platelet activation 
(13, 27). In our experiments, blocking the A2AAR receptor by an A2AAR antagonist 
partially reversed the platelet inhibiting effects by recAP in whole blood (data not shown) 
as well as in PRP (Figure 4A). In contrast, the use of an A2BAR antagonist had no effect 
(data not shown). RecAP might convert ADP into AMP and adenosine, with the latter 
contributing its effect via the A2AAR To confirm that adenosine was indeed generated 
by the turnover from ADP, we measured purine content from the supernantant of the 
PRP pre-treated with recAP or inactivated recAP that had subsequently been stimulated 
withADP and CRP-XL. ADP-stimulated samples demonstrate increased adenosine levels 
when pre-treated with recAP (27 -fold, 17 -49-fold, P=0.02) with negligible ATP and ADP 
levels, indicating their full turnover into AMP and adenosine (Figure 4B). Interestingly, 
CRP-XL induced ADP release when compared to non-stimulated samples (11-fold [2-
69-fold, P=0.02), whkh was completely removed upon pre-treatment with recAP (Suppl. 
Figure 5). Taken together, these data suggest that not only the dephosphorylation of ADP 
inhibits platelet activation and reactivity, but the concomitant formation of adenosine also 
augments the inhibitory effect of recAP on platelet function. 
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Figure 3. RecAP exerts its inhibitory activity directly on platelets. 
(A) Platelet-rich plasma (PRP) was pre-treated for 45 minutes with medium, recAP (40 U/ml) or inactivated 
recAP (in equivalent protein content) prior to stimulation with ADP (ADP (31 pM) or CRP-XL (39 fJM). 
Platelet expression of P-selectin and binding with fibrinogen was determined by flow cytometry. (B) PRP 
was pre-treated with medium, recAP, apyrase (5 U/ml), or a combination of both recAP and apyrase, before 
exposure to ADP or CRP-XL. Data are presented as medians with IQR from 6 healthy donors. ** P < 0.01. 
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Figure 4. Adenosine formation contributes to the platelet-inhibiting activity of recAP. 
(A) PRP was pre-treated with the selective A2AAR antagonist (ZM-241385; 30 uM) for 15 minutes, 
followed by incubation with recAP (40 U/ml). Platelet P-selectin (left panel) and fibrinogen binding to 
platelets (right panel) was determined by flow cytometry after stimulation with ADP (31 uM). Presented 
data are medians with IQR from 6 healthy donors. ** P < 0.01. (B) Purine levels were determined in the 
supernatant ofPRP pre-treated with recAP (40 U/ml) or inactive recAP (in equivalent protein content) and 
subsequently stimulated with ADP (31 uM). Presented data are medians with IQR ftom 4 healthy donors. 
Ex vivo exposure to recAP reverses sepsis-induced platelet hyperreactivity 
We performed platelet function tests on whole blood of septic shock patients (n=5) 
collected on day 1, 3, 5 and 7 after the start of norepinephrine infusion, with or without 
ex vivo recAP pre-treatment. Patients' characteristics are described in Table 1. Patients 
demonstrated a significant increase of platelet activation and aggregation on day 1 
compared to healthy controls which normalized upon measurement on subsequent 
days. Upon ex vivo pre-treatment with recAP, whole blood samples of these patients 
demonstrated reversal of the sepsis-associated platelet hyperreactivity as well as reduced 
platelet-monocyte complex formation (Figure 5). 
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Table 1. Patient characteristics 
~lpati~~ (fi ;; 5) •· ·· ·. , __ .' :. " '• ·. ~ . -. ,. .... 
. 
-... , . 
Demographics 
M/F 4/1 
Age (yrs) 59.8 ± 16.9 
Body mass index (kg/m2) 26.9 ± 1.9 
Acute Physiology and Chronic Health 22.6 ± 4.7 
~U3U~;tlill 
. 
.. 
~ '· 
Systemic inflammatory response syndrome 
Temperature (0 C) 
<36 -
36-38 37.6 [37.5-37.7] 
>38 38.5 [38.5-38.6] 
Leukocytes (x109/L) 
<4 -
4-12 7.1 [5.4-8.7] 
>12 17.0 [12.8-17.7] 
Heart rate (bpm) 108 ± 9 
Patients on ventilator (o/o) 100 
Ptatelet co~t (cdl$xH)9/L) _ ,. 
Day 1 222 ± 89 
Day3 171 ± 71 
Day5 175 ± 84 
Day7 308 ± 194 
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Figure S. Platelet hyperreactivity in sepsis patients. 
(A) A total of five septic shock patients were followed up on day 1, 3, 5 and 7. Whole blood was collected and 
pre-treated ex vivo with or without recAP (40 U/ml) and stimulated with ADP (31 uM) and CRP-XL (39 
uM). Whole blood from healthy controls (n=6) was collected on a single time point. Platelet P-selectin and 
platelet-fibrinogen binding were measured by flow cytometry. (B) Platelet-monocyte complex formation 
was determined by quantifying the MFI of the platelet marker CD61 on CD 14+ cells in whole blood. Data 
from 2 patients on day 1 and day 3 were missing. Presented data are medians with IQR. * P < 0.05 medium 
vs. recAP pre-treatment,** P < 0.01 medium vs. recAP pre-treatment, medium vs. recAP pre-treatment,# 
P < 0.05 healthy controls vs. patient on day 1 (Mann-Whitney test). 
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Discussion 
RecAP is a novel dephosphorylating enzyme currently under investigation as a new 
therapy for sepsis-associated AKI (clinicaltrials.gov, NCT02182440). Its exact 
mechanism of action is still incompletely understood. In the present study, we report 
that recAP reduces platelet reactivity to different platelet agonists in a threshold 
dose-fashion. RecAP strongly inhibited ADP-induced platelet activation in whole 
blood, and additionally CRP-XL-induced platelet activation in PRP. These data from 
PRP confirmed that recAP has a direct effect on platelets. Our data indicate that the 
dephosphorylation of ADP and the formation of adenosine as its turnover product are 
primarily responsible for the observed platelet-inhibiting effects. Additionally, exposure 
of whole blood of patients with septic shock to recAP reversed the sepsis-associated 
platelet hyperreactivity, further substantiating that this mechanism of action may be of 
importance in septic patients. 
ADP directly activates platelets via the P2Y12 and P2Y1 receptors on the platelet 
membrane, resulting in degranulation and aggregation (11, 28). To determine whether 
the platelet -inhibiting effects of recAP also occurs on different platelet activation pathway, 
we studied the platelet reactivity to CRP-XL which activate platelets via their GPVI 
receptor (29). In addition to measuring platelet reactivity to the thrombotic stimulation 
by the aforementioned agonists, we examined the platelet reactivity to immunological 
stimulation by using Pam3CSK4, which induces platelet activation through TLR2 (30, 
31). The release of endogenous ADP from platelet dense granules forms an essential 
amplification mechanism for platelet activation via both GPVI and TLR2 (29, 31), 
which can explain the broad platelet-inhibiting effects of recAP. RecAP resulted in 
a strong inhibition of CRP-XL-induced platelet activation in PRP but not in whole 
blood. Upon CRP-XL-stimulation, ADP release by platelets is known to provide an 
amplification mechanism for platelet activation (29). Indeed, our experiments confirm 
that CRP-XL induced the release of ADP from platelets. In addition, ADP can also be 
taken up by other blood cells like erythrocytes, monocytes and lymphocytes (32-34). 
RecAP exerts its effect through the dephosphorylation of ADP into adenosine; and we 
therefore speculate that the effect of recAP in whole blood is less striking because the 
relative abundance of ADP that is affecting platelets is lower in whole blood compared 
to PRP, thereby limiting the availability of adenosine. In addition, adenosine in whole 
blood is rapidly taken up by erythrocytes, neutrophils and lymphocytes (35). As a 
consequence, higher platelet inhibition by recAP observed in the CRP-XL-stimulated 
PRP samples compared to the whole blood samples is a plausible result. Furthermore, 
there seemed to be a more pronounced platelet inhibition in samples stimulated with 
the TLR2 agonist Pam3CSK4 compared to the platelet agonist ADP. As is the case with 
ADP and CRP-XL stimulation, the extent of platelet activation and consequently its 
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inhibition by recAP, in the Pam3CSK4-stimulated samples may be dose-dependent and 
as such, the percentage of reduction cannot be compared between the different stimuli. 
Our finding that antagonism of the AlA adenosine receptor partly reversed the platelet 
inhibition by recAP underlines the importance of adenosine generation in the effects of 
recAP. Adenosine is released from several different cells or generated from extracellular 
metabolism of ATP, ADP and AMP by different ectoenzymes (36). AP is the only known 
ectonudeotidases which can fully degrade ATP and ADP into adenosine (9), and this 
was confirmed by our data that adenosine was generated as their turnover product. 
Platelet activation is known to be inhibited by the binding of adenosine to the platelet 
AlA (13) and A2B adenosine receptor (27). The A2A receptor is present in higher 
density on platelets, whereas the importance of the A2B receptor is limited to situations 
in which the A2B receptor density is strongly up-regulated or when pathophysiological 
adenosine concentrations are present (27). This could explain why the A2B antagonist 
PSB-1115 had no effect on recAP mediated platelet-inhibition in our experiments. 
New pharmacological treatment options are urgently needed in sepsis. In this study, 
recAP was administered preceding ADP-induced platelet activation, thereby mimicking 
a prophylactic setting. Whether recAP will also exert protective effects in a more clinically 
relevant setting, is currently investigated in a large multicenter randomized controlled 
phase II trial in patients with sepsis-associated AKI. Next to the dephosphorylation 
of endotoxin and ATP, prevention of excessive platelet activation may also contribute 
to the beneficial effects of recAP in sepsis and sepsis-associated AKI as platelets are 
highly activated during sepsis (37). Increased platelet aggregation, platelet-endothelium 
binding, platelet-leukocyte complex formation and accelerated fibrin formation all 
contribute to renal microvascular thrombosis (38). Platelet-derived P-selectin was 
identified as a key component in this process (39) and it is well conceivable that this 
cascade is modulated by the observed effects of recAP as demonstrated by our observation 
that ex vivo recAP treatment reversed platelet hyperreactivity in sepsis patients. These 
results are in accordance with previous findings of Beumer and colleagues which showed 
that calf intestinal AP significantly reduced thrombocytopenia in piglets intravenously 
injected with LPS (40). In vitro exposure of platelets to LPS does not lead to strong 
platelet activation (41, 42) and we therefore refrained from performing experiments 
using LPS in the present study. It is therefore of interest to investigate the effect of recAP 
on platelet activation in sepsis patients in vivo. 
Several studies reported that sepsis resulted in platelet hyporeactivity (43-45), a finding 
dissimilar to that of ours and others (19, 46-48). The seemingly conflicting data of 
platelet activation in sepsis may be explained by several things. Firstly, we used a flow-
cytometry based assay to measure platelet function. Most studies reporting platelet 
hyporesponsiveness used light transmission aggregometry in PRP, which are less reliable 
when platelet counts are low ( 49), as frequently occurring in sepsis. Moreover, as described 
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by Woth and colleagues, it is difficult to detect platelet activation with secondary platelet 
exhaustion using this aforementioned technique (45).1he use ofPRP when compared 
with whole blood flow cytometry is also a disadvantage as mechanical manipulation 
may cause artifactual pre-activation of platelets (49). Additionally, in the in vivo setting 
of sepsis and in that of ours, activated leukocytes and endothelial cells in the milieu of 
whole blood may interact with and influence the platelet microenvironment, in contrast 
to when PRP is used. Leukocytes possess ATP-ase which may convert ATP present in 
whole blood into ADP, and in turn contribute to platelet hyperreactivity (50, 51). 
The ability of AP to inhibit platelet activation, as measured by light transmission 
aggregometry, was first shown more than 20 years ago using bovine-derived kidney 
AP (14-16). Since then, no new data on the platelet effects of AP have emerged. Our 
current data add to the existing knowledge that the novel human recombinant product 
has similar platelet~inhibiting effects and that the dephosphorylation of ADP and 
generation of adenosine account for these effects. In the earlier studies, modification of 
platelet membrane receptors was speculated to mediate the platelet effects (15, 16), but 
our current experiments do not lend support for this mechanism. 
As reviewed recently by Thomas and Storey (52), increasing data on the effects of 
platelet inhibitors on inflammation are available. However, these data are not easy to 
interpret as some studies have shown benefit of the P2Y12 inhibitors in sepsis patients 
(53-55), whereas others did not (55-58). Regardless, the inhibition of platelet reactivity 
to ADP reduces the release of pro-inflammatory mediators from platelet a-granules (52, 
59). In addition, Ticagrelor, a P2Y12 receptor ADP antagonist, shows additional anti-
inflammatory effects through a secondary inhibition of adenosine reuptake ( 60). Recently, 
our group showed that platelets modulate the cytokine responses of monocytes, and 
that ticagrelor administration in healthy volunteers reversed these effects partly through 
the inhibition of platelet-monocyte interaction (41). These immune-modulating effects 
of platelets could explain the observation that bovine-intestinal alkaline phosphatase 
administration reduced systemic levels of several inflammatory mediators during sepsis-
associated AKI (5, 6). 
In conclusion, we demonstrated for the first time that recAP inhibits ex vivo human 
platelet activation through the dephosphorylation of ADP, an important platelet agonist, 
and the formation of adenosine as its turnover product. This platelet-inhibiting effect 
may, at least partly, account for the therapeutic potential of recAP as a new candidate 
to treaf sepsis-induced AKI. In addition, these results may pave the way to further 
investigate the effects of recAP treatment in other diseases in which platelet-activation 
plays a relevant role. 
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Supplemental Figure 1. Flow cytometry gating strategy for determination of P-selectin 
expression on platelets and platelet-fibrinogen binding. 
Platelets are gated based on forward and side scatter characteristics (A) followed by positivity for the platelet 
marker CD61 (B). The median fluorescence intensity (MFl) of P-selectin and fibrinogen, after stimulation 
with ADP (31 flM) and CRP-XL (625 f!M), was determined from the gated platelet population (C). 
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Supplemental Figure 2. The platelet-inhibiting effect of recAP in whole blood is dose- and 
time-dependent. 
(A) Whole blood from healthy volnnteers was pre-treated with different concentrations of recAP for 45 
minutes prior to stimulation using low and high concentrations of ADP or CRP-XL. (B) Whole blood 
from healthy volnnteers was pre-treated with recAP (40 U/ml) with different incubation times prior to 
stimulation using ADP and CRP-XL. The median fluorescence intensiry (MFI) of the platdet surfuce 
expression of P-selectin and platelet-fibrinogen binding was measured by using flow cytometry. Data are 
presented as medians with IQR from 6 healthy donors. * P < 0.05 1 ** P < 0.01. 
109 
Chapter4 
A 30 .. 20 
- - 1=:1 Medium 
~ ~ 
C] Re·cAP 
~ . 15 20 
"' . 0 
.. ~ 
' 
'i: 
S> 10 0.. ;;: ]_ "- 10 .. !I! ::!; 5 
0 
Med-ftJm Pam3CSK4 Medlum Pom3CSK4 
B 20 Cl Me dium 
.. 
+ 
- RecAP ~ 15 
u 
+ 
:! 10 
" ~ 
iA: 
::1! 
Medium Pam3CSK4 
Supplemental Figure 3. The platelet-inhibiting effect of recAP on Pam3CSK4-stimulated 
whole blood. 
(A) Whole blood was pre-treated for 45 minutes with medium or recAP (40 U/ml) prior to stimulation 
with Pam3CSK4. (B) Platelet-monocyte complex formation after exposure to Pam3CSK4 was determined 
by quantifying the MFI of the platelet marker CD61 on CD 14+ cells. Data are presented as medians with 
IQR from 6 healthy donors. ** P < 0.01. 
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Supplemental Figure 4. The direct platelet-inhibiting effect of recAP in platelet-rich plasma 
(PRP) is dose- and time-dependent. 
(A) PRP from healthy volunteers was pre-treated with different concentrations of recAP for 45 minutes prior 
to stimulation using low and high concentrations of ADP or CRP-XL. (B) PRP from healthy volunteers 
was pre-treated with recAP (40 U/rnl) with different incubation times prior to stimulation using ADP 
and CRP-XL. The median fluorescence intensity (MFI) of the platelet surface expression of P-selectin and 
platelet-fibrinogen binding was measured by using Bow cytometry. Data are presented as medians with IQR 
from 6 healthy donors. * P < 0.05, ** P < 0.01. 
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Supplemental Figure 5. Measurement of purine content in CRP-XL-induced PRP. 
Purine levels were determined in the supernatant of PRP pre-treated with recAP (40 U/ml) or inactive 
recAP (in equivalent protein content) and subsequently stimulated with CRP-XL (39 uM). Presented data 
are medians with IQR from 4 healthy donors. 
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Abstract 
Introduction: Systemic inflammation and hypoxia both have been associated 
with increased platelet activation and hypercoagulability. Patients with critical 
illness often suffer from concurrent inflammation and hypoxia, and the possibly 
synergistic effects on platelets and coagulation may affect organ function and 
outcome. However, human data concerning the interaction between inflammation 
and hypoxia on platelet function and coagulation is lacking. 
Materials and methods: Systemic inflammation was elicited by intravenous 
administration of lipopolysaccharide (2 ng/kg) in 20 healthy male volunteers, who 
were randomized to concurrent normoxia or hypoxia (oxygen saturation 80-85%). 
Platelet counts, platelet monocyte complexes (PMCs), platelet reactivity, thrombin 
generation and plasma levels of platelet factor 4 (PF4), von Willebrand Factor 
(vWF), and thrombin-antithrombin (TAT)-complexes were determined. 
Results: Systemic inflammation resulted in a decrease in platelet counts (13% from 
baseline), and an 240% increase in PMCs and 35% increase in platelet reactivity. 
These endotoxemia-induced effects were attenuated by concurrent hypoxia. Systemic 
inflammation also increased plasma levels of vWF and TAT-complexes by 330 and 
60% respectively, but did not affect plasma levels of PF4 and thrombin generation. 
Hypoxia neither modulated plasma concentrations of vWF, TAT-complexes, and 
PF4, nor thrombin generation. 
Conclusion: Systemic hypoxia during systemic inflammation does not augment, 
but rather attenuates endotoxemia-induced decreases in platelet counts and 
endotoxemia-induced PMC formation and platelet reactivity. Therefore, our study 
provides no evidence for procoagulant effects of hypoxia in vivo in humans. 
Keywords 
inflammation, hypoxia, platelet, coagulation, endotoxin, thrombin 
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Introduction 
Systemic inflammation in critical illness, as observed in patients with sepsis and following 
trauma, results in the activation of platelets and coagulation, which can ultimately lead 
to coagulopathy, organ dysfunction and worse outcomes (1,2). Concurrently, systemic 
hypoxia is common in critically ill patients, and is independently associated with adverse 
outcome (3), and tissue hypoxia may arise during inflammatory conditions as a result 
of enhanced metabolic demands, and decreased oxygen delivery(4). Hypoxia has also 
been implied to activate coagulation, as it has been associated with an increased risk of 
thrombotic events(5). Furthermore, hypoxia has been shown to increase platelet reactivity 
in rats(6) and enhance the procoagulant activity of human endothelial cells in vitro(?). 
Therefore, hypoxia may also contribute to altered platelet function and coagulopathy in 
critically ill patients, increasing their risks for organ dysfunction. However, the limited 
number of human studies available have mainly focused on the effects of hypoxia 
on plasmatic coagulation, and most of them do not support procoagulant effects of 
hypoxia(8,9). Human in vivo studies on the effects of hypoxia on platelet function did 
also not identify any effects, but this was only investigated during very mild (10) or 
using very short bouts(11) of hypoxia. 
Although hypoxia and inflammation may both affect platelet function and plasmatic 
coagulation, human in vivo data on the interaction between hypoxia and inflammation 
on coagulation are completely lacking. We recently reported that systemic hypoxia exerts 
profound anti-inflammatory effects in humans in vivo during experimental human · 
endotoxemia (Kiers D. et. al., 2016, submitted). In the present work, we describe the 
effects of systemic hypoxia during human en do toxemia on platelet function, endothelial 
cell activation and plasmatic coagulation. 
Methods 
Study design and population: 
Data were obtained from a previously reported parallel randomized controlled 
experimental endotoxemia study (Kiers D. et. al., 2016, submitted). In this study 
subjects were randomly assigned to normoxia (room air) or hypoxia (peripheral 
oxygen saturation (Sa02 80-85%). All study procedures were in accordance with the 
declaration of Helsinki, including the latest revisions. The study was performed after 
approval of the local ethics committee. Healthy, non-smoking, male volunteers aged 
18-35 years were included after written informed consent and a screening with a normal 
physical examination, routine laboratory tests and ECG. Exclusion criteria were use of 
prescription medication and recent visits to high altitude or airplane flights. 
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Experimental protocol 
The endotoxemia experiments were performed as previously described (Kiers D. et. al., 
2016, submitted). Briefly, purified lipopolysaccharide (LPS, US Standard Escherichia coli 
0:113 endotoxin, National Institute of Health, Bethesda, MD, USA) was administered 
as an i.v. bolus of 2 ng/kg. All subjects received infusion of 1.5L glucose 2.5%/ NaCl 
0.45% in one hour before LPS administration, and were fitted with an air-tight 
respiratory helmet (StarMed, CaStar, Italy) . Room air was supplied to the helmet of the 
subjects randomized to normoxia. In the hypoxia group, a gas mixture of nitrogen and 
room air was titrated to achieve a Sa02 of 80-85%. Subjects wore the respiratory helmet 
for a period of 3.5 h, starting one hour before LPS administration. Blood was collected 
in 3.2% citrate anti-coagulated vacutainers. 
Platelet counts, platelet monocyte complexes and platelet reactivity 
Platelet counts were determined using an automated hematology cell counter. Platelet 
monocyte complexes (PMCs) were measured by incubating whole blood with 
fluorescent antibodies against CD14 as monocyte identification and CD42b as a 
platelet marker. PMCs were identified with flow cytometry as monocytes positive for 
the platelet marker. Platelet reactivity was measured with flow cytometry as described 
previously (12). Briefly, platelet reactivity was measured by staining whole blood with 
PE-labeled anti-CD62P (Bio-Legend, San Diego, USA) and PC7-labeled anti-CD61 
(platelet identification marker; Beckman Coulter, France). Samples were incubated 
with eight concentrations of adenosine diphosphate (ADP; Sigma Aldrich, Germany). 
The mean fluorescent intensity (MFI) of CD62P on platelets was determined for each 
ADP concentration with flow cytometry. The area under the ADP-response curve was 
used as a measure for platelet reactivity. 
Calibrated automated thrombin generation 
Thrombin generation was measured by means of calibrated automated thrombography 
as described by Hemker et al.(13) Briefly, platelet poor plasma and a calibration sample 
with known thrombin activity were incubated with a mixture of tissue factor and 
phospholipids to induce thrombin generation. Hereafter, a fluorogenic, calciumchloride 
and BSA was added. Fluorescence, as a measure of thrombin conversion, was measured 
for one hour on a microplate reader. The endogenous thrombin potential (ETP) is 
the total amount of thrombin formed in one hour and is calculated by comparing the 
fluorescent signal of the subject sample with calibrator sample. 
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ELISAs 
Plasma concentrations of von Willebrand factor (vWF), platelet factor-4 (PF4) and 
thrombin-antithrombin (TAT) complexes were measured using ELISA's, as previously 
described ( 14). 
Statistical analysis 
The effect of endotoxemia was evaluated by performing a one-way analysis of variance 
on the data of normoxic subjects. To evaluate the effects of hypoxia versus normoxia 
during endotoxemia, general linear mixed models were used. Data were analyzed with 
SPSS version 22 (IBM, Chicago, USA). A p-value of <0.05 was considered significant. 
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Results 
Platelet counts, platelet monocyte complexes, platelet reactivity and platelet factor 4 levels 
The experimental procedures, including hydration with 1.5 L of fluid and induction 
of a systemic inflammatory response induced a slight, but significant, decrease in 
platelet counts in the normoxic group (p<O.OOOI), which was less pronounced in the 
hypoxia group (Fig IA). In the normoxic subjects, the percentage of PMCs increased 
during endotoxemia (p=0.0006, Fig IB). Hypoxia attenuated the formation ofPMCs. 
Platelet reactivity showed a very similar pattern as PMCs, peaking at 2.5h after 
LPS administration in normoxic subjects (p<O.OOOI, Fig IC). Hypoxia blunted the 
endotoxemia-induced increase in platelet reactivity. Plasma levels of PF4 in normoxic 
subjects tended to increase in the first 3 hrs following endotoxemia (p=0.08, Fig ID). 
Hypoxia did not modulate this response. 
Von Willebrand factor levels and plasmatic coagulation 
Systemic inflammation resulted in increased plasma concentrations of vWF (p<O.OOOI), 
with a trend towards slightly higher levels in the hypoxia group that did not reach 
statistical significance (p=0.06, Fig IE). Plasmatic coagulation was evaluated by 
measuring thrombin generation and TAT complexes. Endotoxemia tended to induce a 
short-lived increase in thrombin generation (p=0.08, Fig IF), and resulted in increased 
concentrations of TAT complexes (p=0.03, Fig IG). Both measures of plasmatic 
coagulation were unaffected by hypoxia. 
Discussion 
Herein, we report that systemic hypoxia attenuates endotoxemia-induced effects on 
platelets. Endotoxemia-induced decreases in platelet counts as well as increases in 
PMCs and platelet reactivity were all mitigated by concurrent hypoxia. Furthermore, we 
demonstrate that hypoxia does not modulate endotoxemia-induced increase in plasma 
levels of vWF and TAT-complexes. The effects of endotoxemia on platelet degranulation 
marker PF4 and thrombin generation, as a measure of plasmatic coagulation, were not 
modulated by hypoxia. 
In line with our results, previous reports have consistently identified that human 
endotoxemia results in decreased platelet counts(I5) as well as increased PMCs(16), 
platelet reactivity(I7), plasma levels of vWF(15,I7) and TAT complexes(I8). 
Correspondingly, observational studies in patients with sepsis have also identified 
increases in markers of platelet activation(19). To the best of our knowledge, thrombin 
generation has not been previously assessed during endotoxemia and we only observed 
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a borderline significant short-lived rise in thrombin generation potential that was not 
affected by hypoxia. 
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Figure 1. Time course of platelet function and coagulation parameters during experimental 
endotoxemia in normoxic and hypoxic healthy volunteers. 
(A) Whole blood platelet counts. (B) Percentage of platelet monocyte complexes (PMCs). (C) Platelet 
reactivity expressed as the change from baseline of the area under the adenosine diphosphate dose-response 
curve. (D) Plasma concentrations of platelet factor 4 (PF4). (E) Plasma concentrations of von Willebrand 
Factor. (F) Endogenous thrombin generation. (G) Plasma concentrations of thrombin-antithrombin (TAT) 
complexes. The period that subjects were hypoxic or normoxic is indicated with a grey box. LPS was 
administered at t=O hours. Data are expressed as the estimated mean with error obtained from the mixed 
linear model. P-values express the difference between the normoxic and hypoxic endotoxemia model. 
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The few human studies that investigated the influence of hypoxia on platelets reported 
no effects of either eight hours of mild hypoxia or a seven minute period of deep 
hypoxia(ll) on soluble P-selectin levels, platelet-monocyte complexes and platelet 
reactivity. In contrast, severely hypoxic rats exhibited increased platelet activation and 
aggregation(13). Previous studies on the effect of hypoxia on plasmatic coagulation 
have shown conflicting results. One reported that acute hypoxia results in increased 
concentrations of prothrombin fragments 1+2 (Fl+2) and TAT complexes(8), both 
markers of thrombin formation. In contrast, other studies have shown no effects of 
hypoxia on either F 1+2, TAT complexes, endogenous thrombin generating potential or 
several other measures of plasmatic coagulation(16-18). Taken together, most studies 
on the effects of hypoxia in humans in vivo do not identifY procoagulant effects, which 
is consistent with our current findings. Therefore, the assumption that hypoxia itself 
results in a procoagulant state in vivo is not supported by experimental data. 
Several potential mechanisms may explain the attenuating effects of hypoxia on 
endotoxin-induced changes in platelet counts and function. LPS is the archetypal 
ligand for Toll Like Receptor (TLR)-4, and although platelets express TLR4, the ability 
of LPS to directly activate platelets is debated(19). Therefore, it is plausible that the 
endotoxemia-induced effects on platelets are mediated by an indirect effect of endotoxin 
administration, for example by the LPS-induced release of cytokines. Because subjects 
that were exposed to hypoxia exhibited 40 to 50% lower circulating levels of the pro-
inflammatory cytokines TNFa, interleukin(IL)-6 and IL-8 (Kiers D. et. al., 2016, 
submitted). This may explain the attenuated effects on platelets. Alternatively, hypoxia 
might have resulted in increased levels of prostaglandin I2 (PGI2), which is known to 
inhibit platelet activation(20). Lastly, it has been reported that deoxygenated erythrocytes 
produce NO, which is known to inhibit platelets as well(21). Reliable measurements 
of PGI2 production can only be performed in urine, which was not collected in our 
study. Plasma nitrite measurements, as a proxy for NO, are not increased during 
experimental endotoxemia(22). Furthermore, our study has limitations related to the 
experimental human endotoxemia model used, which naturally does not fully represent 
the inflammatory response observed in critically ill sepsis patients. Nevertheless, given 
the paucity of human in vivo data on the subject, it provides valuable insights into the 
complex interactions between inflammation, coagulation, and hypoxia. 
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Conclusion 
Systemic inflammation and hypoxia have been associated with enhanced platelet 
activity and hypercoagulation, both of which may contribute to organ dysfunction 
and affect outcome in critically ill patients. We report that systemic hypoxia during 
systemic inflammation in humans in vivo does not augment, but rather attenuates, 
endotoxemia-induced decreases in platelet counts and endotoxemia-induced increased 
PMC formation and platelet reactivity. 
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Abstract 
Using a novel porcine model of intravenous Streptococcus pneumoniae infection, we 
showed that invasive pneumococcal infections induce marked platelet activation 
and hyperreactivity. This may contribute to the vascular complications seen in 
pneumococcal infection. 
Keywords: platelets, pneumonia, Streptococcus pneumoniae, myocardial infarction, 
platelet activation, infection 
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Introduction 
Community acquired pneumonia (CAP) is associated with an increased short-term 
and long-term risk for cardiovascular events (CVE) (1). The Gram-positive bacterium 
Streptococcus pneumoniae is a major cause of CAP and sepsis. S. pneumoniae is well 
known to interact with and activate platelets ex vivo (2). Platelets play a central role in 
acute CVE and atherosclerosis (3), and we speculate that excessive platelet activation 
may also contribute to the vascular comorbidity in pneumococcal infections. However, 
whether systemic platelet activation and platelet hyperreactivity are prominent features 
of invasive pneumococcal infections in vivo is not well-established. 
Porcine animal models are frequently used in cardiovascular research due to the 
similarities with humans in terms of cardiac anatomy and the haemostatic system (4). 
Pigs are also a natural host of the pathogen Streptococcus suis, which has strong genetic 
similarities with S. pneumoniae. Using a novel porcine model of pneumococcal disease, 
we investigated the hypothesis that invasive pneumococcal infections are associated with 
pronounced platelet activation and hyperreactivity. 
Methods 
Porcine S. pneumoniae infection model 
Full details of the animal experimental model are described elsewhere (5). In short, 
two groups of five piglets received 1 ml intravenous injection of either a low (4.2x106 
Colony-Forming Unit [CFU]Iml) or high dose (2.9xl08 CFUiml) of S. pneumoniae 
strain PBCN214, a serotype 8 invasive strain isolated from a patient with pneumonia, 
meningitis and sepsis. Two other groups of five piglets each received 3 ml of intranasal 
inoculation of a low (2.5xl 06 CPU I ml) or high dose (2. 9x1 08 CPU I ml) of S. pneumoniae 
strain BHN418, a serotype 6B strain previously used in experimental human carriage 
models (6). Piglets were euthanized at day seven post-inoculation, or earlier when 
reaching pre-defined humane end points. The animal experiment was approved by 
the Ethical Committee of the Central Veterinary Institute of Wageningen UR (The 
Netherlands), in accordance with the Dutch law on animal experiments (permit number 
2014004b). 
Porcine platelet activation and reactivity assay 
Platelet activation and reactivity were measured using a flow cytometry-based assay, as 
previously described for pigs (4). The membrane expression of the platelet alpha-granule 
protein P-selectin and the binding of fibrinogen to the activated aiib[33 receptor were 
determined using K02.5-Alexa Fluor 488 (AbD Serotec, Oxford, UK) and FO 111-
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FITC (DAKO Ltd., High Wycombe, UK) antibodies in unstimulated, citrated whole 
blood and after ex vivo stimulation of whole blood by two concentrations (7.8 and 31 .2 
mmol!L) of adenosine diphosphate (ADP). 
In vitro activation of porcine and human platelets by S. pneumoniae 
The ability of the used S. pneumoniae strains to directly activate porcine and human 
platelets was investigated by incubating whole blood and isolated washed platelets with 
lxl08 CFU/mL of heat-killed S. pneumoniae (strains PBCN214 and BHN418) for 
lhr at 3rC. The Gram-negative bacterium Escherichia coli was included as a control. 
Samples were fixed and platelet P-selectin expression and platelet fibrinogen binding 
were measured using flow cytometry as described above. 
Statistical analysis 
Data are expressed as arithmetic means with standard error of the means (SEM). Daily 
changes in platelet reactivity were compared to baseline pre-infection values using a 
linear mixed model with post hoc Bonferroni-Holm correction. Differences in the in 
vitro experiments were analyzed with standard statistical tests. P<0.05 was considered 
statistically significant. 
Results 
All piglets in the intravenous (IV) groups developed fever and positive blood cultures 
for S. pneumoniae, whereas all piglets in the high dose intranasal (IN) group were 
colonized by S. pneumoniae throughout the duration of the experiment. One piglet in 
the latter group had a transient bacteremia. Four of five animals in the high dose IV 
group and one animal in the low dose IV group developed arthritis, which necessitated 
premature euthanization in two animals from the high dose IV group (at day 2 and 4, 
respectively). Detailed clinical and histological findings of the experimental model is 
described elsewhere (5). 
Piglets in the high dose N group, but not those in the low IV group or the intranasal 
groups, demonstrated a transient decrease in mean (SEM) circulating platelet count 
from 489±58x109/L at baseline to 353±37xl09/L (P=0.016; paired T-test) at day one 
after intravenous inoculation (Fig. lA). This was associated with a significant increase 
in platelet CD62P expression and fibrinogen binding in both unstimulated samples 
and upon ex vivo stimulation with a low and high dose of ADP (representative flow-
cytometry plots shown in Fig. lB, platelet reactivity data shown in in Fig lC). There 
was a weak correlation of CD62P expression in unstimulated samples at day one and the 
relative decrease in platelet number between baseline and day one in the high dose N 
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group (Spearman R=0.66; P=0.04). No change in platelet activation markers was found 
in piglets in both IN groups. 
Next, we determined the ability of the used S. pneumoniae strains to directly activate 
porcine and human platelets in vitro. The Gram-negative bacterium Escherichia coli was 
included as control. Whereas E coli did not upregulate platelet P-selectin expression and 
fibrinogen binding, both strains of S. pneumoniae induced the expression of these platelet 
activation markers (Fig. ID), suggesting that the observed platelet hyperreactivity in the 
experimental model above was not merely a result of inflammation, but also through 
direct platelet stimulation by S. pneumoniae. 
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Fig 1. 
(A) Time course of platelet count in piglets (n=S per group) inoculated intravenously with I ml oflow (4xl06 
CFU/mL) or high (2.9xl08 CFU/mL) dose of the invasive S. pneumoniae strain PBCN214. *P<0.05 versus 
the baseline sample before inoculation (paired T-test). (B) Representative plots showing the platelet gating 
strategy whereby platelets were selected on their forward and side scatter characteristics (left panel}, and 
observed differences in platelet P-selectin expression (middle panel) and platelet fibrinogen binding (right 
panel) after ex vivo stimulation with 31.2 mmol/L ADP berween pre-infection sample (day 0) and day 3. (C) 
Time course of P-selectin expression and fibrinogen binding, expressed as mean fluorescence intensity (MFI) 
in arbitrary units, in unstimulated samples and after ex vivo stimulation by 7.8 or 31.2 mmol/L ADP. * P<0.05, 
**P<O.OI versus the baseline sample before inoculation (linear mixed models). (D) P-selectin expression and 
fibrinogen binding of porcine and human washed platelets and whole blood following ex vivo incubation with 
the invasive (PBCN214) and colonizing (BHN418) strains of S. pneumoniae and by Escherichia coli (both 
lxl08 CFU/ml). Data presented are aggregated from a total of 6 piglets and 9 humans. Pvalues determined 
using T-tests. Data in this figure are presented as means with standard error of the means (SEM). 
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Discussion 
This study demonstrates that invasive S. pneumoniae infections induce pronounced 
platelet activation and hyperreactivity. Direct stimulation of platelets by S. pneumoniae 
mediated these effects, at least in part, as porcine washed platelets were activated by ex 
vivo exposure to S. pneumoniae. 
Pneumococcal pneumonia is an independent risk factor for acute CVE among 
patients with CAP (7). Platelets are key cells in acute CVE and the observed platelet 
hyperreactivity may contribute to the increased risk for vascular thrombosis in patients 
with pneumococcal infections. Our data are consistent with a patient study showing 
increased plasma markers of platelet activation in CAP patients with signs of myocardial 
infarction (3). 
Pneumococci can activate platelets directly through different processes, including 
binding to platelet Toll-like receptor (TLR)-2, FcyRIIA and the integrin allbl33 (2). In 
addition, phosphorylcholine residues of the pneumococcal cell wall may also serve as a 
platelet activation factor (PAF) mimetic as well as a bacterial adhesin to PAF receptors, 
which has been reported to be present on porcine platelets (8). Finally, piglets in the 
intravenous group developed fever and significant increases in the pro-inflammatory 
cytokines interleukin(IL)-113 and IL-6 (5). Inflammation and the resulting activation of 
the endothelium and plasmatic coagulation may also contribute to platelet activation. 
Constraints of our study include the fact that a large animal model is restricted in the 
number of animals used, especially because two of the piglets in the high dose IV group 
were euthanized before the end of the study. The group ofintranasally inoculated piglets 
function as a control group showing the stability of our platelet assay in time. Secondly, 
the used model did not allow us to relate platelet hyperreactivity to CVE. Thirdly, the 
invasive S. pneumoniae strain was intravenously inoculated. Although pneumococcal 
bacteremia is a common complication of pneumococcal pneumonia, our findings 
cannot directly be translated to pneumococcal pneumonia without bacteremia. 
ADP is known for its role in the amplification of platelet activation by other platelet 
agonists, and was the sole platelet agonist used in this study. Other commonly used 
platelet agonists in humans, such as thrombin receptor activating peptides (TRAP) and 
collagen, are known to incompletely activate porcine platelets (4). 
The findings of the epidemiologic studies mentioned above, together with our current 
findings, strengthen the case for platelet function inhibitors as a preventive intervention 
to reduce the number of acute vascular thromboses during invasive pneumococcal 
infections. A small placebo controlled trial involving 185 patients found that aspirin 
reduced the occurrence of CVE in CAP patients from 10.6% to 1.1% (9). In addition, 
a large observational study involving over 1000 elderly CAP patients reported lower 30-
day mortality rate for those who had been on chronic treatment with aspirin, compared 
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to those who had not (10). Larger placebo-controlled studies are warranted before 
evidence-based recommendations can be given. A pneumococcal porcine model as used 
in our study may allow for identification of platelet inhibitors to prevent pneumococcal-
induced platelet activation. 
In conclusion, invasive pneumococcal infections induce pronounced in vivo platelet 
activation and platelet hyperreactivity and this may contribute to the increased incidence 
of vascular complications seen in these infections. 
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Abstract 
To improve our understanding about the severity of invasive pneumococcal disease 
(IPD), we investigated the association between the genotype of Streptococcus 
pneumoniaeand disease outcome of349 bacteremic patients. Pneumococcal genome-
wide association (GWAS) analysis demonstrated a strong correlation between 30-
day mortality and the presence of the phage-derived gene, pblB, encoding a platelet-
binding protein of which effects on platelet activation were previously unknown. 
Platelets are increasingly recognized as key players of the innate immune system, 
and in sepsis, excessive platelet activation contributes to microvascular obstruction, 
tissue hypoperfusion and finally multi-organ failure leading to mortality. Our in 
vitro studies revealed that pblB expression was induced by fluoroquinolones but 
not by the beta-lactam antibiotic Penicillin G. Subsequently, we determined pblB 
induction and platelet activation by incubating whole blood with wild type or 
knock-out mutant of pblB, in the presence or absence of antibiotics commonly 
administered in our patient cohort. Pb/B-dependent enhancement of platelet 
activation, as measured by increased expression of the a-granule protein P-selectin, 
the binding of fibrinogen to the activated aiib~3 receptor and the formation of 
platelet-monocyte complex occurred irrespective of the antibiotics exposure. In 
conclusion, the presence of pblB on the pneumococcal chromosome potentially 
leads to increased mortality in patients with an invasive S. pneumoniae infection, 
which may be explained by enhanced platelet activation. This study highlights 
the clinical utility of bacterial GWAS, followed by functional characterization to 
identify bacterial factors involved in disease severity. 
Keywords: Streptococcus pneumoniae, mortality, pblB, fluoroquinolones, platelet 
activation 
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Introduction 
Streptococcus pneumoniae or the pneumococcus is a frequent colonizer of the nasopharynx. 
In a minority of carriers, infection progresses to pneumococcal disease with an estimated 
1.6 million deaths annually (1, 2). The largest clinical burden of invasive pneumococcal 
disease (IPD) is seen in young children and older adults, who present mostly with 
sepsis and meningitis. Case mortality rates are estimated to range from 11 to 30% in 
adults (3-5), with treatment becoming complicated due to the worldwide emergence of 
multi-drug resistance (6). Therefore, it is of utmost importance to fully understand the 
pathogenic mechanisms of pneumococcal disease in order to improve treatment and 
prognosis of critically ill patients. 
Recently, the utilization of whole genome sequencing and analyses for predicting and 
understanding pathogen virulence has been highlighted (7). In this study, we performed 
a genome-wide association analysis (GWAS) on 349 pneumococcal draft genomes of 
blood isolates from patients who were admitted with IPD in two Dutch hospitals. We 
identified a significant association between 30-day mortality and the presence of pblB, 
encoding for a platelet binding protein that was also reported to function in adhesion 
(8). In a subsequent functional study, we investigated the induction of the phage-derived 
pblB expression by fluoroquinolones inS. pneumoniae. Lastly, we simulated the in vivo 
conditions using an ex vivo whole blood assay demonstrating the importance ofPblB in 
enhancing platelet activation. 
Platelets are an important part of the innate immune system, and can interact with and be 
activated by S. pneumoniae. In sepsis, platelet activation and platelet-leukocyte complex 
formation contribute to microvascular obstruction, tissue hypo perfusion and finally multi-
organ failure (9). The role of this phage-derived gene in the clinical outcome and severity 
ofiPD patients and its consequences for platelet activation warrant further study. 
Materials and Methods 
Study population. Consecutive patients hospitalized with a bacteremic pneumococcal 
infection at two Dutch hospitals between 2001 and 2011 were included in the study. 
Detailed clinical data were obtained on patient characteristics, clinical severity, treatment 
and the course of disease. Corresponding blood culture isolates of S. pneumoniae 
were collected and serotyped as described before (10). For 349 of the isolated strains, 
sequencing, assembly of draft genomes and annotation was determined as previously 
described (36). This study was reviewed and approved by the Local Medical Ethical 
Committees. All adult patients and healthy volunteers involved in this study provided 
written informed consent. 
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Orthologous clustering and GWAS. Orthologous genes (OGs) from S. pneumoniae 
used in this study have previously been described by our group (36). Putative protein 
coding sequences were investigated using an "all-versus-all" protein BLAST (blastP), 
with a 10e-15 e-value cut-off and a BLOSUM90 substitution matrix. The results were 
subsequently clustered into clusters of orthologous groups using TribeMCL (36, 37), 
resulting into a total of3021 orthologous genes (OGs), 1075 of which were conserved in 
all isolates in a single copy. The population (sub)structure (sequence clusters; SCs) used 
for population stratification in the study have also been previously characterized (36). 
Basing disease severity on mortality within the first 30 days of admission to the hospital, 
the pneumococcal isolates were categorized into three categories: derived from patients 
who died (n=37), from patients who survived (n=309), and from patients of whom 
the data was not captured (n=3). The Cochran-Mantel-Haenszel (CMH) association 
statistics was employed to test the associations between the presence or absence of 
pneumococcal OGs and 30-day mortality, conditional on the bacterial population 
substructure as proposed by Bayesian Analysis of Population Structure (BAPS) analysis 
(11). All associations were determined using PLINK (38). Candidate OGs were selected 
based on association test with p <0.05 (Bonferroni adjusted for multiple testing). 
Visualization of the results were performed using ITOL (39). 
Adjustment for covariates of mortality. Potentially interesting covariates of 30-day 
mortality were analyzed using binary logistic regression analysis by likelihood ratio based 
backward modeling, entering the pneumococcal OG plus identified possible covariates 
as explaining variables. Detailed statistical methods are described in Method S 1. 
Induction of pblB expression by antibiotics. Three isolates randomly selected from 
the group of deceased patients, containing the pblB gene, were selected: PBCN0103, 
PBCN0226 and PBCN0239. Different concentrations of mitomycin C, penicillin G, 
ciprofloxacin and levofloxacin (all purchased from Sigma-Aldrich, Zwijndrecht, The 
Netherlands) were tested to determine the sub-lethal doses. The pneumococci were 
grown in THY medium to midlog (OD 0.3), then diluted to OD 0.1, supplemented 
with 0.132 flg/ml mitomycin C, 0.0125 flg/ml penicillin G, 0.533 flg/ml ciprofloxacin 
or 0.533 flg/mllevofloxacin, and grown for an additional two hours at 37°C with 5% 
C02• Subsequently, serial dilutions were incubated on blood agar plates (BD) and 
incubated overnight at 3rC with 5o/o C02• Experiments were performed in triplicate 
to determine the expression of pblB. Mitomycin C was included as positive control, 
as it was previously shown to induce pblB expression (40). After two hours of growth, 
pneumococci were harvested by centrifugation. The supernatant was discarded and a 2:1 
volume of RNA protect (Qiagen, Hilden, Germany) was added to the pellet. RNA was 
isolated using the RNeasy kit (Qiagen, Hilden, Germany), following the manufacturer's 
instructions. Residual DNA was removed with a DNAse treatment using the Ambion 
Turbo DNA-free kit according to manufacturer's instructions (Ambion, Austin, Tx, 
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USA). The qRT-PCR was performed as previously described by DeBardeleben et al. ( 40) 
using the following primers: HBgyrAF: AATGAACGGGAACCCTTGGT, HBgyrAR: 
CCATCCCAACCGCGATAC, pblB_F: TACAGCTGTGAAAGCCTTGG, pblB_R: 
GATAGCCATCTGGATTCTCAGG. 
Construction of S. pneumoniae strain PBCN0162.1pb/B. A directed gene deletion 
mutant of S. pneumoniae strain PBCNO 162 was generated by allelic exchange of the target 
gene (pblB) with a spectinomycin resistance cassette (obtained from pR412T7), using 
the megaprimer polymerase chain reaction method, this resulted in PBCN0162~pblB. 
Briefly, flanking regions of ~500 bp, containing less than 150 bp of the coding sequence 
of the target genes, were amplified by PCR, with chromosomal DNA as the template. 
For each flanking region, the primer closest to the target gene (extension plus _L2 
or _R2) contained an additional sequence complementary to primer PBpR412_L or 
PBpR412_R In a second PCR, the PCR products of the two flanking regions and the 
antibiotic resistance cassette were combined, leading to incorporation of the antibiotic 
resistance cassette between the two flanking regions of the target gene, as previously 
described by Burghout et al., 2007 (41). The primer sequences are provided in Table 
52 in the supplemental material. Subsequently, the megaprimer PCR product was used 
for transformation of competent PBCN0162. Mutants, selected on blood agar plates 
containing spectinomycin, were assessed by colony PCR for recombination at the desired 
location on the chromosome. Chromosomal DNA was isolated from the mutants 
and used for transformation of competent strain PBCN0162. Gene inactivation was 
confirmed by quantitative real-time PCR gene expression analyses as described above 
(see 'Induction ofpblB expression by antibiotics'). 
Ex vivo (whole blood) assa}'$• Whole blood was obtained from healthy volunteers (n=6) 
after informed consent using 3.2% citrate-anticoagulated tubes (BD Vacutainer, Becton 
Dickinson, Plymouth, UK) and exposed to lx107 CFU/ml ~pblB or wt pneumococci 
for 30 minutes at 3rC. Subsequently, either medium, penG (0,0125 ug/ml), CPX 
(0,533 ug/ml), or a combination of penG and CPX were added, and samples were 
incubated for 2 hrs at 3rC. RNA isolation and qRT-PCR was performed as described 
in the previous section. These whole blood samples were also collected for measurement 
of platelet activation and PMC by flow cytometry. 
Measurement of platelet activation and platelet-monocyte (PMC) complex 
formation by flow cytometry. Platelet activation was measured by whole blood flow 
cytometry as previously described ( 42) by quantifYing the platelet membrane expression 
of the a-granule protein P-selectin (CD62P) and the binding of fibrinogen to the 
activated allb~3 receptor (GPIIbiiia complex). The following antibodies were used to 
incubate samples from the whole blood ex vivo assay: PE-Iabelled anti-CD62P (Bio-
Legend, San Diego, CA, USA), FITC-labelled anti-fibrinogen (FOlll-FITC; DAKO 
Ltd., High Wycombe, UK) and PC7-labelled anti-CD61 (platelet glycoprotein lila, 
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Beckman Coulter, Miami, FL, USA), the latter as platelet identification marker. The 
percentage of CD62P and fibrinogen on CD61-positive events were determined. 
Formation ofPMC was measured by incubating samples with PC7-labelled anti-CD61 
and PE-labelled anti-CD14 (a-glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein; Bio-Legend). After 20 min incubation, Optilyse B (Beckman Coulter, 
Fullerton CA, USA) was added to lyse erythrocytes. PMC formation was determined by 
quantifYing the MFI of CD 14+ cells that were also positive for the platelet identification 
marker CD61. All samples were measured using a FC500 flow cytometer (Beckman 
Coulter). 
Statistical Analyses. Results from independent experiments (involving n = 6 donors) 
were pooled, data are provided as means with 95% confidence interval unless otherwise 
stated. Generalized linear mixed model with post-hoc Bonferroni corrections were used 
to statistically analyze our experimental data. In the in vitro induction of pblB in culture 
medium, antibiotics were analyzed as a fixed effect on pblB expression, whereas inter-
donor variation was analyzed as a random effect (random intercept). For the whole 
blood assay, the presence or absence of bacteria and the different antibiotics, as well 
as their interactions, were analyzed as fixed effects on platelet activation and the inter-
donor variation were analyzed as a random effect (random intercept). All analyses were 
performed using SPSS version 20 (SPSS, Chicago IL, USA). The level of significance 
was set at p<0.05. 
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Results 
pblB is an independent determinant of 30-day mortality in IPD patients. We 
conducted an unbiased association study for the presence or absence of pneumococcal 
genes and mortality within the first 30 days of hospitalization (Figure 1A). Analysis 
was performed on 349 sequenced pneumococcal isolates, collected from a clinical IPD 
cohort, which comprised of strains from multiple lineages (1 O) (Figure IB). GWAS 
was stratified for population structure, whereby the sequence cluster membership as 
determined by Bayesian Analysis of Population Structure (BAPS) was used as a covariate 
in a Cochran-Mantel-Haenszel test (II). The overall30-day mortality within this IPD 
cohort was 11 o/o (37/346, outcome unknown for 3 cases). We observed that out of the 
1946 orthologous genes (OGs) of the pneumococcal accessory genome, pb!B had a 
strong statistical correlation with 30-day mortality, with a Bonferroni corrected p-value 
of 0.00034, and was present in 48% of the 349 clinical isolates. 
We identified pb!B as the phage-derived gene potentially most relevant in the 
pathophysiology of IPD through its interaction with platelets although it co-occurred 
with other phage genes (Table S1). Sequence examination of a representative clinical 
isolate PBCNO 103 revealed that two copies of pb!B were located within the same phage 
element next to OG_175 (holin) and OG_675 (hypothetical protein), which both co-
occurred with pb!B and were also significantly associated with 30-day mortality (Figure 
S1). In addition, OG_58, located in a different phage operon than the aforementioned 
genes, is also significantly associated with 30-day mortality (Table S1). Strikingly, these 
4 OGs were present simultaneously in 168 out of349 isolates (Figure S2). 
Among the IPD cases caused by pneumococci containing the pb!B gene (pb!B' ), 27 out 
of 165 died within 30 days (16.4%), compared to only 10 out of 181 (5.5%) caused by 
those not containing the pb!B gene (pb!B-) (p=O.OOll; OR3.3). In a sub-analysis of cases 
who died without any limitations of medical treatment, 30-day mortality was 15/165 
(9.1 %) in pb!B+ and 6/171 (3.3%) in pb!B- cases, which remained statistically significant 
(p=0.022; OR 2.8). For all cases, the presence of pb!B was an independent determinant 
of 30-day mortality (OR 3.4, 95% CI: 1.5-7.6), next to Charlson comorbidity index 
score (OR 1.5, 95% CI: 1.2-1.7) and meningitis (OR 4.6, 95% CI: 1.6-13.7). For 
pneumonia cases separately, in addition to Pneumonia Severity Index (PSI) score (OR 
1.4, 95% Cl: 1.1-1.7) and Charlson comorbidity score (OR 1.02, 95% CI: 1.01-1.04), 
both designed to predict mortality, the presence of pb!B was an independent risk factor 
for 30-day mortality (OR 3.4, 95% Cl: 1.2-9.5). 
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Figure 1A. Flowchart of the computational method used to identify the association between the presence of orthologous genes (OGs) and 30-
day mortality. B. A phylogenie tree of the variable sites from the core genome of all blood clinical isolates used in study. 
Phylogeny and sequence clustering were obtained from Cremers et al. (35). Pneumococcal clades are colored according to their sequence dusters. Filled squares: 
present, open squares: absent. In red: 30-day mortality. In dark green: pblB. In blue: other significantly associated genes (top to bottom: OG_675, OG_58, 
OG_1885, OG_2439, OG_1220, OG_558, OG_2259, OG_866, OG_2298, OG_l029, OG_l75 [phage holin], OG_2232). 
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Fluoroquinolones induced the expression of pblB. It was unknown whether pb/B-
containing temperate pneumophages are specifically induced by this group of antibiotics 
in vitro. Therefore, different doses of ciprofloxacin (CPX) and levofloxacin (LVX); both 
belonging to the fluoroquinolone group of antibiotics), mitomycin C (MitC) and 
penicillin G (PenG; a beta-lactam antibiotic) were tested on three pb/B-containing 
pneumococcal strains (PBCN0103, PBCN0226, PBCN0239) in THY medium to 
determine the sublethal dose of the four antibiotics (data not shown). To confirm that 
the selected doses were not bactericidal, the number colony forming units (CPU) were 
determined after exposure of MitC, PenG and the fluoroquinolones for two hours at 
37 oc and 5o/o C02 (Figure S3). At the same time point, the difference in expression of 
pblB, relative to gyrA, was measured. The DNA cross-linking agent MitC was included 
as positive control. Both the fluoroquinolones CPX and LVX (data not shown) induced 
the expression of pblB, which appeared specific for this group of antibiotics, as the beta-
lactam antibiotic PenG did not induce the expression. Furthermore, strong variation 
was found between the different pneumococcal strains (Figure 2). 
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Figure 2. Sublethal doses of antibiotics induced pneumococcal expression of the pblB phage 
in culture medium. 
Induction of pblB expression after two hours of incubation with sub-lethal doses of aotibiotics were 
determineJ in 4 Jifferent pneumococcal clinical isolate strains (PBCN0162, PBCN0239, PBCN0103 aod 
PBCN0226) by qRT-PCR measuring levels of mRNA relative to the control gyrA. Data presented are 
means with 95o/o confidence interval from three independent experiments. 
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Simulation of the clinical conditions in a whole blood ex vivo assay. Of the 312 patients 
with sequenced strains and known empirical treatment, 28% (n=88) received only beta-
lactam, 4% (n= 11) received only fluoroquinolones, and 44% received a combination of a 
beta-lactam and a fluoroquinolone. To simulate the aforementioned clinical conditions, 
we incubated live pneumococci strain PBCNO 162 containing a mutationally-inactivated 
pblB gene (11pblB) or wild type (wt) , with and without antibiotics (PenG, CPX, and a 
combination of PenG and CFX) in whole blood, determined the expression of pblB 
using qPCR (Figure 3A) and measured in the same samples the activation of platelets. 
We were able to measure pblB expression of the wt pneumococci in the whole blood 
samples without antibiotics (mean Cq value 30.6, 95% confidence interval29.5-31.7) 
and its increase in the presence of antibiotics. We first analyzed whether the different 
antibiotics significantly affect the wt-/ !1pb/B-bacteria-mediated platelet activation state 
in whole blood using a liner mixed model. We found that in all cases, stronger activation 
of platelets was observed with wt pneumococci as compared to 11pblB, which clearly 
indicates that PblB induces enhanced platelet activation irrespective of the exposure to 
antibiotics (Figures 3B). 
Whilst PenG did not strongly induce expression of pblB in THY-medium-grown 
pneumococci (Figure 2B), we observed PenG-dependent induction ("'3-fold) of 
expression in whole blood (Figure 3A). This might be caused by an indirect effect as 
a consequence of the bactericidal effect of PenG leading to the production of reactive 
oxygen species (ROS) which has DNA damaging effects, inducing the expression 
of pblB. Despite the fact that expression of pblB was much stronger in whole blood 
containing CPX, platelet activation is not increased accordingly, indicating a close to 
maximum activation under these conditions. 
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Figure 3. Live wild type pneumococci in an ex vivo whole blood assay showed increased ex-
pression of pblB upon exposure to fluoroquinolones and induced higher platelet activation 
as compared to the pblB knock-out mutant, irrespective of antibiotics exposure. 
Uve pneumococci (strain PBCN0162) containing a mutationally-inactivatedpbLB gene (11pblB) or wild type 
(Wf pblB) were incubated in whole blood in the presence or absence of penicillin G (PenG), ciprofloxacin 
(CPX), or a combination of both. After rwo hours of incubation at 37 oc and 5 o/o C02 the expression 
of pblB was determined using qRT-PCR measuring levels of mRNA relative to the control samples. One 
extreme outlier value, as determined by the Grubbs' test, in the CPX-exposed sample was excluded from 
the figure (A). Platelet expression of P-selectin, platelet-fibrinogen binding and platelet-monocyte complex 
formation were measured in the same samples using flow cytometry and expressed in percentage of positivity 
(B). Data presented are means with 95% confidence interval from three independent experiments with 
blood derived from a total of 6 human volunteers. 
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Discussion 
In the present study, GWAS was performed using the sequences of 349 S. pneumoniae 
invasive disease isolates to test for associations between the presence or absence of genes 
in the pneumococcal accessory genome and 30-day mortality. The presence of the phage-
encoded pb/B gene was positively associated with 30-day mortality in patients with IPD. 
This finding suggested the role of pb/B in the pathogenesis and expected cause of death 
of IPD. The presence of the pb/B phage gene as risk factor remained after adjustment 
for the local pneumococcal population structure using BAPS. We therefore speculate 
that similar studies in other areas with different pneumococcal populations would yield 
similar findings, although this requires confirmation by other studies. The pb/B phage 
in our cohort was barely present in serotypes 1 and 7F, which are associated with a lower 
risk of death than other serotypes (12). 
Past observations reported that 75% of pneumococcal clinical isolates carry 
bacteriophages (pneumophages) (13), which may be distributed among pneumococcal 
isolates with different capsular serotypes, indicating that these mobile genetic elements 
are widely spread among clinically relevant pneumococcal strains (14). The hypothesis 
that bacteria acquire virulence properties from phages is widely accepted (15), however, 
there has been a paucity of data supporting the role ofbacteriophages in the pathogenesis 
of S. pneumoniae-caused diseases. Interestingly, pb/B co-occurred with two other genes 
in the phage element, one encoding for a hypothetical protein and the other for Holin, 
both of which were also found to be significantly associated with 30-day mortality. 
The simultaneous co-occurrence of these genes in almost 50% of our clinical isolates 
further indicates a functional link between PblB expression and 30-day mortality. Holin 
is involved in the release and mounting ofPblB on the bacterial surface of S. mitis (16), 
allowing the PblB interaction with and propagation of platelet activation. Furthermore, 
PblB expression was also found to contribute to virulence in an in vivo rabbit model of 
infective endocarditis (17)(16). These findings indicate that pb/B has an important role 
in endovascular infection. 
Most patients in this cohort were treated with a combination of penicillin and 
ciprofloxacin, which represented a common first line empiric antibiotic regime 
for severe community acquired pneumonia in the Netherlands (18). We therefore 
proceeded with ex vivo experiments in which live pneumococci were incubated in whole 
blood supplemented with penicillin or ciprofloxacin or a combination of the two, to 
simulate the clinical conditions. The wild type pneumococci dearly demonstrated 
enhanced platelet activation. Interestingly, there were differences in platelet activation 
between knock-out mutant and wild type pneumococci even in the absence of high 
pb/B induction by the antibiotics. This may be explained by a constitutive expression of 
pb/B, which despite its low level was sufficient to induce platelet activation, as had been 
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described inS. mitis (17). 
S. pneumoniae has been shown to directly activate platelets mainly through TLR2 (19), 
with FcyRIIA and integrin allb~3 being involved in the amplification of bacteria-
induced platelet activation (20). This leads to platelet degranulation and subsequently 
the release of an array of chemokines and inflammatory mediators which may modulate 
not only their own function but also cells around them (21, 22). Our findings that 
whole blood exposure to WT pneumococci result in higher platelet activation compared 
to the pblB knock-out mutant may explain why bacteremic patients, infected with 
pneumococci containing the pblB gene, have a higher chance to die within 30 days. 
An approximate of 20% increase from baseline values in platelet P-selectin expression 
and PMC has been associated with adverse cardiovascular events and the acute phase 
of ischaemic stroke (23, 24), and the increase in platelet activation associated with pblB 
in our ex vivo assays exceeded this aforementioned value. By causing enhanced platelet 
activation, bacteria can become engulfed in a septic thrombus and protected from 
other cells of the immune system, allowing them to persist in the circulation (25). We 
speculate that the pblB-enhanced platelet activation may confer this survival advantage 
for S. pneumoniae. On the other hand, the resulting excess of platelet activation together 
with platelet clumping, platelet-leukocyte and platelet-endothelium aggregation 
and increased fibrin formation result in enhanced thrombo-inflammatory responses, 
microvascular obstruction, tissue hypoperfusion and finally multi-organ failure in sepsis 
(26, 27). The increase ofPMC formation predicts mortality in older septic patients (28), 
and platelet consumption associated with platelet activation in sepsis patients leads to 
thrombocytopenia, which has been shown to increase the risk of mortality (29-31). 
Our results have several potential clinical implications. We found that the presence 
of pblB was an independent determinant of 30-day mortality, which illustrates that 
bacterial GWAS potentially identifies intra-species variation related to clinical risks 
associated with human infection. Knowledge of the bacterial genotype might improve 
clinical management, by increasing alertness for a particular disease manifestation, in 
this case, diffuse intravascular coagulation in pblB-positive IPD patients. However, as 
disease manifestations are generally the product of multiple covariates, the contribution 
of bacterial genotype may vary across clinical settings. Secondly, our results demonstrated 
that fluoroquinolones induce higher pblB expression. However, the presence of 
fluoroquinolones was not required by the pblB-expressing wild type pneumococci to 
enhance platelet activation when compared with the knock-out mutant. Given that 
fluoroquinolones are frequently used in the management of community-acquired 
pneumonia for the coverage of atypical pathogens (32), sufficiently-powered studies are 
needed to investigate the clinical outcomes of the interplay between antibiotics regimen 
and pblB before drawing any conclusions. Thirdly, our study further highlights the 
importance of platelet-bacterial interaction and platelet activation, both in providing 
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a survival advantage for bacteria and in posing increased risk of mortality in patients. 
There is more and more data on the use of platelet function inhibitors in sepsis, however, 
these results at times contradict (9). Platelet inhibition by the P2Y12 receptor antagonists 
reduces the release of pro-inflammatory mediators from the platelet a-granules (33). 
Taken together with our findings, the benefit of anti-platelet agents as adjunctive therapy 
in sepsis warrants further investigation. 
The limitation of our study is the paucity of information on PblB protein expression 
on the pneumococcal surface. Previously, PblB of S. mitis was shown to function in 
adhesion by interacting with a 2-8-linked sialic acid residues on platelet membrane 
gangliosides (34). More recently, Hsieh and colleagues showed that pblB knock-out 
mutant pneumococci had decreased adherence to respiratory epithelial cells and 
platelets (8). Further work to demonstrate pneumococcal pblB expression at the protein 
level, as well as identifYing its binding domain on platelets, is needed. To the best of 
our knowledge, this is the only patient-based study which reveals the role of pblB gene 
expression in the pathogenesis of IPD based on an extensive analysis of both bacterial 
genomics and clinical data, independently adding substantial evidence to only two 
previous studies on pneumococcal pblB in vitro and in mice (8, 35) . 
In conclusion, we have integrated genome sequencing and GWAS with functional 
characterization to investigate the clinical role of genomic pblB presence in the mortality 
of patients with IPD. Bacterial GWAS may be an important tool to study the potential 
predictive value of certain virulence genes. As genomic sequencing is increasingly being 
utilized, we believe that this integrated approach will assist greatly in elucidating the 
mechanisms of bacterial pathogenesis, leading to the development of novel diagnostics 
and new therapeutic approaches. 
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Supplemental Material 
MethodS!. 
Adjustment for covariates of mortality. 
Certain patients had predetermined limitations of medical treatments, for example, 
opted not to be transferred to the intensive care unit. Therefore, the relation between 
OGs and 30-day mortality was also established separately for those who died after fully-
applied treatment. For potential covariates of the associations between OGs and 30-
day mortality, differences between patients with or without the OGs were assessed to 
decide which variables to include in the initial multivariable logistic regression model 
with 30-day mortality as dependent variable. The variables included were gender, age, 
year of inclusion, comorbidities (i.e. cancer, COPD, diabetes mellitus, liver-, renal-, 
cardiovascular- and cerebrovascular disease, Charlson comorbidity index score), clinical 
diagnosis, blood C-reactive protein level, presence of Systemic Inflammatory Response 
Syndrome (SIRS) and pleural effusion, Pneumonia Severity Index (PSI) score, admission 
to ICU, mechanical ventilation, and class of antibiotics administered. By manual 
stepwise backward elimination, the initial model was reduced to the final model, which 
only included covariates that contributed to the model with a p-value <0.10. These 
analyses were performed using IBM SPSS statistics version 23. 
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Table St. 
Associations between patients mortality within the first 30 days of hospitalization (30-
day mortality), and the presence and/or absence of genes in the pneumococcal isolates 
(represented as orthologous groups;OG). The p-values are Bonferroni corrected for multiple testing 
and stratified for population substructure using BAPS dusters [See material and methods]. 
OG_ID . .. Anbotanon clnuicafe4) .. .. P,r~~nce COtre~ted p~:vM~e 
OG_675 Hypothetical protein 163 0.000228 
OG_17 Phage hyaluronidase PblB 166 0.000344 
OG_58 Phage protein 177 0.001017 
OG_1885 Phage protein (prophage LambdaSa2) 85 0.001923 
OG_2439 Hypothetical protein 41 0.00201 
OG_1220 Phage protein 93 0.002032 
OG_558 ROK family protein 318 0.002231 
OG_2259 Hypothetical protein 64 0.002756 
OG_866 Phage protein 106 0.003589 
OG_2298 Phage protein 27 0.003685 
OG_1029 Hypothetical protein 78 0.003737 
OG_175 Phage holin 171 0.004332 
OG_2232 DNA-binding protein 41 0.045225 
Table S2. List of primers 
'kg~t ~Sfutt . . · .. .· Pi-W~ ·. ·.· •. ' .. ... . . '· .... ·, 
· . . . ',· 
' 
· . •. 
CvdG_pblB_PBCN162_L1 CGTTATCCAAATCGCAGGAC 
CvdG_pblB_PBCN162_L2 CCACTAGTTCTAGAGCGGCGGCTCTGTCAAATTGTCGTC 
CvdG_pblB_PBCN162_R1 AATTGGCGACGGCCATTTAC 
CvdG_pblB_PBCN162_R2 GCGTCAATTCGAGGGGTATCGACTATACCGCTTTAGTTCC 
PBpR412_L GCCGCTCTAGAACTAGTGG 
PBpR412_R GATACCCCTCGAATTGACGC 
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Figure Sl. Part of the operon of a phage element. 
Genes are directed in reverse. Labels indicate gene products and unlabeled arrows indicate hypothetical gene 
products. A total of 349 clinical isolates from patients with IPD were sequenced, annotated and the genes 
were clustered into orthologous groups (OG). Sequence examination of a representative clinical isolate 
PBCNO 103 revealed that two copies of pblB are located within a phage element in next to OG_l75 (holin) 
and OG_675 (hypothetical protein), both of which were also associated with 30-day mortality. 
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Figure S2. Co-occurrence of pb!Bwith other OGs associated with 30-day mortality. 
Thirteen OGs were statistically associated with 30-day mortality, of which four, namely OG_17 (pblB), 
OG_l75 (holin), OG_67S (hypothetical protein) and OG_S8 (phage protein), were present simultaneously 
in 168 out of the 349 pneumococcal genomes. We tested whether these OGs co-occur within the same 
clinical isolates rather than being randomly distributed. The number of isolates that contain zero, one, two, 
three or all four of these OG(s) simultaneously was counted ("Observed"). The expected co-occurrence 
of the four OGs over the 349 genomes was mathematically calculated by multiplying the probability that 
a randomly picked genome contains 0, 1, 2, 3 or all 4 OGs with the total number of genomes (349) 
("Expected"). 
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Average CFU values were determined after incubation of the three clinical pneumococcal strains 
(PBCN0162, PBCNOi39, PBCN0103, PBCN0226) for two hours at 37"C and 5% C02 in THY medium 
with sub--lethal doses of antibiotics; mitomycin C (MitC), penicillin G (PenG), ciprofloxacin (CPX) and 
levofloxacin (LVX). The condition without antibiotics(-) was included as negative control. 
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Abstract 
Platelets may play a role in the high risk for vascular complications in Gram-positive 
sepsis. We compared the platelet reactivity of 15 patients with Gram-positive sepsis, 
17 with Gram-negative sepsis and 20 healthy controls using a whole blood flow 
cytometry-based assay. Patients with Gram-positive sepsis had the highest median 
fluorescence intensity (MFI) of the platelet membrane expression of P-selectin 
upon stimulation with high dose adenosine-diphosphate (ADP; P=0.002 vs. Gram-
negative and P=0.005 vs. control groups) and cross-linked collagen-related peptide 
(CRP-XL; P=0.02 vs. Gram-negative and P=0.0001 vs. control groups). The Gram-
positive group also demonstrated significantly higher ADP-induced fibrinogen 
binding (P=0.001), as well as platelet-monocyte complex formation (P=0.02), 
compared to the Gram-negative group and had the highest plasma levels of 
platelet factor 4, ~-thromboglobulin and soluble P-selectin. In contrast, thrombin-
antithrombin complex and C-reactive protein levels were comparable in both 
patient groups. In conclusion, common Gram-positive pathogens induce platelet 
hyperreactivity which may contribute to a higher risk for vascular complications. 
160 
Higher platelet reactMty and platelet-
monocyte complex formation in Gram-positive sepsis compared to Gram-negative sepsis 
Introduction 
The concept that platelets play an important role in immunity and host defence, besides 
their role in haemostasis, has become widely accepted. Many different bacteria, viruses 
and other micro-organisms have been shown to interact with platelets, changing the 
platelet phenotype and the interaction of platelets with leukocytes [1, 2]. Whereas 
platelet activation is important in innate immune responses, excessive platelet activation 
may contribute to organ dysfunction and increase the risk for cardiovascular events 
(CVE) and infective endocarditis [3, 4]. Acute bacterial infections are associated with 
an increased risk for CVE, but the magnitude of this risk, as well as the risk for infective 
endocarditis, depends on the type of infections [5-7]. 
Bacteria are generally divided in Gram-positive and Gram-negative bacteria. In contrast 
to Gram-negative bacteria, Gram-positive bacteria usually have a thick multi-layered 
peptidoglycan cell wall rich in teichoic acid with virtually absent lipopolysaccharide 
(LPS) [8]. Clinical studies have shown a high incidence of cardiovascular complications 
in patients with Gram-positive bacterial infection [9, 10]. This risk appears lower for 
urinary tract infections, which are usually caused by Escherichia coli or other Gram-
negative bacteria [5, 11]. In addition, infective endocarditis is predominantly caused by 
Gram-positive bacteria [12]. 
Laboratory studies have shown that Gram-positive bacteria, such as Staphylococcus 
aureus and Streptococcus spp., bind to and activate platelets, whereas this has not been 
demonstrated for most Gram-negative bacteria [13]. Interestingly, our group recently 
demonstrated that bacteremia due to Streptococcus pneumoniae in pigs lead to platelet 
hyperreactivity [14]. On the other hand, data on the platelet-activating properties 
of E coli LPS, which exerts potent inflammatory effects, have been conflicting and 
challenging to transiate to the human in vivo setting [15-18]. 
Studies on the platelet-activating properties ofbacteria were most frequently done either 
ex vivo or in animal models. To the best of our knowledge, no study has provided human 
in vivo data comparing platelet reactivity in patients with Gram-positive or Gram-
negative sepsis. We therefore studied platelet reactivity, platelet-monocyte complex 
(PMC) formation and activation of the plasmatic coagulation in a cohort of patients 
with either Gram-positive or Gram-negative sepsis. 
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Methods 
Study population 
We enrolled adult patients admitted with a Gram-positive or Gram-negative sepsis in the 
Radboud university medical center, Nijmegen, the Netherlands. A list of patients with 
positive blood cultures was generated daily by the Department of Medical Microbiology 
and patients were reviewed for in- and exclusion criteria. Blood was drawn for platelet 
reactivity and haemostasis tests within 72 hours after the first blood culture collection 
and initiation of antibiotic treatment. Exclusion criteria were admission to the intensive 
care unit (ICU), renal replacement therapy, use of P2Y12 receptor antagonists, active 
malignancy, the presence of any chronic viral infection, including HIV or hepatitis 
B/C and a positive blood culture with a possible contaminant (e.g. coagulase-negative 
staphylococci). ICU patients were deliberately excluded to avoid confounding of organ 
failure on the assessment of the effects of bacteremia on platelet reactivity. Use of a low 
dose of aspirin or vitamin K antagonists was not a reason for exclusion, as these drugs 
have no influence on the platelet reactivity assay used [19, 20]. A group of healthy 
volunteers were enrolled as controls. Patients and healthy controls were included after 
written informed consent was obtained. The study is approved by the ethical committee 
of the Radboud university medical center. 
Laboratory assays 
Platelet reactivity 
Venous blood was collected in citrated Vacutainer tubes (3.2% sodium citrate; Becton 
Dickinson, USA). Platelet reactivity was determined within 1 hour after blood drawing 
by a flow cytometry assay that was described earlier [21, 22]. In short, the expression 
of the a-granule protein P-selectin and binding of fibrinogen to the activated integrin 
allbj33 are measured as markers of platelet degranulation and aggregation, respectively, 
in unstimulated samples and after ex vivo platelet stimulation by adenosine diphosphate 
(ADP, low dose of 7.8 j.J.M and high dose of 31.2 j.J.M, Sigma-Aldrich, USA) or cross-
linked collagen-related peptide (CRP-XL, low dose of 39 ng/L and high dose of 625 
ng/L, kind gift from Pro£ dr. R. Farndale, Cambridge, UK). Whole blood was added 
to a mixture of HEPES-buffered saline and saturating concentrations of PE-labeled 
anti-CD62P (P-selectin; Bio-Legend, San Diego, USA), FITC-labeled anti-fibrinogen 
(DAKO Ltd. , High Wycombe, UK) and PC7-labeled anti-CD61 (platelet identification 
marker; Beckman Coulter, France). After 20 minutes incubation at room temperature, 
0.2% paraformaldehyde was added and samples were analyzed using an FC500 flow 
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cytometer (Beckman Coulter, France). Platelets were gated based on their forward- and 
sideward-scatter properties and positivity for CD61, which was defined as a median 
fluorescence intensity (MFI) exceeding that of its matched isotype control. Next, the 
MFI of CD62P and fibrinogen relative to their matched isotype controls on CD61-
positive events was determined. 
Platelet-monocyte complexes 
The formation of PMC, which is considered a sensitive marker for platelet activation 
[23], was determined by incubating citrated whole blood with PC7-labelled anti-CD61 
and PE-labelled anti-CD14 [a glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein; Bio-Legend] as a monocyte identification marker. Optilyse B, which 
contains both lysing buffer and fixative (Beckman Coulter, USA) was added after 30 
min followed by distilled water. The PMC formation was quantified based on the MFI 
ofCD61 on CD14-positive cells. 
Soluble platelet proteins and thrombin-antithrombin complexes 
Platelet-poor plasma was harvested from citrate-anticoagulated whole blood by 
centrifugation (1500 g without brake, 15 min, 20°C) . Plasma concentrations of 
platelet factor 4 (PF4), b-thromboglobulin (b-TG), soluble P-selectin and thrombin-
antithrombin (TAT) complexes were subsequently measured using ELISA as previously 
described [24]. Human PF4 (MAB7951, AF795), ~-thromboglobulin (MAB393, 
BAF393) and soluble P-selectin (DYE137) antibodies were purchased form R&D 
systems, Abbington, UK. Sheep anti-human thrombin (SAHT-AP, SAHT-HRP) 
antibodies were purchased from Kordial Affinity Biologicals, USA. 
Full blood count and C-reactive protein 
A full blood count was determined using a standard hematology analyser (Sysmex XE 
5000) calibrated for standard patient care. C-reactive protein (CRP) was determined 
using immunologic agglutination detection and the urinary concentration of creatinine 
was determined with enzymatic colorimetric detection using Abbott Aeroset analyzer 
(Abbott Laboratories). 
Statistical analysis 
Differences in patient characteristics across groups were compared using analysis of 
variance (ANOVA) with post-tests and chi-square test for proportions. Data on platelet 
reactivity are expressed as medians with interquartile range (IQR), while data on plasma 
soluble markers and PMC formation are expressed as medians with IQR, minimum and 
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maximum values. The Mann-Witney U test was used to analyse statistical differences in 
the time intervals between the haemostatic tests and antibiotic treatment initiation or 
blood culture, in the CRP levels among the patient groups and in the platelet reactivity 
of patients with or without aspirin. Platelet reactivity and plasma markers levels between 
multiple groups were compared using the non-parametric Kruskal-Wallis test with 
Dunn's post-test. Analyses were performed with GraphPad Prism (GraphPad Software, 
USA). Pvalues less than 0.05 were considered statistically significant. 
Results 
Thirty-two patients with sepsis were enrolled, of whom 15 had a Gram-positive and 17 
a Gram-negative sepsis, with 20 healthy individuals as controls (Table 1). Patients in the 
Gram-positive group presented clinically with sepsis (n=8), erysipelas (n=3), pneumonia 
(n=2), and infected diabetic foot ulcer (n= 1). The most common clinical diagnosis in the 
Gram-negative group was urosepsis (n=ll), followed by cholecystitis and intravascular 
catheter-related infection (each n=2) , as well as endometritis and infected diabetic foot 
ulcer (each n=1) . Patient characteristics in both groups were similar, including time 
intervals between the haemostatic tests and antibiotic treatment initiation or blood 
culture (Fig 1A). The levels of CRP, measured on the day (± 24 hrs) when haemostasis 
assays were also performed, were comparable across both patient groups (Fig 1B). The 
mean age of the controls was lower than the patients in both sepsis groups. 
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Table 1. Characteristics of study population 
. . ·':···: 
.: -
,_ .. G:tam~vt)s~rl:~ : ~-Negati~'- ~eatthy ~iitto~ • .· .Pv4~~' . -
Number 15 17 20 
Male, n (%) 12 (80) 11 (65) 12 (60) 0.99 
Age, years 67 (8) 70 (13) 31 (8) <0.001* 
Haemoglobin (y/ dL) 7.6 (1) 7.2 (0.9) ND 0.24 
Leukocytes (x109/L) 12.2 (4.4) 10.4 (4.4) ND 0.26 
Platelets (x109/L) 178 (45) 202 (110) ND 0.44 
Creatinine (my/ dL) 98 (27) 118 (57) ND 0.23 
C-reactive protein (mg/L) 163 (97) 136 (85) ND 0.41 
Aspirin, n (%) 4 (27) 6 (35) 0 (0) 0.30 
Vitamin K antagonist, n (%) 3 (20) 4 (24) 0 (O) 0.41 
Causative pathogens, n (%) 
Gram-positive 
Staphylococc-.JS aureus 10 (67) 
Streptococcus 2 (13) 
pneumoniae 
Group G Streptococcus 2 (13) 
Group C Streptococcus 1 (7) 
Gram-negative 
Escherichia coli 12 (71) 
Citrobacter spp. 1 (6) 
Haemophilus influenzae 1 (6) 
Klebsiella oxytoca 1 (6) 
Serratia spp. 1 (6) 
Bacteroides fragilis 1 (6) 
Data depicted are means with SD unless otherwise indicated. ND, not determined. Statistical differences 
are analysed by using AN OVA with post-tests or chi-square test. * P values were statistically significant for 
differences between healthy controls vs. Gram-positive and Gram-negative groups. 
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Figure 1. Timing of haemostatic tests and plasma concentration of C-reactive protein (CRP). 
Box plots of the (A) time interval between platelet reactivity and haemostatic test and positive blood culture 
(left panel) or start of antibiotics (right panel). (B) CRP levels at the day (+I- 24 hrs) of the haemostasis assays. 
Presented data are medians with IQR, minimum and maximum values. NS, not statistically significant. 
Participants in the Gram-positive group had a significantly higher ADP- and CRP-
XL-induced P-selectin expression than participants in the Gram-negative group and 
controls (Fig 2A). Upon stimulation with high dose ADP (31.2 uM), the Gram-positive 
group demonstrated the highest MFI of P-selectin (median 49.2, IQR 34.6 - 55.2) 
compared to the Gram-negative (28.1, 25.3- 38.3; P=0.002) and control groups (29.7, 
26.2- 35.7; P=0.005). When induced with high dose CRP-XL (625 ng/ml), patients in 
the Gram-positive group had a significantly higher P-selectin (89.8, 72.4 - 95.4) than 
both the Gram-negative (69, 67.7- 80.3; P=0.02) and control groups (67.6, 64.3-
72.4; P=0.0001). ADP-induced platelet-fibrinogen binding was also significantly higher 
in this group (18.3, 15.6 - 24.2 vs. 12.6, 10.8 - 13.9; P=0.001 vs. Gram-negative 
group). There were no differences in these parameters between the Gram-negative group 
and the controls. 
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The Gram-positive group had significantly higher PMC formation compared to Gram-
negative group. Median (IQR) MFI values of the platelet marker CD61 on CD14-
positive cells were 15.6 (13.7- 17.1) in the Gram-positive group compared to 8.5 (8.1-
9.5; P=0.02)) in the Gram-negative group and 3.1 (2.0- 6.5; P<O.OOO I) in controls (Fig 
2B). The difference between the Gram-negative group and controls was also significant 
(P=0.004). There was a weak positive correlation between the platelet expression of 
P-selectin and PMC formation in the patients (Spearman, R2=0.22; P=0.008) 
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Figure 2. Platelet reactivity and platelet-monocyte complex in patients with Gram-positive 
and Gram-negative sepsis. 
(A) Platelet membrane expression of P-selectin and platelet-fibrinogen binding is depicted as median 
fluorescence intensity (MFI) in arbitrary units, at baseline and after stimulation with two concentrations of 
the platelet agonists adenosine diphosphate (ADP) and collagen-related peptide (CRP-XL) in healthy controls 
(n=20), patients with Gram-positive (Gram+, n=l5) and Gram-negative (Gram-, n=l7) sepsis. (B) Platelet-
monocyte complex (PM C) formation is depicted as the MFI of the platelet marker CD61 on CD14-positive 
cells. Data depicted are medians with IQR (platelet reactivity) or median with IQR, minimum and maximum 
values (PM C). * Gram-positive vs. Gram-negative, #Gram-postive vs. healthy controls. 
167 
ChapterS 
Activated platelets release their a-granule contents, including P-selectin, PF4 and ~ -TG 
in the plasma. Plasma concentrations of these proteins were significantly higher in the 
Gram-positive group compared with the Gram-negative group and the healthy controls. 
Median (IQR) concentrations ofPF4 in these respective groups were 32.1 ng/ml (18.6 
- 46.2 ng/ml), 16.5 ng/ml (2.1 - 25.3 ng/ml; P=0.01 vs. Gram-positive) and 7.8 ng/ml 
(5.0- 9.8 ng/ml; P<0.001 vs. Gram-positive). ~-TG concentrations were 200.7 ng/ml 
(150.6- 250 ng/ml), 126.5 ng/ml (77.1-174.9; P=0.038 vs. Gram-positive) ng/ml and 
81.7 ng/ml (66.8- 96.8 ng/ml; P=0.0008 vs. Gram-positive). P-selectin concentrations 
were 136.4 ng/ml (92.9- 168.4 ng/ml), 111.2 ng/ml (96.7-137.1 ng/ml; P=0.61 vs. 
Gram-positive) and 84.4 ng/ml (72- 99 ng/ml; P=0.015 vs. Gram-positive). The latter 
protein was the only soluble platelet parameter that was significantly higher in the Gram-
negative group compared to controls (P=0.045). In contrast, there were no significant 
differences across the three groups in the plasmatic coagulation marker TAT complexes 
(Fig 3). In all patients, soluble P-selectin were weakly correlated with PMC formation 
(Spearman, R2=0.23; P=0.01). Data of these plasma soluble markers were missing in 2 
patients diagnosed with S. aureus sepsis in the Gram-positive group. 
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Figure 3. Plasma concentrations of platelet and coagulation activation markers. 
Data depicted are medians with IQR, minimum and maximum values. 
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We performed subanalyses within the patient groups and found that those with a S. 
aureus or Streptococcus spp sepsis in the Gram-positive group had comparable platelet 
P-selectin expression upon induction with high dose ADP (MFI 47.4, 40.7- 53.8 vs. 
44.5, 26.9- 58.2; P=0.67) and platelet-fibrinogen binding (MFI 19.0, 14.7-24.0 vs. 
17.4, 13.6- 22.3; P=0.61), as well as PMC formation (18.3, 15.3-21.9 vs. 14.4, 12.1-
16.5; P=0.26). Similarly, there were no differences in these parameters between patients 
with E. coli and other Gram-negative bacteria (data not shown). Aspirin treatment 
did not influence ADP- and CRP-induced platelet reactivity, PMC formation or the 
plasma soluble markers (data for ADP-induced platelet reactivity and PMC formation 
shown in Fig 4). There was no significant correlation between ADP-induced P-selectin 
expression and the time interval between haemostatic tests and the start of antibiotics 
administration (Spearman, R2=0.06, P=0.07). 
A P-selectin 8 Platelet-monocyte complex 
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Figure 4. Platelet reactivity in aspirin and non-aspirin using patients. 
Data depicted are medians with IQR, minimum and maximum values. 
Discussion 
~ 
Non-Aspirin 
Our data reveal that a sepsis with common Gram-positive pathogens is associated with 
more pronounced platelet activation, platelet hyperreactivity and PMC formation 
compared with sepsis due to common Gram-negative pathogens. These differences were 
observed despite comparable CRP plasma concentrations, suggesting that inflammation 
by itself is not a major driving force in sepsis-induced platelet activation. In contrast, 
there were no dear differences in the plasmatic coagulation parameter TAT complexes 
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between the Gram-positive and Gram-negative groups. 
The majority of patients in the Gram-positive group had aS. aureus sepsis, whereas E. coli 
was the most common bacteria in the Gram-negative group. S. aureus and Streptococcus 
spp. are able to directly bind and activate platelets and different mechanisms through 
which these pathogens activate platelets have been reviewed recently by Hamzeh-
Cognasse et. al. [13]. S. aureus can release toxins or use surface protein such as protein 
A and clumping factor A, which can subsequently bind platelet receptors directly or 
indirectly [25, 26]. Furthermore, FcyRIIa on platelets is essential for the amplification 
of their reactivity to these bacteria. The engagement of FcyRIIA by bacteria-bound 
plasma IgG, together with the integrin aiibl33 activation, results in integrin/FcyRIIA 
ITAM signalling which further triggers ADP, thromboxane ~ (T~) and PF4 release 
and leading to a strong positive feedback cascade of platelet activation [27]. Other S. 
aureus proteins, including lipoteichoic acid [28], inhibit platelet activation, although 
our present findings indicate that the platelet-activating potential of S. aureus are 
dominant in vivo. It was beyond the scope of our current study to characterize the 
pathways of platelet activation by the isolated pathogens. E. coli was also recently 
demonstrated to activate platelets in a FcyRIIa-dependent manner [29, 30], although 
ex vivo data of platelet activation by E. coli lipopolysaccharide are conflicting [ 15-17, 
31]. Administration oflipopolysaccharide to healthy volunteers also does not appear to 
strongly activate platelets [32, 33], a finding supported by our data of limited platelet 
activation in patients with E. coli sepsis. 
Vascular complications are common in patients with staphylococcal or streptococcal 
septicaemia [10, 34]. We speculate that the strong platelet-activating potential of these 
micro-organisms contributes to these complications. Platelet function inhibitors might 
reduce the risk for these complications [35], but this may not be without hazard, as 
activated platelets are able to limit the growth of and engulfS. aureus [36, 37]. In a 
mouse model, platelet inhibition also reduced killing of S. aureus [38, 39]. 
Limitations of our study include the limited number of patients in both groups and 
that the haemostatic assays were only performed once after the blood cultures became 
positive. Gram-negative bacteria can be rapidly killed by antibiotics and, even though 
no correlation existed between platelet reactivity and the time intervals between 
haemostatic tests and antibiotic treatment initiation, we cannot exclude that increased 
platelet activation was present in the Gram-negative group at presentation and that this 
normalized promptly after administration of antibiotics (i.e. before the blood culture 
became positive). Furthermore, many Gram-positive and Gram-negative bacteria exist 
and our findings cannot be extrapolated to other pathogens that were not included in 
this study, as their platelet-activating properties may differ. Finally, some patients used 
aspirin, which inhibits platelet activation via the COX-1 pathway [40]. This was, in 
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our study, not associated with decreased platelet reactivity via the ADP and collagen 
pathway or PMC formation. 
In conclusion, Gram-positive sepsis is associated with marked platelet activation, in 
contrast to Gram-negative sepsis, and this may contribute to the vascular complications 
seen in these infections. Given the role of platelets in immunity and host defence, studies 
are currently undertaken investigating the possible role of platelet inhibition in sepsis 
patients [41]. It is important that causative pathogens are taken into account, as clear 
differences exist in the platelet-activating potential of bacteria, which influences the risk 
of vascular complications. 
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Abstract 
Objective: Platelets are key cells in atherosclerosis and acute cardiovascular events. 
Platelet hyperreactivity and increased platelet-monocyte aggregation (PMA) are 
found in HIV-infected patients and may contribute to the excess cardiovascular risk. 
The integrase inhibitor raltegravir (RAL) has been associated with better residual 
viral suppression and reduction in inflammatory and coagulation biomarkers. The 
aim of our study was to investigate whether RAL-treated patients have reduced 
platelet reactivity and PMA. 
Design and methods: We performed a cross-sectional study involving 80 
virologically suppressed adult HIVl-infected patients on a RAL-based (n=25), non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based (n=30) or a protease (PI)-
based (n=25) regimen and 30 healthy controls. Platelet reactivity was determined by 
measuring platelet P-selectin expression and the binding of fibrinogen to platelets to 
stimulation with two concentrations of adenosine disphosphate (ADP). PMA was 
determined by measuring the expression of the platelet marker CD42b on CD 14 
positive cells. 
Results: HIV-infected individuals had higher platelet reactivity and PMA than 
controls. RAL-treated individuals showed significantly lower P-selectin expression 
to stimulation with low (P=0.026 vs. NNRTI and P=0.005 vs. PI-group) and high 
dose ADP (P=0.009 vs. NNRTI and P=0.003 vs. PI-group). A similar trend for was 
found for fibrinogen binding although only the difference in P-selectin expression 
between RAL- and PI-treated patients reached statistical significance (P=0.038). 
PMA was also lower in the RAL group compared with the NNRTI (P=0.037) and 
PI (P=0.034) groups. 
Conclusion: Use of a RAL-based regimen was associated with a reduction in 
persistent HIV-induced platelet hyperreactivity and PMA compared with NNRTI-
and PI-based regimen. 
Keywords: HN, platelet, cardiovascular, raltegravir, platelet-monocyte aggregation 
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Introduction 
Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in 
HN-infected individuals (1, 2). The precise mechanisms that contribute to this increased risk 
fur CVD remain to be elucidated, but an important role is attributed to persistent immune 
activation and inflammation (3, 4). 
Atherosclerosis is an inflammatory disorder, and platelet plays a pivotal role in its onset and 
progression (5). Inflammation activates platelets, which results in the release of a variety of 
inflammatory mediators that among others promote platelet adherence to the endothelium, 
leukocyte recruitment and formation of atherosclerotic lesions (6, 7). Platelet reactivity is 
helpful in predicting the risk of future cardiovascular events (8, 9), and activated platelets 
fOrm aggregates with circulating monocytes, rendering them more proinflammatory and 
proatherogenic (1 0-14). 
IncreytSed platelet monocyte aggregation (PMA) and platelet reactivity to platelet agonists 
are found in HN-infected patients (15-19). However, the impact of different regimens of 
antiretroviral therapy (ART) on platelet function and PMA has not been rigorously studied. 
Intensification of ART with the integrase inhibitor raltegravir (RAL) was recently shown 
to suppress residual viral replication and reduce plasma levels of the coagulation marker 
d-dimer (20). In addition, switching from a protease inhibitor (PI) or enfuvirtide to RAL 
decreased inflammatory and coagulation biomarkers (21). This suggests that a raltregravir-
based regimen may also be associated with reduced platelet hyperresponsiveness and PMA. 
We aimed to investigate whether virologically suppressed HN-infected patients using a 
RAL-based regimen have reduced platelet reactivity and PMA compared to those using a 
non-nucleoside reverse transcriptase reverse inhibitor (NNRTI)-based or PI-based regimen. 
Methods 
Study population and design 
We performed a cross-sectional single cohort study enrolling adult HN-infected patients 
during routine outpatient visits between November 2013 and April20 14 in the Radboud 
university medical center. All patients had a suppressed viral load(:-;:; 40 copies/mL) and 
were on a stable ART regimen for more than four months. The regimen consisted of 
a backbone of two nucleoside reverse transcriptase inhibitors (NRTis) with one of the 
following options: RAL; an NNRTI (efavirenz, rilpivirin or nevirapine) or a ritonavir-
boosted PI (darunavir, atazanavir, or lopinavir). Exclusion criteria were the use of aspirin 
or other platelet function inhibitors, as well as the presence of any other concurrent 
infection including active hepatitis B, C or syphilis infection. Data on platelet function 
and PMA in this cohort were compared with healthy adult volunteers of comparable age 
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and gender. The ethical committee of the Radboud university medical center approved 
this study and all participants provided written informed consent to participate. 
Platelet reactivity and platelet-monocyte aggregation assay 
Venous blood was collected in Vacutainer tubes containing 3.2% sodium citrate (Becton 
Dickinson). Baseline platelet activation status and platelet reactivity were measured using 
a novel flow cytometry-based assays which details were recently described (22, 23). In 
this assay, platelet membrane expression of the alpha-granule protein P-selectin ( CD62P) 
and binding of fibrinogen to the activated anbl33 receptor (the GPIIbiiia complex) are 
measured as markers of platelet activation at baseline and after low (7.8 uM) and high 
dose (31.2 uM) of the platelet agonist adenosine diphosphate (ADP) with the following 
two combinations ofPE-labeled anti-CD62P together with FITC-labeled anti-CD42b 
(anti-glycoprotein (GP)-1 ba; platelet-identification marker; both antibodies from 
Bio-Legend, San Diego, USA) or FITC-labeled anti-fibrinogen (DAKO Ltd., High 
Wycombe, UK) with PE-labeled anti-CD42b (Bio-Legend, San Diego, USA). After 
incubation for 20 minutes at room temperature, 0.2% paraformaldehyde was added. 
Samples were analyzed with a Becton Dickinson flow cytometer. Platelets were gated 
based on their forward- and sideward-scatter (FSC/SSC) properties and positivity for 
CD42b, which was defined as a mean fluorescence intensity (MFI) exceeding that of 
the matched isotype control. Next, the MFI and percentage positivity of CD62P and 
fibrinogen on CD42b positive events were determined. 
PMA was determined by incubating citrated whole blood with FITC-labeled anti-
CD42b with PE-labeled anti-CD14 (a glycosylphosphatidylinositol (GPI)-linked 
membrane glycoprotein; Bio-Legend, San Diego, USA) as a monocyte identification 
marker. Optilyse B (Beckman Coulter, Fullerton, CA) and distilled water were added 
after 30 minutes. PMA was determined using the proportion ofCD14+ cells that were 
also positive for CD42b and the MFI ofCD42b on CD14+ cells. 
Statistical analysis 
Differences in patient characteristics across the ART-regime groups were compared 
using ANOVA with post-tests or chi-squared tests for proportions. Data of platelet 
reactivity are expressed as means with standard deviation (SD). PMA is expressed as 
median with interquartile range (IQR). Differences between groups were analysed with 
Student t-tests (platelet reactivity data) or with Mann-Whitney U test (PMA data). 
Subsequently, platelet reactivity data were analyzed in a general linear model with 
P-selectin expression and fibrinogen binding as dependent variables, ART group and 
duration of treatment as fixed factors and age, hypertension, and statins and abaca vir use 
as covariates. All analyses were performed with SPSS version 20 (SPSS, Inc., Chicago, 
Illinois). P<0.05 were considered statistically significant. 
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Table 1. Characteristics of study population 
Figure lA-B shows the results of the platelet reactivity assay. A significantly lower 
P-selectin expression was observed in RAL-treated patients compared with NNRTI- and 
PI-treated patients, using both the low (P=0.026 vs. NNRTI and P=0.005 vs. PI-group) 
and high dose ADP concentration (P=0.009 vs. NNRTI and P=0.003 vs. PI-group). A 
similar trend for was found for fibrinogen binding. The RAL-treated group had lower 
fibrinogen binding to platelets, although this difference was only significant for the 
comparison with the PI-group after high dose ADP (P=0.038). P-selectin expression 
.. 
' 
. ' RA4 NNR.TI ·py · C<tntrols · 
' 
< ··' 
Number 25 30 25 30 
Male, n (%) 18 (72) 26 (87) 20 (80) 24 (80) 
Age, years 50 (11)* 47 (11) 42 (9) 41 (9) 
CD4 count, x109/L 667 (300) 666 (207) 721 (244) NA 
Cholesterol, mmol/L 4.8 (0.8) 4.7 (0.7) 4.7 (0.8) ND 
Platelets, x 109 /L 212 (35) 218 (58) 217 (36) ND 
Abacavir containing-regime, n (%) 6 (24) 9 (30) 3 (12) NA 
Hypertension history, n (%) 3 (12) 4 (13) 1 (4) NA 
Diabetes mellitus history, n (%) 1 (4) 4 (13) 2 (8) NA 
Statin use, n (%) 5 (20) 7 (23) 1 (4) NA 
Duration of ART use NA 
4-6 months, n (%) 3 (12) 5 (17) 0 (0) 
7-12 months, n (%) 1 (4) 6 (20) 1 (3) 
> 12 months, n (%) 21 (84) 19 (63) 24 (80) 
Data depicted are mean with SD unless otherwise indicated. Statistical differences are analyzed by using 
ANOVA with post-tests or chi-squared test. * P<0.05 versus PI and control group. RAL, raltegravir, 
NNRTI, non-nuclease reverse transcriptase inhibitor, PI, protease inhibitor, NA, not applicable, ND, not 
determined. 
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Figure 1. Platelet reactivity and platelet-monocyte aggregation in HIVl-infected individuals 
using different antiretroviral regimens. 
(a) Platelet P-selectin expression and (b) fibrinogen binding to platelets, depicted as the mean fluorescence 
intensity (MFI) in arbitrary units (AU), at baseline and after stimulation with 2 concentrations of ADP 
in HNl-infected individuals using a raltegravir (RAL)-based (n=25), non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based (n=30) or protease inhibitor (PI)-based (n=30) regimen. (c) Platelet-monocyte 
aggregation is depicted as the MFI of the platelet marker CD42b on CD14 positive cells. (d) Fibrinogen 
binding to platelets is shown in individuals using an abacavir (ABC) vs. non-ABC containing regimen. 
Data depicted are means with SD (platelet reactivity) or median with IQR (PMA). * P<0.05 RAL versus 
the NNRTI- and PI-treated groups; t P<0.05 control versus RAL group;# P<0.05 versus the PI group; ## 
P<0.05 versus the non-ABC group. 
Results 
A total of80 HIV-infected patients were enrolled with a minimum of25 patients per ART 
group and 30 individuals as healthy controls. Characteristics of the study participants 
are presented in Table 1. The groups were well matched for all characteristics except for 
age, which was significantly higher in the RAL group compared with the PI- and control 
group. 
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remained significantly higher in the RAL-treated group compared to healthy volunteers 
(P=0.011 and P=0.026 for low and high dose ADP, respectively). In unstimulated 
samples, the RAL group and the controls had a significantly lower mean (±SD) baseline 
P-selectin expression and platelet-fibrinogen binding compared to the PI group (MFI 
P-selectin: 4.8±0.8 and 4.7±0.5 vs. 5.9±1.5; P<0.005 and MFI fibrinogen binding: 
3.3±0.5 and 3.2±0.6 vs. 3.8±0.7; P<0.02). 
P-selectin mediates binding of platelets to monocytes (24). The RAL-treated group 
had a lower PMA compared to the NNRTI (P=0.004) and PI (P=0.001) groups, as 
indicated by a lower MFI of the platelet identification marker CD42b on CD 14 positive 
cells (Figure 1 C). 
The NRTI abacavir has previously been shown to increase platelet reactivity (25). 
Abacavir was used by 17 (19.8%) of the HIV-infected participants in our study. 
Abacavir-treated individuals had a trend for increased platelet reactivity with higher 
P-selectin expression and fibrinogen binding (Figure 1D, only fibrinogen binding 
shown). The only significant difference was fibrinogen binding to the low ADP 
concentration (P=0.02). There were no significant differences in PMA between abacavir 
and non-abacavir treated individuals (data not shown). Finally, in a general linear model 
adjusting for duration of ART treatment, age, hypertension and the use of statins and 
abacavir, P-selectin expression in the RAL-treated group remained significantly lower 
compared to the NNRTI- (P=0.002 and P=0.003 for low and high dose ADP) and PI-
treated group (P=0.001 and P=0.002, respectively). 
Discussion 
Our study shows that HIV-infected individuals on a RAL-based regimen show reduced 
platelet hyperreactivity and PMA compared with those on a NNRTI- or PI-based 
regimen. Our results also supports findings from previous studies that persisting platelet 
hyperreactivity and increased PMA are found in HIV-infected patients despite ART use 
(15-19), although reduced platelet aggregation by impedance aggregometry was also 
recently reported in both treated and untreated HIV-infected individuals (26). 
Platelets play a pivotal role in atherosclerosis and acute cardiovascular events (5) and 
persisting platelet hyperreactivity may explain some of the excess risk for cardiovascular 
events in HIV beyond that explained by traditional cardiovascular risk factors (27). Our 
finding that a RAL-based regimen was associated with reduced platelet hyperreactivity 
and PMA may therefore be clinically relevant as higher values of these parameters are 
associated with an increased risk for future cardiovascular events (9, 12, 28-30). 
Increased expression of both P-selectin, which mediates the interaction of platelets with 
monocytes, and the active conformation of a1Ib~3' which allows platelets to aggregate and 
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adhere via fibrinogen, which were both determined in our study, have been previously 
related to faster progression of atherosclerosis (7, 31, 32). 
The mechanism underlying the lower platelet reactivity to AD P and PMA in RAL-treated 
individuals is still unexplained. The switch to a RAL-based regimen was associated with 
a decrease in inflammatory and coagulation markers in some studies (20, 21, 33) and 
reduced inflammation may be responsible for the lower platelet reactivity. Vice versa, 
the reduction in PMA and platelet hyperreactivity may also contribute to the decrease in 
inflammation in itself, as PMA and platelet activation induce a more proinflammatory 
status. Other possible mechanisms include the near absence of metabolic consequences 
ofRAL (34) and its better control of residual HN replication (35, 36) which may also 
influence platelet function as platelets have been shown to endocytose HN virions (37). 
Our findings that the abacavir-treated individuals had a trend for higher platelet 
reactivity are consistent with those reported by Satchell (25). The confounding effect 
of abacavir on our results seems limited, as only two patients in the PI group and a 
comparable proportion of patients in the NNRTI and RAL groups used an abacavir-
containing regimen. 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or 
statins, have been shown to inhibit platelet activation in vivo (38, 39) as well as having 
an anti-inflammatory effect (40). However, only a minority of participants in our study 
used a statin, limiting the possible confounding effects of statin use on our results. 
The fact that fewer patients in the PI group used a statin, despite the fact that mean 
cholesterol level across the groups were similar and PI's are associated with dyslipidemia, 
is probably explained by the choice of non-PI regimens in those with hyperlipidemia. 
Whether reduced platelet reactivity and PMA in RAL-treated individuals are indeed 
associated with reduced cardiovascular complications requires studies with longer follow-
up periods. Due to its near absence of adverse effects on glucose and lipid metabolism 
(34), RAL is among the preferred ART in patients with a high cardiovascular risk. Despite 
needing further clinical study, our findings provide an extra argument to consider a 
RAL-based regimen in these high risk patients. Our data also strengthen the case for 
preventive use of platelet function inhibitors in high risk patients. Aspirin was recently 
shown to attenuate platelet activation and immune activation in ART-treated patients 
in a small study (41). The increased platelet reactivity to ADP in our study supports the 
use of P2Y12 receptor antagonists, also because these have been shown to reduce PMA 
(42). Finally, platelet function assays are currently not routinely used to identify patients 
with high platelet reactivity, but this may change with the availability of easy to use and 
sensitive assays as used in our study. 
Limitations of our study are the fact that we used only one platelet agonist. However, 
previous studies performed by our group showed that platelet hyperreactivity to ADP 
is also associated with hyperreactivity to other agonists such as collagen or thrombin 
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receptor activating peptide (TRAP) (43). Secondly, due to the cross sectional nature 
of our study, causality cannot be proven. This will require a longitudinal, randomized 
study in which patients on a NNRTI- or PI-based regimen are switched to RAL. 
In conclusion, we demonstrated lower platelet hyperreactivity and PMA in RAL-treated 
individuals. These observations warrant a larger randomized study in which the clinical 
benefits of a switch from other ARTs to a RAL-based regimen can be further investigated. 
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Abstract 
Background: Severe leptospirosis is frequently complicated by a hemorrhagic 
diathesis, of which the pathogenesis is still largely unknown. Thrombocytopenia 
is common, but often not to the degree that spontaneous bleeding is expected. 
We hypothesized that the hemorrhagic complications are not only related to 
thrombocytopenia, but also to platelet dysfunction, and that increased binding of 
von Willebrand factor (VWF) to platelets is involved in both platelet dysfunction 
and increased platelet clearance. 
Methodology/Principle findings: A prospective study was carried out in 
Semarang, Indonesia, enrolling 33 hospitalized patients with leptospirosis, of 
whom 15 developed clinical bleeding, and 25 healthy controls. Platelet activation 
and reactivity were determined using flow cytometry by measuring the expression 
of P-selectin and activation of the aiibl33 integrin by the binding of fibrinogen 
in unstimulated samples and after ex vivo stimulation by the platelet agonists 
adenosine-diphosphate (ADP) and thrombin-receptor activating peptide (TRAP). 
Platelet expression ofVWF, before and after VWF stimulation by ristocetin, as well 
as plasma levels ofVWF, active VWF, the VWF-inactivating enzyme ADAMTS13, 
thrombin antithrombin complexes (TAT) and P-selectin were also measured. 
Bleeding complications were graded using the WHO bleeding scale. Platelets of 
the leptospirosis patients were activated with increased P-selectin and fibrinogen 
expression. In contrast, upon ex vivo platelet stimulation, P-selectin and fibrinogen 
expression were lower compared with healthy controls, which is indicative of 
platelet dysfunction. Patients with clinical bleeding had more pronounced platelet 
dysfunction than patients without bleeding and there was a significant inverse 
correlation of bleeding score with TRAP-stimulated P-selectin and fibrinogen 
expression (R=-0.72; P=0.003 and R=-0.46; P=0.034, respectively), but not with 
platelet count. Patients with bleeding also had a significantly higher platelet-VWF 
binding. Platelet counts were inversely correlated with platelet-VWF binding (R=-
0.74; P=0.0009), but not with TAT levels. 
Conclusion/Significance: Platelet dysfunction is common in leptospirosis patients 
with manifest bleeding. Increased VWF-platelet binding may contribute to 
activation and clearance of platelets. Our data suggest that platelet transfusion or 
possibly novel anti-VWF therapies may have clinical benefit in leptospirosis patients 
with bleeding. 
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Introduction 
Leptospirosis is a zoonotic disease of global importance caused by the pathogenicspirochaetes 
of the genus Leptospira [1, 2]. A modeling exercise by the World Health Organization's 
(WHO's) Leptospirosis Burden Epidemiology Group, estimated that 873,000 cases and 
48,600 deaths occur worldwide each year [3]. The clinical manifestations ofleptospirosis 
range from a mild, self-limited febrile illness to a fulminant life-threatening illness with 
multi-organ failure [1, 2]. Bleeding complications are common in severe leptospirosis, 
being reported in up to 60% of all hospitalized patients. Although the majority of 
bleeding events are mild, some patients may develop severe gastrointestinal or pulmonary 
haemorrhage, the latter having an alarmingly high mortality of> 50% [ 4, 5]. 
The pathophysiological mechanisms responsible for bleeding remain incompletely 
understood. Thrombocytopenia is frequently observed and is associated with poor 
outcome, [6] but its severity is not to the extent that spontaneous bleeding is expected 
[7]. Platelet dysfunction might also contribute to bleeding. Measuring platelet function 
in thrombocytopenic conditions is technically demanding as commonly used techniques 
such as light transmission aggregometry are not useful [8]. To the best of our knowledge, 
no studies on platelet function in leptospirosis have been performed. 
The binding of von Willebrand factor (VWF) to the glycoprotein (GP)-1b receptor 
on platelets is a well-known platelet clearance mechanism [9]. VWF is a multimeric 
glycoprotein that predominantly originates from the endothelium. Its main function 
is the recruitment of platelets to sites of vascular injury. Under normal conditions, 
most of the VWF circulates in non-platelet binding form. VWF may however undergo 
a conformational change to a more active, platelet-binding form facilitating platelet 
aggregation [1 0]. An increase in this so-called 'active' VWF has been described in a 
number of infectious and non-infectious diseases [11-13]. A deficiency in ADAMTS13 
(a disintegrin and metalloproteinase thrombospondin type 1 motif, member 13), an 
enzyme that cleaves large VWF multimers into their inactive conformation, may also 
lead to excessive intravascular platelet agglutination [14] . Recently, it was shown that 
excessive VWF binding to platelets not only leads to thrombocytopenia, but also to 
thrombocytopathy in von Willebrand disease type 2B [15] . 
We hypothesized that thrombocytopenia in leptospirosis is associated with increased 
VWF-platelet binding and that the hemorrhagic complications are associated with 
thrombocytopathy due to excessive platelet activation and VWF-platelet binding. 
We therefore characterized VWF binding to platelets, platelet activation and platelet 
reactivity using flow cytometry in adult Indonesian patients with severe leptospirosis 
and determined whether these parameters were related to bleeding complications. In 
addition, we determined the plasma levels ofVWF, active VWF, P-selectin, the plasmatic 
coagulation factor thrombin antithrombin complexes (TAT) and ADAMTS13 activity. 
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Methods 
Study population 
We carried out a prospective study at the Department oflnternal Medicine of Dr. Kariadi 
Hospital, Semarang, Indonesia, between December 2013-March 2014. We enrolled 
adult patients admitted with a high clinical suspicion of leptospirosis using the case 
definition of the World Health Organization South East Asia Regional Office (WHO 
SEARO, 2009) and a positive result of rapid IgM lateral flow test, which had reported 
sensitivity and specificity of 85.6% and 96.2%, respectively [16]. Clinical diagnosis 
of leptospirosis was confirmed in a single acute sample by microscopic agglutination 
test (MAT) with a panel consisting of 31 serovars (28 pathogenic serovars: Australis, 
Bratislava,Autumnalis, Rachmati, Ballum, Castellonis, Bataviae, Benjamini, Whitcombi, 
Cynopteri, Grippotyphosa, Hebdomadis, Copenhageni, Hardjo, Icterohaemorrhagiae, 
Lai, Naam, Coxi, Javanica, Panama, Pomona, Proechimys, Pyrogenes, Sarmin, 
Saxkoebing, Sejroe, Shermani, Tarassovi; three non-pathogenic serovars: Andamana, 
Patoc and Semaranga). A titre of~1/320 on a single sample was considered positive. All 
diagnostic tests were performed at the National Reference Laboratory for Leptospira, 
Dr. Kariadi Hospital, Semarang, Indonesia. Patients and healthy controls were included 
after written informed consent was obtained. Blood samples were obtained on inclusion 
day (day 1) and upon follow up (day 4). The study is approved by the ethical committee 
of the Faculty of Medicine Diponegoro University-Dr. Kariadi Hospital, Semarang, 
Indonesia. 
Platelet activation and reactivity and platelet-von Willebrand factor binding 
Whole blood was collected from patients by using venipuncture from the antecubital 
vein into citrate-anticoagulated tubes (3.2%; BD Vacutainer, Becton Dickinson). All 
samples were processed within one hour after blood collection. Platelet activation and 
reactivity were determined by flow cytometry using a method previously described [17, 
18]. In short, the platelet membrane expression of P-selectin (CD62P) and platelet-
fibrinogen binding, which correspond with platelet degranulation and aggregation, were 
determined in unstimulated whole blood and in whole blood stimulated 20 min with 
the platelet agonists adenosine-diphosphate (ADP; 7.8 llM and 31.2 llM) or thrombin 
receptor-activating peptide (TRAP; 39 j..LM and 625 j..LM) diluted in HEPES-buffered 
saline. Saturating concentrations of the following monoclonal antibodies were used: 
PE-labeled anti-CD62P (Bio-Legend, San Diego, USA), FITC-labeled anti-fibrinogen 
(DAKO Ltd., High Wycombe, UK), and PC7-labeledanti-CD61 (plateletidentification 
marker; Beckman Coulter, France). Platelets were gated based on their forward- and 
sideward-scatter (FSC/SSC) properties and positivity for CD61, which was defined as a 
median fluorescence intensity (MFI) exceeding the MFI of the matched isotype control. 
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The binding of vWF to platelets was determined by adding whole blood sample to a 
mixture ofHEPES-buffered saline and saturating concentrations ofFITC-labeled anti-
von Willebrand factor (Abeam, Cambridge, UK) and PC7-labeled anti-CD61, with 
or without the addition of ristocetin (0,84 mg/ml and 1,5 mg/ml). After incubation 
for 20 minutes at room temperature, a fixative solution (0.2% paraformaldehyde) was 
added and samples were analyzed with a BD FACS Canto II flow cytometer (Becton 
Dickinson, USA). Next, the MFI of CD62P, fibrinogen and VWF on CD61-positive 
events were determined. 
Plasma markers 
Platelet-poor plasma was obtained from citrate-anticoagulated whole blood by 
centrifugation (1500 g without brake, 15 min, 20°C). Plasma concentrations of 
thrombin-antithrombin (TAT) complexes were subsequently measured with enzyme-
linked imn_mnosorbent assay (ELISA) as previously described [24]. Sheep anti-human 
thrombin (SAHT-AP, SAHT-HRP) antibodies were purchased from Kordia/Affinity 
Biologicals, USA. Piasma VWF concentrations were determined with ELISA as 
described previously [19] . Active VWF was quantified by ELISA using a nanobody 
(AU/VWFa-11) that recognizes the GPib binding configuration ofVWF, as described 
previously [20]. We express the relative amount of VWF that circulates in its active, 
platelet binding conformation by using the term VWF activation factor. VWF activation 
factor of normal pooled plasma was referred to as 1. ADAMTS13 activity was quantified 
using the fluorescence resonance energy transfer (FRETS) assay (Peptides International, 
Lexington, USA), whereby the ADAMTS13 activity of normal pool plasma was set at 
100%, and the values obtained in study participant samples were expressed as percentage 
of normal pool plasma [21]. 
Statistical a,nalysis 
Differences in subject characteristics were compared with analysis of variance (AN OVA) 
with posttests for comparing more than two groups, and with Mann-Whitney U-test or 
chi-square test for comparing the two patient groups. Data are presented as median with 
interquartile range (IQR) unless stated otherwise. Relationships between parameters 
were assessed with the Spearman correlation coefficient. All analyses were performed 
with SPSS version 20 (SPSS, Inc., Chicago, Illinois, USA). Pvalues less than 0.05 were 
considered statistically significant. 
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Results 
Patient characteristics 
A total of 33 consecutive hospitalized leptospirosis patients with a positive rapid IgM-
based, lateral flow serology were enrolled together with 25 healthy controls. Twelve 
(36%) of these patients had a positive result of the MAT (titer >1/320). Characteristics 
of participants are presented in Table 1. Fifteen patients (45.5%) presented with or 
developed clinical relevant bleeding manifestations during hospitalization. The most 
common were gastrointestinal (n=12) and genitourinary (n=8) bleeding events. The 
severity of bleeding events in patients were graded using the WHO bleeding scale, which 
has been used extensively worldwide [22-24]. Ten out of 15 patients who experienced 
clinical bleeding developed Grade 2 bleeding (i.e. epistaxis with a total duration of 
all episodes in previous 24 hours of >30 minutes, grossly visible blood in urine, stool 
or emesis), while 4 developed that of Grade 1 (i.e. epistaxis with a total duration in 
previous 24 hours of <30 minutes, microscopic hematuria and petechiae). There was 1 
patient with grade 3 bleeding whose haematemesis and melena caused haemodynamic 
instability. One grade 1 and three grade 2 patients died during hospitalization. 
196 
Ali patients 
. . :.· ...... 
Numbers(%) 33 
Male sex, n (%) 22 (67) 
Age (years) 47 (36-53) 
Bleeding events, n (%) 
Oral, nasal, skin 
Epistaxis 
Petechiae 
Gastrointestinal 
Hematochezia 
Hematemesis 
Melena 
Genitourinary 
Microscopic hematuria 
Gross hematuria 
Days post-onset illness, n 8 (7-11) 
Hb (gr/dl) 13.3 (10.8-15) 
Platelet count (xl 09/1) 114 (60-172) 
Thrombocytopenia <150 x109/l (%) 17 (52) 
Thrombocytopenia <100 x109/l (%) 9 (27) 
Bilirubin (mg/dl) 1.6 (0.8-6.4) 
AST (Uil) 89 (44-147) 
ALT (U/1) 93 (63-160) 
Ureum (mg/dl) 47 (31-196) 
Creatinine (rngldl) 1.7 (1.1-4.6) 
15 (46) 18 (54) 
7 (46.7) 15 (83) 
52 (38-59) 48 (40-52) 
2 (6) 
2 (6) 
1 (3) 
5 (15) 
4 (12) 
3 (9) 
5 (15) 
7 (6-10) 7(7-12) 
10.9 (9.4-13.2) 14.8 (13.9-16.5) 
105 (56-152) 123 (106-183) 
10 (67) 7 (39) 
7 (47) 2 (11) 
2.0 (1.5-5.2) 1.3 (0.8-5.3) 
84 (58-131) 95 (46-138) 
87 (62-131) 99 (79-193) 
64 (46-221) 36 (24-49) 
2.0 (1.4-5.1) 1.4 (1-2) 
12-15 
150-300 
0-1.0 
15-35 
15-60 
15-39 
0.6-1.3 
25 
17 (68) 
·p · 
value 
0.03 
36 (32-50) 0.24 
0.12 
0.004 
0.003 
0.11 
0.03 
0.28 
0.72 
0.68 
0.06 
0.12 
Numbers represent median (IQR) values of 33 patients. P values represent difference between bleeders and non-bleeders (Mann-Whitney U-test or chi-square test 
when appropriate). APvalue <0.05 was considered statistically significant. 
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Median (IQR) platelet count was significantly lower in the group of bleeders compared 
with the non-bleeders (105 (56-152) x109/l vs. 123 (106-183) x109/l; P=0.003). Five 
patients had a platelet count lower than 50 x109/l (bleeders: 12 x109/l, 17.4 x109/l, 29.7 
x109/l, 30.0 x109/l; non-bleeder: 48.6 x109/l). Additionally, the haemoglobin levels were 
lower in the bleeders group than the non-bleeders group (10.9, 9.4-13.2 gr/dl vs. 14.8, 
13.9-16.5 gr/dl; P=0.004), with six patients having haemoglobin levels below lOgr/dl 
(bleeders: 8.2 gr/dl, 8.9 gr/dl, 9.1 gr/dl, 9.4 grldl, 9.8 gr/dl; non-bleeder: 9.5 gr/dl). 
Bleeding is associated with higher platelet activation with platelet dysfUnction 
Figure 1A shows the fibrinogen binding to the activated allb[33 receptor and expression 
of P-selectin on platelets. Patients with bleeding had a significantly higher platelet-
fibrinogenbinding(MFI2601, 1726-2938vs.1577, 1460-1752;P=O.OOl)andP-selectin 
(MFI 1095, 798-1685 vs. 654, 575-1056; P=0.002) in unstimulated blood samples 
than controls, suggesting increased platelet activation. The non-bleeding patients also 
had a significantly higher membrane P-selectin expression compared to controls (MFI 
1179, 910-1444; P=0.003). Platelet reactivity was assessed by ex vivo stimulation of 
whole blood with two concentrations of the platelet agonists ADP or TRAP. In contrast 
to the findings in unstimulated samples, P-selectin expression and fibrinogen binding in 
response to TRAP or ADP were lower in the bleeders compared with non-bleeders and 
controls, suggestive of platelet dysfunction. A reduction in platelet reactivity, albeit to a 
lesser extent, was also found in the non-bleeders in response to TRAP. 
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Figure 1. Platelet reactivity, soluble P-selectin and the relationship between bleeding and 
thrombocytopathy. 
(A) Platelet-fibrinogen binding and the platelet membrane expression of P-selectin (depicted as median 
fluorescence intensity (MFI) in arbitrary units) in unstimulated samples and after stimulation with two 
concentrations of the platelet agonists thrombin receptor activating peptide (TRAP) and adenosine diphosphate 
(ADP) in leptospirosis patients with bleeding (bleeders, n=15) and without bleeding (non-bleeders, n= 18) and 
in healthy controls (n=25). Data depicted are medians with IQR * P<0.05 bleeders vs. non-bleeders,# P<0.05 
bleeders vs. healthy controls, ### P<O.OOl bleeders vs. healthy controls, c; P<0.05 non-bleeders vs. healthy 
controls, c;c;c; P<O.OOl non-bleeders vs. healthy controls. (B) Correlation between the severity of bleeding, as 
measured using the WHO bleeding scale, and plarelet P-selectin expression in response to TRAP (625 !JM; 
left panel) as well as platelet count (right panel) . Shown are the Spearman correlation coefficient. (C) Plasma 
concentration of soluble P-selectin and thrombin-antithrombin (TAT) complex. Data depicted are medians. 
199 
ChapterlO 
Interestingly, bleeding score was associated with impaired platelet P-selectin expression 
and platelet-fibrinogen binding in response to TRAP (R=-0.72; P=0.003 and R=-0.46; 
P=0.034, respectively) but not with platelet count (data for bleeding score correlation 
with P-selectin and platelet count shown in Fig 1B). The flow cytometric findings of 
platelet activation in bleeders were supported by measurement of plasma concentrations 
of soluble P-selectin, which was significantly higher in bleeders compared to both the 
non-bleeders and healthy controls (Fig 1C). Plasma P-selectin in the non-bleeders was 
comparable with that of the controls. Overall, leptospirosis patients also had significantly 
higher plasma TAT concentrations, suggesting activation of the plasmatic coagulation, 
with the highest concentrations found in the bleeders (Fig 1C). 
Follow up data at day four were available in 11 bleeders and 10 non-bleeders. Bleeders, 
but not the non-bleeders, remained having a significantly reduced platelet reactivity in 
the follow up on day 4 compared to healthy controls. (Suppl. Fig 1A). Plasma P-selectin 
also remained significantly increased at day 4 in bleeders (Suppl. Fig IB). 
Platelet von-Willebrand foetor binding was highest in bleeders 
Binding of VWF to platelets is associated with platelet clearance, platelet activation 
and also possibly platelet dysfunction [15, 25]. We determined platelet-VWF binding 
using flow cytometry and measured plasma VWF levels, VWF activation factor and 
ADAMTS 13 activity. Bleeders had a significantly higher VWF expression on circulating 
platelets (MFI 9069, 7470-10554) than non-bleeders (MFI 6999, 4707-8250; P=0.01) 
and healthy controls (MFI 7296, 6877-7867; P=0.002) (Fig 2A). Upon activation of 
VWF by ristocetin, the bleeding patients demonstrated the highest increase in VWF 
expression on platelets (Fig 2B). These flow cytometric findings were consistent with 
the observation that bleeders had the highest plasma VWF concentration (Fig 2C) and 
that the VWF activation factor was about twofold higher in both the bleeding and non-
bleeding leptospirosis patients than in healthy controls, indicating that a higher amount 
of the circulating VWF was in an active, platelet-binding conformation (Fig 2D). Data 
on follow-up measurements on day 4 are presented in Suppl. Fig 2A-C. 
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Figure 2. Platelet-von Wille brand factor (VWF) binding, plasma VWF, VWF activation factor 
and ADAMTS13 levels. 
VWF expression on platelets (depicted as median fluorescence intensity (MFI) in arbitrary units) in 
unstimulated samples (A) and after ex vivo stimulation with two concentrations of ristocetin (B). * P<0.05 
bleeders vs. non-bleeders, ### P<O.OOl bleeders vs. healthy controls. (C-E) Plasma concentrations ofVWF, 
VWF activation factor a...'ld ADAMTS13 activity. Data are shown as medians with IQR. (F) Spearman 
correlation coefficient ofVWF activation factor and platelet-VWF binding (left panel) , as well as plasma 
VWF and ADAMTS 13 activity (right panel) of leptospirosis patients with and without bleeding. 
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ADAMTS13 functions as a natural regulator that de-activates the VWF by proteolysis 
[26] and can be consumed by high level of circulating VWF [12]. ADAMTS13 activity 
levels were decreased in leptospirosis patients and was lowest in bleeders (Fig 2E). Three 
patients in the bleeders group had ADAMTS13 activity level lower than 10%. An 
ADAMTS13 activity below 50% was found in 11 (73%) patients in the bleeders group 
and only in three (25%) patients in non-bleeders group. In the leptospirosis group as a 
whole, VWF expression on platelets correlated positively with the VWF activation factor 
(R=0.62; P=0.001). Although ADAMTS13 activity did not show any correlation with 
VWF ctivation factor, it had an inverse correlation (R=-0.65; P=0.0009) with plasma 
VWF levels, suggesting consumption of ADAMTS13 by VWF (Fig 2F). 
Platelet-v W'F binding is correlated with degree of thrombocytopenia 
Next, we checked associations between parameters to explore possible mechanisms 
underlying the leptospirosis-associated thrombocytopenia and platelet dysfunction (Fig 
3). First, there was a strong inverse correlation of platelet count with platelet-VWF 
binding and to a lesser extent with the platelet membrane expression of P-selectin (Fig 
3A-B, day 4 data presented in Suppl. Fig 2D). In contrast, plasma level of the coagulation 
activation marker TAT complex did not correlate with platelet numbers. Finally, VWF-
platelet binding was associated with fibrinogen expression in unstimulated samples 
and after TRAP and ADP stimulation (data from unstimulated and TRAP- stimulated 
fibrinogen expression shown in Fig 3D). 
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Figure 3. Platelet count and platelet-VWF binding correlates. 
(A-C) Spearman correlation of platelet count with platelet-VWF binding, platelet P-selectin expression 
and thrombin anti-thrombin complex. (D) Spearman correlation of platelet-VWF binding and platelet-
fibrinogen binding in unstimulated sample (left panel) and upon TRAP (625 !JM) stimulation (right 
panel). Data for leptospirosis patients with and without bleeding are shown. 
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Discussion 
Our study reveals four important findings. First, platelet activation is a feature of 
leptospirosis with bleeding manifestations. Second, circulating platelets in leptospirosis 
patients express more VWF and this has a strong negative association with platelet 
number, in contrast with the plasmatic coagulation marker TAT complex. Third, 
VWF binding to platelets was associated with platelet activation, but not with platelet 
dysfunction, as recently reported for von Willebrand disease type 2B [15]. Four, 
bleeding complications are predominantly associated with platelet dysfunction rather 
than absolute platelet count. 
To the best of our knowledge, this is the first study measuring in vivo platelet activation and 
reactivity in human leptospirosis. Platelet function studies are logistically challenging, as 
blood samples need to be processed without delay. In conditions with thrombocytopenia, 
aggregometry is also less reliable and flow cytometry-based assays are preferred [8]. To 
our knowledge, our study is the first to report results from platelet function assays in 
leptospirosis. Our findings are in line with earlier observations that activated platelets are 
present in the lung capillaries of patients who died of leptospirosis [29] and in hepatic 
sinusoids from guinea pigs experimentally infected with leptospirosis [30]. The latter 
study also showed that thrombocytopenia was not related to disseminated intravascular 
coagulation, as is also suggested by our findings showing an absent correlation ofTAT 
complex levels with platelet count. Another animal study, using a virulent serovar of 
Leptospira interrogans in gerbils, reported increased levels of platelet-activating factor 
acetylhydrolase (PAF-AH), which might contribute to inhibition of platelet activation 
[31]. Our observation that platelet function, rather than the absolute platelet count, 
determined the bleeding risk also does not stand alone. Increasing evidence from 
patients with immune thrombocytopenic purpura (ITP) has identified platelet function 
as an important determinant of bleeding risk [32-34]. 
High plasma VWF levels, together with elevations in other endothelial cell activation 
markers, were recently reported in patients with leptospirosis [35]. Our findings add to 
this by showing that the circulating VWF is in an active, GPiba-binding conformation, 
and that circulating platelets indeed have more VWF on their surface. Most VWF is 
derived from endothelial cells. However, platelets also contain VWF in their granules 
[36] and to what extent this contributes to the increased VWF expression on the platelet 
membrane is unknown. We also found a concurrent decrease in ADAMTS13 activity 
levels. This enzyme regulates the multimeric size and function of VWF through the 
cleavage ofVWF within the A2 domain. A severe reduction in ADAMTS 13 activity as a 
result of auto-antibodies are a hallmark of the rare disease thrombotic thrombocytopenic 
purpura (TTP) [37]. Indeed, severe leptospirosis shows some similarities with TTP with 
thrombocytopenia and organ failure. Cases ofleptospirosis-associated TTP have also been 
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described, including that with severely reduced ADAMTS 13 activity [38, 39]. Infections 
may lead to a significant reductions in ADAMTS 13 as a results of different mechanisms, 
as recently reviewed by Schwameis [40]. Multiple studies have shown that conditions 
with increased VWF release are associated with secondary ADAMTS 13 consumption, 
such as in severe systemic infections [27] and after desmopressin~induced VWF release 
[28]. Inhibition of ADAMTS13 activity can also occur due to inflammation-induced 
IL~6 release [41] or proteolytic cleavage of ADAMTS13 by neutrophils [42]. And lastly, 
competition of ADAMTS 13 with thrombospondin-1 for the interaction with VWF~A3 
domain may slow the proteolysis ofUL~VWF multimers [40]. 
The mechanisms underlying the observed platelet activation and platelet dysfunction 
in our study population remain to be elucidated. It is unknown whether pathogenic 
Leptospira interrogans strains are able to directly interact with and activate platelets. 
Leptospiral lipopolysaccharide (LPS) was shown to be a ligand of Toll-like receptor 
(TLR)-2 in humans and ofTIR-4 and TLR~2 in mice [43]. Platelets harbor both TLRs 
and especially ligation ofTLR-2leads to a strong thrombotic platelet activating response 
[44]. Alternatively, increased platelet-VWF binding may activate platelets [45]. In 
patients with von Willebrand disease type 2B (VWD type 2B), a diseases characterized 
by gain-of-function mutations in VWF that enhances its spontaneous binding to the 
platelet GPiba, increased platelet-VWF binding is associated with thrombocytopathy 
due to inhibition of allb~3 activation [15]. However, pla.telet-VWF binding was 
not correlated inversely with fibrinogen binding to the activated allb~3 receptor in 
response to platelet agonists, rendering this as a less likely cause for thrombocytopathy 
in leptospirosis. Rather, we speculate that excessive platelet activation with secondary 
platelet 'exhaustion' underlies the observed platelet dysfunction. We previously found a 
similar phenotype in patients with dengue [ 46]. 
In contrast, we did find a strong inverse correlation of VWF-platelet binding and 
platelet number, suggesting that VWF expression on the platelet membrane is involved 
in platelet clearance. Increased platelet-VWF interaction in VWD type 2B results in 
increased platelet clearance by the liver [47]. How the VWF-platelet complexes are 
being cleared remains to be determined. Evidence suggests that glycans on GPiba are 
critical in mediating platelet clearance via receptors containing carbohydrate~binding 
domains on the macrophage aM~2 integrin and the hepatic Ashwell-Morell receptor 
[25, 48, 49]. One plausible mechanistic explanation is that the increased platelet-VWF 
binding results in a structural unfolding of the GPiba extracellular domain and triggers 
signaling into the platelet, desialylation of the platelet surface and platelet clearance 
[50]. 
The limitations of our study include the small number of patients tested positive with 
the MAT and the fact that patients were included based on rapid lgM seropositivity 
and clinical manifestations consistent with leptospirosis. Regardless, the use of MAT as 
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a gold standard of leptospirosis diagnosis in the real clinical setting has been criticized 
for its low sensitivity of 70% even in the ideal situation, in which convalescent-phase 
samples were obtained from all patients [ 16]. Our study was also performed in Semarang, 
Indonesia, where leptospirosis is a common cause of undifferentiated fever [51]. 
In conclusion, we found that platelet activation and platelet dysfunction are features 
of leptospirosis, which are associated with the severity of bleeding events. Circulation 
platelets also express more VWF, and although this does not explain the observed platelet 
dysfunction, it may play a role in enhanced platelet clearance. Bleeding remains as a 
serious, life-threatening complication of leptospirosis and our findings warrant further 
study on the clinical utility of platelet function test, as it is thrombocytopathy rather 
than thrombocytopenia that is associated with the severity of bleeding events. In severe 
bleeding, platelet transfusion may temporarily reverse the platelet dysfunction. Potential 
future therapeutics can be directed at inhibiting platelet-VWF binding, for example by 
using an anti-VWF humanized single-variable-domain immunoglobulin, caplacizumab 
to inhibit the GPib binding site of VWF [52] or an antagonist of the platelet GPib 
receptor, anfibatide [53]. Alternatively, administration of recombinant ADAMTS13 
might have a therapeutic role in those with severely reduced ADAMTS 13 activity [54]. 
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Suppl. Fig l_ Platelet reactivity and soluble P-selectin upon follow up. 
(A) Platelet-fibrinogen binding and the platelet membrane expression of P-selectin (depicted as median 
fluorescence intensity (MFI) in arbitrary units) in unstimulated samples and after stimulation with two 
concentrations of the platelet agonists thrombin receptor activating peptide (TRAP) and adenosine diphosphate 
(ADP) in leptospirosis patients with bleeding (bleeders, n=l5) and without bleeding (non-bleeders, n=l8) 
and in healthy controls (n=25). * P<0.05 bleeders vs. non-bleeders, # P<0.05 bleeders vs. healthy controls, c; 
P<0.05 non-bleeders vs. healthy controls. (B) Plasma concentration of soluble P-selectin. Data depicted are 
medians with IQR. Data of patients were from day 4, while data from healthy controls were from day I. 
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Suppl. Fig 2. Platelet-von Willebrand factor (VWF) binding, plasma VWF, VWF activation 
factor and platelet count correlates upon follow up. 
(A) VWF expression on platdets (depicted as median fluorescence intensity (MFI) in arbitrary units) in 
unstimulated samples and after ex vivo stimulation with two concentrations of ristocetin. (B-C) Plasma 
concentrations ofVWF and VWF activation factor. (D) Spearman correlation coefficient of platelet count 
and platelet-VWF binding as well as platelet P-sdectin expression. Data are shown as medians with IQR. 
Data from patients were from day 4, while data from healthy controls were from day 1. 
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General Discussion 
The first part of this doctoral thesis focuses on the interactions of platelets with 
inflammation and immunity. Studies were predominantly performed in healthy 
volunteers and included the interlinking of platelet reactivity and inflammatory 
responses at the functional and genetic levels (chapter 2) and the differential effects of 
platelets on Toll-like Receptor (TLR)-2 and TLR-4-induced immune responses (chapter 
3). In addition, we described the platelet-inhibiting action of recombinant alkaline 
phosphatase (recAP) and its mechanisms of action (chapter 4) and studied the effects of 
hypoxia (chapter 5) on platelet function in the context of systemic inflammation. 
The second part of this thesis focuses on the alterations of platelet function due to 
infections. Studies were performed in an animal model and in patients with infectious 
diseases. We investigated changes in platelet activation associated with pneumococcal 
bacteremia (chapter 6), a phage-derived gene of Streptococcus pneumoniae (chapter 7), 
Gram-positive/Gram-negative bacteremia (chapter 8) and different treatment regimens 
ofHN-infected individuals (chapter 9). We also investigated changes in platelet function 
in leptospirosis patients and related this to bleeding complications (chapter 10). 
The interaction between platelets and inflammation 
Platelets alter inflammatory and immune respomes 
Platelets are known to play a key role in inflammation and host defense. Platelet function 
is therefore likely to affect immune responses and the pathogenesis of certain infectious 
diseases. The opposite also occurs: inflammation and infections significantly affect 
platelet numbers and function. The extent and mechanisms of these interactions remain 
to be fully elucidated. Most available data originate from in vitro or animal studies 
(reviewed in (1 -3)), and from clinical studies in patients with infections (4-6) or chronic 
inflammation (7-9). At the genetic level, studies have identified quantitative trait loci 
(QTLs) regulating platelet function (reviewed in (1 O)) or immune responses (11, 12) but 
have not interlinked these two processes. In chapter 2, we performed platelet reactivity 
assays and measurements of cytokine responses of whole blood and peripheral blood 
mononuclear cells (PBMCs) in the 500-Human Functional Genomics (500FG) cohort 
of approximately 500 Caucasian, healthy individuals as part of the Human Functional 
Genomics Project (HFGP). We assessed the associations between platelet number and 
reactivity as well as cytokine responses. We found that platelet reactivity was associated 
with differential interferon (IFN)-y and interleukin (IL)-1 ~/IL-6 cytokine responses in 
whole blood and peripheral blood mononuclear cells (PBMCs). Through a series of ex 
vivo experiments, we determined that while the addition of isolated washed platelets 
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downregulated IFN-y and upregulated IL-l~/IL-6 cytokine responses of PBMCs to 
several bacterial ligands, recombinant IFN -g and IL-l ~/IL-6 had no effect on platelet 
function. We also found that the genetic variations which determine platelet function 
had overlapping associations with cytokine responses to different ligands. Although 
some of these variants are located in gene . regions previously associated with immune 
properties or responses, others are known to be exclusively associated with platelet 
function. Vice versa, genetic variations determining cytokine responses to several ligands 
were also found to be associated with platelet reactivity. Our data suggest that platelets 
play an important role as cellular mediators in the crosstalk between haemostasis and 
inflammation, and indicate platelets as having a shared genetic regulatory mechanism 
with inflammation. 
Ex vivo studies have reported that clopidogrel reduces pro-inflammatory responses 
to TLR4 stimulation, (13) but increases pro-inflammatory response upon TLR2 
stimulation (14). We hypothesized that differences in platelet responses and platelet-
monocyte complex (PMC) formation to TLR2 and TLR4 ligands influence the 
inflammatory response by leukocytes and that this also explains the seemingly opposite 
effects ofP2Y12 inhibitors on the inflammatory responses in the aforementioned studies. 
In chapter 3, we described through a series of ex vivo studies, that platelets attenuated 
the production of pro-inflammatory cytokines following PBMC stimulation with 
the TLR2/TLR1 ligand Pam3CSK4, whereas they increase the production of these 
cytokines following stimulation with the TLR4 ligand LPS. These effects of platelets 
are dependent on direct PMC formation and for the Pam3CSK4-induced response, on 
phagocytosis of platelets by monocytes. In line with these results, in our ex vivo study, 
healthy volunteers receiving ticagrelor showed increased pro-inflammatory cytokines in 
whole blood stimulated ex vivo with Pam3CSK4, while showing decreased cytokines 
in LPS-stimulated blood. Data from clinical studies in humans on the effects of P2Y12 
receptor antagonists on the susceptibility and outcome of infections are limited, if not 
somewhat conflicting. On one hand, clopidogrel has been reported to increase the risk 
for surgical site infections and bacteremia following coronary artery bypass surgery (15), 
as well as community acquired pneumonia (CAP), while on the other hand its use was 
also associated with a more favourable outcome in pneumonia and sepsis ( 16, 17). Our 
findings are of potential clinical relevance as the use of platelet inhibitors may alter 
the immune response during infections while the attenuation or augmentation of this 
response may depend on the type of microorganism and TLRs involved. 
Modulation of platelet fonction during systemic inflammation 
Platelets can complicate the systemic inflammatory response as excessive platelet 
activation may lead to the formation of microthrombi, release of proteins with immune 
modulatory properties and interaction with leukocytes leading to their activation (18). 
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In sepsis, the therapeutic strategy may be directed at intervening with the dysregulated 
response of platelets during systemic inflammation (19). Acute kidney injury (AKI) 
often develops in severe sepsis and platelets may play an etiological role in this 
complication (18, 20). The human recombinant alkaline phosphatase (recAP) is a novel 
dephosphorylating enzyme currently under investigation as a new therapy for sepsis-
associated AKI due to its dephosphorylating effect on LPS and adenosine diphosphate 
(ADP). Bovine-derived alkaline phosphatase had previously been reported to inhibit 
platelet activation, but the precise mechanisms remained only partly understood. In 
chapter 4, we described the platelet-inhibiting action of recAP and its mechanisms of 
action through a series of ex vivo experiments in healthy volunteers and sepsis patients. 
We demonstrate that recAP strongly inhibits ADP-induced platelet activation in whole 
blood and cross-linked collagen-related peptide (CRP-XL)-induced platelet activation 
in platelet-rich plasma. This study reveals a previously undescribed mechanism of how 
recAP inhibits platelet function. The dephosphorylation of ADP, which is the most 
potent activator of the P2Y12 receptor and amplifier of the platelet response, and 
the formation of adenosine as its turnover product are primarily responsible for the 
observed platelet-inhibiting effects. Additionally, exposure of whole blood of patients 
with septic shock to recAP reversed the sepsis-associated platelet hyperreactivity. This 
platelet-inhibiting effect may contribute to the therapeutic potential of recAP as a new 
candidate to treat sepsis-induced AKI. In addition, our findings support the idea that 
further studies are needed to investigate the effects of recAP treatment in other diseases, 
in which platelet-activation plays a relevant role. 
Systemic inflammation, which may lead to the activation of platelets and coagulation, 
commonly co-occur with hypoxia in sepsis patients. Hypoxia may arise in sepsis due 
to enhanced .metabolic demands, and decreased oxygen delivery (4). Both systemic 
inflammation and hypoxia were associated with adverse outcome in sepsis patients. 
Hypoxia had been implied to increase platelet reactivity in rats (21) and activate 
coagulation (22), but in vivo data in humans were largely missing. In chapter 5, we 
studied the effect of hypoxia during human endotoxemia on platelet activation. Our 
data showed that systemic hypoxia during systemic inflammation in humans in vivo does 
not augment, but rather attenuates, endotoxemia-induced platelet-monocyte complex 
formation and platelet hyperreactivity. This platelet-attenuating effect of hypoxia may 
be explained by lower levels of circulating pro-inflammatory cytokines such as Tumor 
Necrosis Factor (TNF)-u, IL-6 and IL-8 in these subjects. Alternatively, hypoxia 
might result in increased levels of prostaglandin 12 (PGI2), which is known to inhibit 
platelet activation (20). Our study has limitations regarding the experimental human 
endotoxemia model used, which does not fully represent the inflammatory response 
observed in critically ill sepsis patients. However, given the paucity of human in vivo 
data on the effect of hypoxia on platelet reactivity, it provides valuable insights into the 
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complex interactions between inflammation, coagulation, and hypoxia. 
Infections alter platelet function 
Increased platelet activation and reactivity during infections 
Acute bacterial infections are associated with an increased risk for cardiovascular 
events (CVE), but the magnitude of this risk depends on the type of infections (23-
25). Clinical studies have shown a high incidence of cardiovascular complications in 
patients with Gram-positive bacterial infection (26, 27). Additionally, community 
acquired pneumonia (CAP), which is frequently caused by the Gram-positive bacteria 
Streptococcus pneumoniae, is associated with an increased short-term and long-term risk 
for CVE. Such risks appears lower for urinary tract infections, which are usually caused 
by Escherichia coli or other Gram-negative bacteria (23, 28). In addition, infective 
endocarditis is predominantly caused by Gram-positive bacteria (29). Platelets play a 
central role in acute CVE and atherosclerosis, but whether systemic platelet activation 
and platelet hyperreactivity indeed occur in vivo during Gram-positive bacterial 
infection, or invasive pneumococcal infection in particular, is not well-established. 
In chapter 6, using a novel porcine model of pneumococcal disease we demonstrated 
that invasive S. pneumoniae infections induce pronounced in vivo platelet activation 
and hyperreactivity. Direct stimulation of platelets by S. pneumoniae mediated these 
effects, at least in part, as porcine washed platelets were activated by ex vivo exposure to 
S. pneumoniae. Pneumococci can activate platelets directly through different processes, 
including binding to plateletTLR2, FcyRIIA and the integrin aiib~3 (30), or activation 
of the platelet activation factor (P AF) receptor (31). 
The study of pneumococcal pathogenicity also benefits from advances in bacterial 
genome sequencing. This technique, for example, has allowed for the prediction of 
which bacterial isolates tend to cause severe disease from their genome sequence alone 
(32, 33). In chapter 7, we sequenced 349 clinical isolates from patients with invasive 
pneumococcal disease and found that the phage-derived gene pblB was associated with 
death within 30 days ofhospitalization. PblB of Streptococcus mitis was shown to function 
in the bacterial adhesion to platelets by interacting with a 2-8-linked sialic acid residues 
on platelet membrane gangliosides (34). PblB expression of S. mitis was also found 
to contribute to virulence in an in vivo rabbit model of infective endocarditis. This 
study indicated that PblB may be important for platelet deposition onto the infected 
valve surface, and the resultant formation of macroscopic vegetations (35)(16). More 
recently, Hsieh and colleagues showed that pblB knock-out mutant pneumococci had 
decreased adherence to respiratory epithelial cells and platelets (36). Through a series 
of ex vivo experiments, we found that fluoroquinolones, an antibiotic that is frequently 
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used in our Dutch patient cohort as empiric therapy for severe CAP together with 
penicillin, induced pblB expression. Finally, we found that wild type, pblB-expressing 
pneumococci induced higher platelet P-selectin expression, platelet-fibrinogen binding 
and PMC formation in whole blood when compared to the pblB knock-out mutant, 
irrespective of antibiotics exposure. This may explain why bacteremic patients, infected 
with pneumococci containing the pblB gene, have a higher chance to die within 30 days. 
An approximate of 20% increase from baseline values in platelet P-selectin expression 
and PMC has been associated with adverse cardiovascular events and the acute phase 
of ischaemic stroke (9, 37) , and the increase in platelet activation associated with pblB 
in our ex vivo experiments exceeded this aforementioned value. This study also shows 
the value of integrating extensive bacterial genomics and clinical data in predicting and 
understanding pathogen virulence, which in turn will help to improve prognosis and 
therapy. 
As mentioned previously, in chapter 3 we found that ex vivo, the TLR2 synthetic ligand 
Pam3CSK4 strongly induced PMC formation whereas LPS, a synthetic ligand ofTLR4 
did not. TLR2 and TLR4 ligations represent the immunological recognition against 
Gram-positive and Gram-negative bacteria, respectively (38). We speculated that the 
higher risk for CVE in Gram-positive bacterial infection compared to the Gram-negative 
bacterial infection (26-28) can be explained by differences in the platelet function of 
these patient groups. In chapter 8, we studied platelet reactivity, PMC formation and 
activation of the plasmatic coagulation in a cohort of patients with either Gram-positive 
or Gram-negative sepsis. We found that sepsis with common Gram-positive pathogens 
is associated with more pronounced platelet activation, platelet hyperreactivity and 
PMC formation compared with sepsis due to common Gram-negative pathogens. The 
majority of patients in the Gram-positive group had a S. aureus sepsis, whereas E. coli was 
the most common bacteria in the Gram-negative group. S. aureus and Streptococcus spp. 
are able to directly bind and activate platelets and different mechanisms through which 
these pathogens activate platelets have been reviewed recently by Hamzeh-Cognasse 
et. al. (39). E. coli was also recently demonstrated to activate platelets in a FcyRIIa-
dependent manner (40, 41), although ex vivo data of platelet activation by E. coli LPS 
are conflicting (42-45). Our data of limited platelet activation in patients with E. coli 
sepsis are in line with reports that LPS administration to healthy volunteers does not 
appear to significantly activate platelets ( 46, 47). This study was limited by the relatively 
small number of patients in each group and the fact that the platelet reactivity assay was 
only performed once after the blood cultures became positive. Additionally, our results 
cannot be extrapolated to other Gram-positive and Gram-negative bacteria not included 
in our study, as the platelet-activating properties of these bacteria may differ. However, 
this study provides the evidence that Gram-positive sepsis is associated with marked 
platelet activation, in contrast to Gram-negative sepsis, and this may contribute to the 
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vascular complications seen in these infections. 
These findings support the case for platelet function inhibitors as a preventive 
intervention to reduce acute vascular complications during invasive pneumococcal 
disease and other Gram-positive bacterial infections. A small placebo controlled trial 
involving 185 patients found that aspirin reduced the occurrence of CVE in CAP 
patients from 10.6% to 1.1% (48). In addition, a large observational study involving 
over 1000 elderly CAP patients reported lower 30-day mortality rate for those who had 
been on chronic treatment with aspirin, compared to those who had not (49). Larger 
placebo-controlled studies are warranted to provide evidence-based recommendations. 
Another infection with an increased risk of cardiovascular diseases (CVD) (50) is HIV. 
HIV is has been associated with platelet activation (51). Intensification of antiretroviral 
therapy (ART) with the integrase inhibitor raltegravir (RAL) was reported to suppress 
residual viral replication and reduce plasma levels of the coagulation marker D-dimer (52). 
The switch from a protease inhibitor or enfuvirtide to RAL also decreased inflammatory 
and coagulation biomarkers (53). We therefore hypothesized that virologically 
suppressed HIV-infected patients using a RAL-based regimen have reduced platelet 
reactivity and PMC formation compared with those using a nonnucleoside reverse 
transcriptase reverse inhibitor (NNRTI)-based or protease inhibitor-based regimen. In 
chapter 9, we describe that HIV-infected individuals on a RAL-based regimen show 
reduced platelet hyperreactivity and PMA compared with those on an NNRTI or a 
protease inhibitor based regimen. Our findings are clinically relevant as higher values 
of these parameters are associated with an increased risk for future cardiovascular events 
(54, 55). Whether reduction in platelet reactivity and PMC in RAL-treated individuals 
are indeed associated with reduced cardiovascular complications requires studies with 
longer follow-up periods. However, due to its near absence of adverse effects on glucose 
and lipid metabolism (56), RAL is among the preferred ART in patients with a high 
cardiovascular risk. Our findings provide an extra argument to consider a RAL-based 
regimen in these high-risk patients. 
Platelet dysfunction and bleeding complications during infections 
Infections may not only lead to platelet hyperreactivity, but also platelet dysfunction, 
such as during dengue virus infection (57). Severe leptospirosis, a disease caused by 
the pathogenic Leptospira spp., is often complicated by bleeding complications, of 
which the pathogenesis is still largely unknown. We hypothesized that the hemorrhagic 
complications are not only related to thrombocytopenia, but also to platelet dysfunction, 
and that increased binding of von Willebrand factor (VWF) to platelets is involved 
in both platelet dysfunction and increased platelet clearance. We described in chapter 
10 a prospective study in Semarang, Indonesia, enrolling 33 hospitalized patients with 
leptospirosis, of whom 15 developed clinical bleeding, and 25 healthy controls. We 
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measured platelet reactivity, platelet-VWF binding and assessed bleeding complications 
using the WHO bleeding scale. Our study reveals four important findings. First, platelet 
activation is a feature of leptospirosis with bleeding manifestations. Second, circulating 
platelets in leptospirosis patients express more VWF and this has a strong negative 
association with platelet number, in contrast with the plasmatic coagulation marker TAT 
complex. Third, VWF binding to platelets, mediated by the platelet GPib, was associated 
with platelet activation, but not with platelet dysfunction. Four, bleeding complications 
are predominantly associated with platelet dysfunction rather than absolute platelet 
count. Platelet activation in leptospirosis may occur due to TLR4 and TLR2 ligation 
by Leptospira spp., the latter having a stronger platelet-activating properties, or increased 
platelet-VWF binding. We also speculate that excessive platelet activation with secondary 
platelet 'exhaustion' underlies the observed platelet dysfunction, as previously found in 
patients with dengue (57). Increased platelet-VWF binding may play a role in increased 
platelet clearance. Platelet-VWF binding results in a structural unfolding of the GPiba 
extracellular domain and triggers signaling into the platelet, desialylation of the platelet 
surface and increased uptake of platelets by the Ashwell-Morell receptor (58). 
Considerations about the clinical implications of our findings: the use of 
platelet function inhibitors during inflammation and infection 
Platelet hyperreactivity increases the risk for thrombotic vascular disease and may affect 
the inflammatory response at the same time. On the other hand, reduced platelet 
function during inflammation/infection may not only lead to bleeding complications 
but also lower the effect of platelets on the inflammatory response. Platelet inhibition 
has been suggested to have beneficial effects during sepsis as platelets contribute to 
platelet-leukocyte complex formation, microvascular thrombosis, tissue hypoxia and 
eventually organ failure. Depending on the stimulus, platelet-leukocyte interaction 
may have different effects. It may result in a pro-inflammatory phenotype, accelerating 
organ injury (18) or inhibition of the release of inflammatory mediators, resulting in 
an anti-inflammatory phenotype (59) . Anti-platelet therapy may therefore influence 
inflammation, either directly or via platelet-leukocyte complex formation. The 
cydooxygenase inhibitor aspirin and P2Y12 receptor antagonists are the therapy of choice 
for prevention of thrombotic vascular events. All these drugs influence inflammation and 
the drugs in the latter group, dopidogrel and prasugrel, have also been found to inhibit 
the interaction between platelets and leukocytes and as such attenuate inflammation 
(60, 61). In line with this is our finding (chapter 3) that the administration of P2Y12 
receptor antagonist ticagrelor in healthy volunteers led to ex vivo inhibition of platelet-
monocyte complex formation and subsequent reduction in proinflammatory cytokine 
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response after TLR4 stimulation. 
Apart from its effects on inflammation, platelets can also play a more direct role in 
the innate and adaptive response against micro-organisms. Platelets are for instance 
able to enhance the phagocytosis of bacteria by neutrophils (62) or trigger neutrophil 
extracellular trap formation (63). The question is therefore whether and how platelet 
function inhibitors influence the host response to infectious diseases. A limited number 
of studies are available, sometimes with seemingly conflicting results. A retrospective 
cohort study of 1677 patients undergoing coronary artery bypass surgery showed 
that the preoperative use of aspirin plus clopidogrel increased the 30-day incidence of 
postoperative surgical site infection and bacteremia when compared with aspirin alone 
(15). This clinical study showed that suppression of platelet function was associated 
with the vulnerability to infection and bacteremia. Results of the PLATelet inhibition 
and patient Outcomes (PLATO) trial showed an opposite effect in patients with sepsis 
and critical illness. The lower overall mortality in the PLATO patients treated with 
ticagrelor compared to clopidogrel was partly the result of a lower death rate from 
pulmonary adverse events and sepsis (64). In patients with sepsis, aspirin was found to 
reduce mortality (65) and incidence of acute lung injury (ALI) (66, 67), while another 
study did not find its association with ALI (68). One study reported that although 
clopidogrel reduced the severity of sepsis, it increased the incidence of CAP ( 17). We 
hypothesized, based on the results of our studies, that these differences in outcomes may 
be due to the differences in the causative pathogens involved. Our ex vivo study (chapter 
3) demonstrated namely that platelets have opposing inflammatory effects on cytokine 
response of PBMC depending on the TLR stimulation involved. The patient study 
described in chapter 8 also showed differences in platelet reactivity as only patients with 
a Gram-positive sepsis demonstrated increased platelet reactivity and PMC formation 
in contrast to those with Gram-negative sepsis. This may also be an underlying factor of 
why Gram positive bacteremia is associated with a higher risk for vascular complications 
and infective endocarditis (27, 29, 69, 70). 
The inhibition of platelet function may therefore be of value to prevent vascular 
complications after infections caused by this group of pathogens. The benefit of 
prophylaxis should however be weighted against the risk of bleeding and attenuation 
of the inflammatory response. Furthermore, it should also be considered whether 
aspirin is used and at what dosage or whether P2Y12 inhibitors are preferred, alone or 
in combination with aspirin. Patients with Gram-positive bacterial infections possibly 
benefit the most from adjunctive P2Y12 inhibition, due to their concomitant inhibition 
of platelet-leukocyte complex formation, but this should first be investigated in an 
appropriate model. Our novel porcine model of pneumococcal disease, as described in 
chapter 6, could provide insight on the beneficial or detrimental effects of the various 
anti-platelet drugs. It is thereby important to consider which strain of pneumococcus is 
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used, as was demonstrated in chapter 7. Finally apart from aspirin and P2Y12 inhibitors, 
the use of other agents that may inhibit platelet function, such as recAP (chapter 4), 
needs to be studied in infectious disease and inflammatory conditions with increased 
platelet activation. 
Platelet hyperreactivity is not only seen in Gram-positive bacterial infection but also in 
viral infections such as HIV (chapter 9). Aspirin is adviced for the primary prevention 
of thrombotic vascular disease in HIV-infected patients based on the age-stratified 10-
year coronary heart disease (CHD) risk score for men and the 10-year stroke risk score 
for women (71). The use ofP2Y12 inhibitors is generally not considered in the current 
guidelines. Cytochrome P450 interaction may have limited the use of P2Y12 inhibitors 
in treated HIV infected subjects so far, but the guidelines can be reconsidered with the 
recent introduction of integrase inhibitors that do not affect cytochrome P450 activity. 
HIV is characterized by persistent inflammation with increased risk for thrombotic 
vascular events as a result. Consequently, the effect of P2Y12 inhibitors is possibly more 
favorable compared to aspirin as it is a better inhibitor of platelet-leukocyte interaction. 
Infectious diseases may not only result in platelet hyperreactivity, but may lead to 
platelet dysfunction as well. Researchers from our group have recently described this 
in dengue virus infections (57) and a similar phenomenon is described for leptospirosis 
in chapter 10. Our finding that platelet-WVF complex formation was associated with 
thrombocytopenia suggests that inhibition of the platelet-VWF interaction may be 
considered as a therapeutic option in patients with leptospirosis. Two newly developed 
drugs should be studied for that purpose: anti-VWF humanized single-variable-domain 
immunoglobulin (caplacizumab) has been developed that inhibits the GPib binding 
site ofVWF (72) or an antagonist of the platelet GP1b receptor, anfibatide (73). These 
drug have been developed as an anti-thrombotic therapy while haemorhage is a main 
complication -of a severe leptospirosis infection. However, they may have a favorable 
effect in lepto$pirosis as our data suggest that excess platelet-VWF complex formation 
play a role in its pathogenesis. This concept should be thoroughly tested in an animal 
model before being tried in a clinical setting. 
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Platelets are traditionally known for their role in hemostasis. Mounting evidence also 
highlights their novel role as key effector cells of inflammation and host defense. Platelets 
interact with professional immune cells and play a major role in atherosclerosis and 
acute cardiovascular events (CVE). Thus, on the one hand, platelets may modulate the 
immune response and pathogenesis of infectious diseases, whereas on the other hand, 
inflammation and infections may affect platelet numbers and function. 
Chapter 1 contains a general introduction to the physiology of platelets and their role 
as effector cells of inflammation and immunity. It also describes the background of the 
flow cytometry-based platelet function assays that were used in this thesis. Finally, we 
described the background of studies on platelet reactivity that we performed in both 
healthy volunteers and patients with infectious diseases. 
Despite findings that platelet numbers and function influence inflammation and 
immune response and vice versa, the mechanisms of these interactions have not been 
well-established. In chapter 2, as part of the Human Functional Genomics Project 
(HFGP), we related platelet number and platelet reactivity to inflammatory markers 
and cytokine responses of whole blood and peripheral blood mononuclear cells 
(PBMCs) in the 500-Human Functional Genomics (500FG). This cohort consisted 
of approximately 500 healthy, Caucasian individuals. Our main findings were that 
platelet numbers were positively associated with circulating IL-l P levels and that platelet 
reactivity was associated with differential interferon (IFN)-y and interleukin (IL)-113/ 
IL-6 cytokine responses. We found that genetic variations in platelet function had 
overlapping associations with cytokine responses to multiple ligands. Wee versa, genetic 
variations determining cytokine responses were also found to be associated with platelet 
reactivity. 
The effects of platelets on immune responses may depend on the immune stimulus. In 
chapter 3, we described through a series of ex vivo studies, that platelets attenuate the 
production of pro-inflammatory cytokines following PBMC stimulation with the Toll-
like receptor (TLR)2/TLR1 ligand Pam3CSK4, whereas they increase the production of 
these cytokines following stimulation with the TLR4 ligand lipopolysaccharide (LPS). 
These effects of platelets are dependent on direct platelet-monocyte complex (PMC) 
formation and for the Pam3CSK4-induced response, on phagocytosis of platelets by 
monocytes. In line with these results, healthy volunteers receiving the P2Y12 receptor 
antagonist ticagrelor showed increased pro-inflammatory cytokines in whole blood 
stimulated ex vivo with Pam3CSK4, while showing decreased cytokines in LPS-
stimulated blood. Our findings are of potential clinical relevance as the use of platelet 
inhibitors may thus alter the immune response during infections. The direction of this 
alterations will depend on the type of micro-organism and the TLRs involved. 
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Excessive platelet activation plays a role in the pathogenesis of sepsis. Adjunctive therapies 
aimed at platelets may improve the outcome of sepsis. Recombinant alkaline phosphatase 
(recAP) is a dephosphorylating enzyme that is currently under clinical investigation as 
a new therapy for sepsis-associated acute-kidney injury (AKI). How recAP modulates 
sepsis-associated organ failure is not well established. Chapter 4 describes experiments 
using blood ofhealthyvolunteers and sepsis patients showing that recAP inhibits platelet 
activation. RecAP promotes the dephosphorylation of ADP, which is the most potent 
activator of the P2Y12 receptor and amplifier of the platelet response, and the formation 
of adenosine as its turnover product. This platelet-inhibiting effect may contribute to 
the therapeutic potential of recAP as a new candidate to prevent sepsis-induced AKI. 
In chapter 5, the effect of hypoxia on platelet activation and PMC formation during 
human endotoxemia is studied. The data show that systemic hypoxia during systemic 
inflammation in humans in vivo does not augment, but rather attenuates, endotoxemia-
induced PMC formation and platelet hyperreactivity. Given the paucity of human in 
vivo data on the effect of hypoxia on platelet reactivity, our study provides valuable 
insights into the complex interactions between inflammation, coagulation, and hypoxia. 
The risk for vascular complications differs across bacterial infections. In general, vascular 
and thrombotic complications appear to be more common in infections caused by Gram-
positive bacteria than in Gram-negative bacteria. Infections with the Gram-positive 
bacteria Streptococcus pneumoniae are well known for their cardiovascular complications. 
We demonstrated in chapter 6, using a novel porcine model of pneumococcal disease, 
that invasive S. pneumoniae infections induce pronounced in vivo platelet activation 
and hyperreactivity. Direct stimulation of platelets by S. pneumoniae mediated these 
effects, at least in part, as porcine washed platelets were activated by ex vivo exposure 
to S. pneumoniae. In chapter 7, we sequenced 349 pneumococcal clinical isolates from 
patients with invasive pneumococcal disease and found that the phage-derived gene 
pblB was associated with death within 30 days of hospitalization. Previously, PblB of 
Streptococcus mitis was shown to function in the bacterial adhesion to platelets and 
contribute to virulence in an in vivo rabbit model of infective endocarditis. We further 
found that wild type, pb/B-expressing pneumococci induced higher platelet P-selectin 
expression, platelet-fibrinogen binding and PMC formation in whole blood when 
compared to the pblB knock-out mutant, irrespective of antibiotics exposure. This may 
explain why bacteremic patients, infected with pneumococci containing the pblB gene, 
have a higher chance to die within 30 days. 
In chapter 8, results from an observational study are described, showing that sepsis 
with common Gram-positive pathogens is associated with more pronounced platelet 
activation, platelet hyperreactivity and PMC formation compared with sepsis due to 
common Gram-negative pathogens. This may explain why vascular complications are 
more common in Gram-positive bacterial infections. 
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Another infection that is associated with an increased risk of cardiovascular diseases 
(CVD) is HIV. Persistent platelet activation despite the use of antiretroviral therapy 
(ART) has been described. In chapter 9, we show that HN-infected individuals on a 
raltegravir-based regimen had reduced platelet hyperreactivity and platelet-monocyte 
aggregates compared with those on a nonnucleoside reverse transcriptase inhibitor-
based or protease inhibitor-based regimen. 
Infections may not only lead to platelet hyperreactivity, but also platelet dysfunction, 
and this may lead to a bleeding tendency. In chapter 1 0, a prospective study is 
described enrolling patients with severe leptospirosis in Semarang, Indonesia. Of the 
33 hospitalized patients, 15 developed clinical bleeding. We found increased platelet 
activation in leptospirosis patients who developed bleeding manifestations. This group 
of patients also showed more binding of von-Willebrand factor (VWF) to the platelet 
glycoprotein (GP)Ib, and this was negatively associated with platelet number. This 
suggests that increased platelet-VWF binding plays a role in increased platelet clearance, 
possibly through glycan structural changes leading to the increased uptake of platelets 
by the hepatic Ashwell-Morell receptor. Interestingly, the bleeding complications in 
patients were predominantly associated with platelet dysfunction rather than absolute 
platelet number. Our findings suggest that excessive platelet activation with secondary 
platelet 'exhaustion' underlies the observed platelet dysfunction, as previously found in 
patients with dengue. 
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Platelet secara tradisional diketahui berperan dalam hemostasis. Bukti-bukti juga 
menunjukkan peran baru mereka sebagai sel efektor kunci dalam inflamasi dan 
pertahanan pejamu. Platelet berinteraksi dengan sel imun profesional dan memainkan 
peran besar dalam aterosklerosis dan kejadian kardiovaskuler akut. Di satu sisi, platelet 
dapat memodulasi respon imun dan paragenesis penyakit infeksi, sedangkan di sisi lain, 
inflamasi dan infeksi dapat mempengaruhi jumlah dan fungsi platelet. 
Bah 1 memuat pengantar umum fisiologi dari platelet dan peran mereka sebagai 
sel efektor dari inflamasi dan imunitas. Bab ini juga menjelaskan latar belakang tes 
fungsi platelet berbasis flow cytometry yang kami gunakan dalam tesis ini. Kami juga 
menjelaskan latar belakang dari penelitian reaktivitas platelet yang kami lakukan pada 
sukarelawan sehat dan pasien penyakit infeksi. 
Walaupun terdapat temuan-temuan bahwa jumlah dan fungsi platelet mempengaruhi 
inflamasi serta respon imun dan sebaliknya, mekanisme interaksi ini belum diketahui 
secara pasti. Dalam bah 2, sebagai bagian dari Human Functional Genomics Project 
(HFGP), kami menghubungkan jumlah dan reaktivitas platelet dengan penanda 
inflamasi dan respon sitokin dari darah dan sel mononuklear darah tepi/ peripheral blood 
mononuclear cells (PBMCs) dalam 500-Human Functional Genomics (500FG). Kohort 
ini terdiri dari sekitar 500 individu Kaukasia sehat. Temuan utama kami adalah bahwa 
jumlah platelet terasosiasi dengan respon sitokin interferon (IFN)-y dan interleukin 
(IL)-1 ~/IL-6 yang berbeda. Kami juga menemukan bahwa variasi genetik dari fungsi 
platelet juga terasosiasi dengan respon sitokin terhadap berbagai ligan. Sebaliknya, variasi 
genetik yang menentukan respon sitokin juga terasosiasi dengan reaktivitas platelet. 
Efek dari platelet terhadap respon imun dapat bergantung pada stimulus imun yang 
terlibat. Dalam bah 3, kami menjelaskan melalui penelitian ex vivo, bahwa platelet 
menekan produksi sitokin pro-inflamasi setelah stimulasi PBMC dengan ligan Toll-
like receptor (TLR)2/TLRJ Pam3CSK4. Di lain pihak platelet meningkatkan produksi 
sitokin-sitokin ini setelah stimulasi dengan ligan TLR4 yaitu lipopolisakarida (LPS). 
Efek platelet ini bergantung pada formasi kompleks platelet-monosit, sedangkan respon 
yang diinduksi oleh Pam3CSK4 bergantung pada fagositosis platelet oleh monosit. 
Sejalan dengan hasil ini, sukarelawan sehat yang diberi antagonis reseptor P2Y12, 
ticagrelor, menunjukkan peningkatan sitokin pro-inflamasi di darah yang distimulasi ex 
vivo dengan Pam3CSK4, dan sebaliknya menunjukkan penurunan sitokin pada darah 
yang distimulasi LPS. Temuan kami berpotensi untuk memiliki relevansi klinis karena 
penggunaan inhibitor platelet dapat mengubah respon imun selama infeksi. Arah 
perubahan ini akan bergantung pada tipe mikroorganisme dan TLR yang terlibat. 
Aktivasi platelet yang berlebihan memainkan peran dalam paragenesis sepsis. Terapi 
tambahan yang diarahkan terhadap platelet dapat memperbaiki luaran sepsis. 
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Recombinant alkaline phosphatase (recAP) adalah enzim defosforilasi yang sedang diteliti 
secara kinis sebagai terapi baru untuk cedera ginjal akut akibat sepsis. Bagaimana 
recAP dapat memodulasi gagal organ pada sepsis belum diketahui dengan pasti. Bah 4 
menjelaskan eksperimen menggunakan darah dari sukarelawan sehat dan pasien sepsis 
yang menunjukkan bahwa recAP menghambat aktivasi platelet. RecAP meningkatkan 
defosforilasi adenosin difosfat (ADP), yang merupakan aktivator dari reseptor P2Y12 
dan penguat respon platelet yang paling paten, dan meningkatkan formasi adenosin 
sebagai produk hasil degradasinya. Efek inhibisi terhadap platelet dari recAP dapat 
berkontribusi terhadap potensinya sebagai kandidat terapi untuk mencegah cedera 
ginjal akut yang diinduksi sepsis. 
Dalam bah 5, kami membahas efek hipoksia terhadap aktivasi platelet dan formasi 
kompleks platelet-monosit selama endotoksemia manusia. Data kami menunjukkan 
bahwa hipoksia sistemik saat inflamasi sistemik pada man usia in vivo tidak meningkatkan, 
namun justru menurunkan formasi kompleks platelet-monosit dan hiperreaktivitas 
platelet. Karena sedikitnya data in vivo manusia mengenai efek hipoksia terhadap 
reaktivitas platelet, penelitian kami menghasilkan tilikan penting mengenai interaksi 
kompleks antara inflamasi, koagulasi dan hipoksia. 
Risiko komplikasi vaskuler berbeda-beda tergantung dari jenis infeksi bakterial yang 
dialami. Secara umum, komplikasi vaskuler dan trombotik lebih umum terjadi pada 
infeksi yang disebabkan bakteri Gram positif dibanding bakteri Gram negati£ Infeksi 
akibat bakteri Gram-positif Streptococcus pneumoniae khususnya diketahui menimbulkan 
komplikasi kardiovaskuler. Kami menunjukkan dalam bah 6, dengan menggunakan 
binatang coba babi, bahwa infeksi invasif S. pneumoniae menginduksi peningkatan 
aktivasi platelet yang bermakna. Stimulasi langsung platelet oleh S. pneumoniae 
memerantarai sebagian efek ini karena platelet babi dapat teraktivasi oleh paparan ex 
vivo terhadap S. pneumoniae. Dalam bah 7, kami melakukan sekuensing genetik atas 
349 isolat klinis pneumokokus dari pasien dengan penyakit pneumokokal invasif, dan 
menemukan bahwa gen pb!B yang berasal dari phage terasosiasi dengan kematian yang 
terjadi dalam 30 hari sejak rawat inap dimulai. Sebelumnya, PblB dari Streptococcus mitis 
dilaporkan berperan dalam perlekatan bakteri ke platelet dan berkontribusi terhadap 
virulensi bakteri tersebut dalam sebuah model kelinci dari endokarditis infekti£ 
Karni juga menemukan bahwa galur liar pneumokokus yang mengekspresikan pblB 
menginduksi ekspresi P-selectin platelet, ikatan platelet-fibrinogen dan formasi kompleks 
platelet-monosit yang lebih tinggi dalam darah dibandingkan dengan mutan knock-
out pblB, terlepas dari adanya paparan terhadap antibiotik. Hal ini dapat menjelaskan 
mengapa pasien bakteremik yang terinfeksi dengan pneumokokus yang mengandung 
gen pblB berisiko lebih tinggi mengalami kematian dalam waktu 30 hari. 
Dalam bah 8, kami memaparkan hasil studi observasional kami yang menunjukkan bahwa 
sepsis akibat patogen Gram positif terasosiasi dengan aktivasi platelet, hiperreaktivitas 
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platelet dan formasi platelet-monosit yang bermakna dibandingkan dengan sepsis akibat 
patogen Gram negati£ Hal ini dapat menjelaskan mengapa komplikasi vaskuler lebih 
banyak ditemui pada infeksi bakteri akibat Gram positi£ 
Infeksi lain yang terasosiasi dengan peningkatan risiko penyakit kardiovaskuler adalah 
HIV. Aktivasi platelet yang persisten tetap terjadi meskipun pasien menggunakan terapi 
anti-retroviral. Dalam bah 9 kami menunjukkan bahwa individu terinfeksi HIV yang 
menggunakan regimen berbasis raltegravir mengalami penurunan hiperreaktivitas 
platelet dan agregat platelet-monosit dibanding mereka yang menggunakan regimen 
berbasis nonnucleoside reverse transcriptase inhibitor atau protease inhibitor. 
Infeksi tidak hanya menimbulkan hiperreaktivitas platelet, namun juga disfungsi 
platelet dan hal ini dapat menyebabkan kecenderungan terjadinya perdarahan. Dalam 
bah 10, kami menjelaskan penelitian prospektif kami yang melibatkan pasien dengan 
leptospirosis berat di Semarang, Indonesia. Dari 33 pasien yang dirawat di rumah 
sakit, 15 mengalami perdarahan klinis. Kami menemukan peningkatan aktivasi platelet 
pada pasien leptospirosis yang mengalami manifestasi perdarahan. Kelompok pasien 
ini juga menunjukkan lebih banyak ikatan antara von-Willebrandfactor (VWF) dengan 
glycoprotein (GP)Ib pada platelet, dan hal ini terasosiasi negatif dengan jurnlah platelet. 
Hal ini menunjukkan bahwa peningkatan ikatan platelet-VWF memainkan peranan 
dalam meningkatkan penyingkiran platelet dari sirkulasi, kemungkinan melalui 
. perubahan struktur glikan yang menyebabkan meningkatnya konsumsi platelet oleh 
reseptor Ashwell-Morell di hati. Menariknya, komplikasi perd.arahan pada pasien lebih 
terasosiasi dengan disfungsi platelet dan bukannya dengan jumlah platelet. Temuan 
kami menunjukkan bahwa aktivasi platelet berlebih, dengan adanya kelelahan platelet 
sekunder, mendasari terjadinya disfungsi platelet sebagaimana yang sebelumnya telah 
ditemukan pada pasien dengue. 
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Bloedplaatjes (thrombocyten) zijn bekend om hun rol in de bloedstolling. Recent 
wetenschappelijk onderzoek laat echter zien dat zij ook belangrijk zijn in ontsteking 
en afweer. Thrombocyten interacteren intensief met witte bloedcellen en zijn 
betrokken bij atherosderose en acute cardiovasculaire incidenten (CVI). Enerzijds 
moduleren thrombocyten dus de afweerreactie tegen infectieziekten, anderzijds kunnen 
infectieziekten en inflammatie de functie van thrombocyten bei'nvloeden. 
Hoofdstuk 1 geeft een algemene inleiding in de f}rsiologie van thrombocyten en hun 
rol in ontsteking en afweer. Het beschrijft de principes van de thrombocytenfunctietest 
op basis van flow cytometry die is gebruikt in verschillende hoofdstukken van dit 
proefschrift. Tenslottewordt de achtergrond beschreven van de studies oververanderingen 
in bloedplaatjesfunctie die zijn uitgevoerd bij zowel gezonde vrijwilligers als patienten 
met infectieziekten. 
Er is nog veel onbekend hoe precies thrombocytenaantal en -functie de afweerrespons 
be1nvloeden en omgekeerd. Hoofdstuk 2 beschrijft de assoctattes tussen 
thrombocytenaantal en functie enerzijds en inflammatiemarkers en cytokineresponsen 
anderzijds in een cohort van 500 gezonde mensen. Deze studie maakte deel uit van het 
Human Functional Genomics Project (HFGP). De belangrijkste bevindingen waren 
dat thrombocytenaantal positief geassocieerd is met circulerend interleukin (IL)-113 
en dat thrombocytenreactiviteit positief geassocieerd is met IL-113 I IL-y responsen en 
negatief met interferon(IFN)-g responsen. Genetische variatie in thrombocytenfunctie 
had meerdere overlappende associaties met cytokineresponsen en vice versa. 
De effecten van thrombocyten op de immuunrespons is afhankelijk van de 
immuunstimulus. Hoofdstuk 3 beschrijft dat thrombocyten de productie van pro-
inflammatoire cytokines door leukocyten remmen na stimulatie met de Toll-like 
receptor (TLR)2/ TLR1 ligand Pam3CSK4, terwijl ze de productie van deze cytokines 
verhogen na stimulatie met de TLR4 ligand lipopolysaccharide (LPS). Deze effecten 
waren afhankelijk van de adhesie van thrombocyten aan leukocyten. Het remmend effect 
van thrombocyten op de cytokinerespons op Pam3CSK4 was daarnaast afhankelijk van 
fagocytose (opname) van thrombocyten door leukocyten. Deze bevindingen worden 
ondersteund door de observatie dat gezonde vrijwilligers die de thrombocytenremmer 
ticagrelor hadden ingenomen meer pro-inflammatoire cytokines maakten na stimulatie 
met Pam3CSK4, en minder cytokines na stimulatie met LPS. Het potentiele klinisch 
belang van deze observaties is dat thrombocytenremmers dus verschillende effecten 
kunnen hebben op de afweerrespons tegen infecties en dat deze effecten afhankelijk zijn 
van het type micro-organisme en de bctrokken TLRs. 
Overmatige thrombocytenactivatie speelt een rol in de pathogenese van sepsis. Nieuwe 
therapieen die aangrijpen op thrombocyten kunnen mogelijk de prognose van 
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sepsispatienten verbeteren. Recombinant alkalisch fosfatase (recAP) is een defosforylerend 
enzym dat momenteel in een grote klinische trial onderzocht wordt als aanvullende 
therapie in sepsis. Een eerdere studie liet zien dat dit middel vooral het ontstaan van 
nierschade bij sepsis voorkomt. Hoe recAP deze orgaanschade voorkomt is nog niet 
volledig opgehelderd. Hoofd.stuk 4 beschrijft experimenten waarbij recAP de activatie 
van thrombocyten remt in bloed van gezonde vrijwilligers en sepsispatienten. recAP 
stimuleert de defosforylering van ADP, een belangrijke activator van thrombocyten, 
en de vorming van adenosine, dat een plaatjesremmende functie heeft. Aangezien 
overmatige activatie van thrombocyten bijdraagt aan de orgaanschade tijdens sepsis, 
kunnen deze thrombocytremmende effecten van recAP bijdragen aan het voorkomen 
van nierschade in sepsis. 
Hypoxie treedt vaak op bij sepsis. Hoofd.stuk 5 beschrijft het effect van hypoxie 
op thrombocytenactivatie en thrombocyt-monocyt interactie tijdens een humaan 
endotoxemie model, waarbij gezonde vrijwilligers LPS krijgen toegediend. Systemische 
hypoxie bleek de reactiviteit van thrombocyten en thrombocyt-monocyt interactie te 
remmen. Deze studie geeft zo inzicht in de complexe effecten van hypoxie op stalling 
en inflammatie bij de mens. 
Het risico van vasculaire complicaties verschilt per bacteriele infectie. Vasculaire en 
trombotische complicaties komen in het algemeenvakervoor bij infecties veroorzaakt door 
Gram-positieve bacterien dan bij Gram-negatieve bacterien. De Gram-positieve bacterie 
Streptococcus pneumoniae (pneumokok) is een veelvoorkomende oorzaak van pneumonie 
en invasieve infecties en is relatief vaak geassocieerd met cardiovasculaire complicaties. 
Hoofd.stuk 6 beschrijft een nieuw ontwikkeld pneumokokken varkensmodel, waarin 
S. pneumoniae bacteriemie leidde tot een uitgesproken activatie van thrombocyten en 
de vorming van thrombocyt-monocytcomplexen. Directe stimulatie van thrombocyten 
door S. pneumoniae veroorzaakte deze effecten. Hoofdstuk 7 beschrijft de resultaten 
van een studie waarin 349 pneumokokkenisolaten van patienten met invasieve 
pneumokokkeninfecties zijn gesequenced. Aanwezigheid van het faag-afgeleide 
gen pblB bleek geassocieerd met een verhoogde kans op overlijden binnen 30 dagen 
na ziekenhuisopname. Eerder onderzoek liet zien dat PblB bij de bacterie Streptococcus 
mitis een rol had in de bacteriele adhesie aan thrombocyten en de virulentie van S. mitis 
in een konijnenmodel van endocarditis. Wildtype pneumokokken die pblB tot expressie 
brachten, induceerden meer activatie van thrombocyten dan pneumokokken zonder 
pblB, en dit effect was onafhankelijk van blootstelling aan antibiotica. We hypothetiseren 
dat dit effect op thrombocyten de hogere mortaliteit op 30 dagen verklaart. 
Hoofd.stuk 8 beschrijft de resultaten van een observationele studie waaruit blijkt dat 
thrombocyten van sepsispatienten met vaak voorkomende Gram-positieve bacterien 
aanzienlijk meer geactiveerd zijn dan thrombocyten van patienten met Gram-
negatieve bacterien. Thrombocyt-monocyt complexen waren ook meer toegenomen bij 
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Gram-positieve sepsis. Deze bevindingen kunnen mede verklaren waarom vasculaire 
complicaties vaker voorkomen bij Gram-positieve bacteriele infecties. 
HIV is een andere infectie die geassocieerd is met een verhoogd risico op hart- en 
vaatziekten. HIV-ge"infecteerde personen hebben persistente thrombocytenactivatie, 
ondanks het gebruik van antiretrovirale therapie (ART). Hoofdstuk 9 laat zien dat 
personen die een ART regime gebruiken dat gebaseerd is op de integrase remmer 
raltegravir, minder thrombocytenactivatie en thrombocyt-monocyt complexen hadden, 
vergeleken met hen die een regime met een nonnucleoside reverse transcriptase remmer 
of proteaseremmer gebruikten. 
Infecties kunnen niet aileen leiden tot thrombocyten activatie en hyperreactiviteit, maar 
ook tot thrombocyten dysfunctie. Dit kan leiden tot een bloedingsneiging. Hoofdstuk 
10 beschrijft een prospectieve studie in patienten met ernstige leptospirose in 
Semarang, Indonesie. Bijna de helft van deze patienten hadden bloedingen. De 
bloedplaatjes van patienten met ernstige leptospirose waren minder goed activeerbaar 
en dus dysfunctioneel. De mate van thrombocytdysfunctie was sterker geassocieerd 
met bloedingen dan het thrombocytenaantal. Von Willebrand factor (VWF) speelt 
een rol in de adhesie van thrombocyten aan de vaatwand en zorgt voor verwijderen 
van thrombocyten uit de circulatie. Thrombocyten van de leptospirosepatienten 
hadden meer VWF op hun membraan en dit was negatief gecorreleerd met de 
thrombocytenaantal. Deze gegevens dragen bij tot een beter inzicht in de oorzaak van 
de thrombocytopenie en bloedingscomplicaties bij leptospirose en de ontwikkeling van 
toekomstige therapeutische opties. 
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